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Vascular disease is currently the leading cause of mortality worldwide, with coronary heart disease, 
peripheral arterial disease and strokes accounting for upwards of 30% of all deaths in Europe. Bypass 
grafting is one of the major approaches utilised in the treatment of vascular disease. This technique 
involves diverting blood flow around an arterial blockage by grafting in an alternative path. This 
surgery is widely used in the treatment of coronary heart disease and peripheral arterial disease. This 
is either done with a synthetic material, such as PTFE, or by using an autologous vessel such as the 
saphenous vein or the internal thoracic artery. The grafting of autologous vessels is considered the 
gold standard for small diameter bypass grafts due to the higher patency rates compared to their 
synthetic counterparts. However, there are only a finite amount of vessels that can be harvested and in 
many cases the vessels are not of a high enough quality for use in surgery. Therefore, there is an 
urgent need for the development of novel biomaterials that can improve patency rates in bypass grafts. 
As a push for solutions to this problem, the field has placed a focus on improving the biofunctionality 
of materials in vitro as a means of testing the translatability of the material. 
This thesis presents four different methods of improving the bioactivity of scaffolds for vascular 
tissue engineering through alteration of the morphology and composition of the scaffold: 1) Altering 
the fibre diameter of electrospun polycaprolactone (PCL) scaffolds to enhance the morphology for 
seeded cells. 2) Native aortic and heart bovine extracellular matrices (ECM) were incorporated into 
PCL scaffolds. 3) Cell secretome was bound to the PCL scaffolds to enhance the bioactivity of the 
scaffold. 4) Altering the cell’s response through environmental factors such as hydrostatic pressure 
and hypoxia.  
Scaffolds were either seeded with human umbilical vein endothelial cells (HUVECs) or human 
umbilical vein smooth muscle cells (HUVSMCs) and their response to their microenvironments were 
analysed. Gene expression analysis and immunohistochemical analysis showed that altering the fibre 
diameter of the scaffold had evident effects on cellular response. For example, increasing fibre 
diameter had the effect of increasing cellular infiltration for both cell types. HUVECs upregulated key 
phenotypic genes when seeded on the largest fibre diameter. On the contrary, the HUVSMCs 
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upregulated key genes when cultured on the smallest fibre diameter. Likewise, the incorporation of 
ECMs into the scaffold altered their mechanical properties and changed the biological response of the 
seeded cells. Incorporating ECM had the effect of decreasing stiffness and increasing scaffold 
elasticity. Furthermore, the incorporation of aortic ECM into the fibres led to higher cell viability for 
both cell types. Additionally, the binding of proteins released by cultured cells to the PCL scaffold 
was shown to alter gene expression and cell survival. 
Each method undertaken altered cellular responses such as gene expression and cell viability, 
indicating that these methods provide a viable and translatable platform for vascular tissue 
engineering. These scaffold have great potential for vascular tissue engineering and offer 




Vascular disease is the leading cause of mortality worldwide and current treatments do not lead to 
long-term full functionality. Bypass grafting is a means of treating various vascular diseases by 
allowing blood to flow around a blockage in the vessel. The gold standard treatment option for bypass 
grafting is not available to all patients due to the finite resources within the body. Unfortunately, the 
synthetic grafts being made in the lab for these patients do not provide the patients with a long-term 
solution. 
Vascular tissue engineering aims to provide hope for these patients by finding new treatments and 
materials to offer longer-term solutions. Bioengineers use a combination a materials science and 
biology to come up with novel solutions. Eventually, the hope is to provide scientist with platforms 
for the testing of new drugs and patients with artificial organs. 
Electrospinning is a manufacturing technique that creates fibrous sheets of polymer with similar 
structural characteristics to that of the extracellular matrix (ECM). The extracellular matrix is 
composed of proteins and growth factors and provides the local cells with a framework to attach 
themselves to and grow around. This project focusses on ways to alter the structure and composition 
of these fibrous electrospun polymer sheets, to eventually use them as replacements for the native 
vascular ECM. 
This research has looked at several ways to alter the morphology and composition of these 
electrospun polymer sheets. Firstly, the size of the individual fibres in the polymer sheet were 
changed to see how this aspect of the morphology influenced vascular cells (endothelial cells and 
smooth muscle cells). The second method looked at how altering the composition of these fibres 
influenced vascular cells. Decellularized native ECMs were incorporated into the fibres to provide the 
cells with some of the proteins and growth factors found in native tissue. The third method looked at 
how proteins and growth factors secreted by cells could be attached to the polymer fibre and how this 
would influence vascular cells. Cells were grown in the lab and their secreted proteins and growth 
factors were collected in media and then bound to the surface of the electrospun polymer fibres, 
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providing the vascular cells with the proteins and growth factors released by the cells in culture. 
Finally, environmental stimuli were used test how the electrospun sheets and vascular cells would 
respond to the native environment. Hydrostatic pressure was used to simulate the forces seen by the 
cells in the body, with the hope of altering the proteins and growth factors secreted so that different 
proteins could be bound to the electrospun sheet. Hypoxia (low oxygen) was used to assess the 
viability of these electrospun sheets for vascular cells when in a diseased state.  
Each of the scaffolds designed in this thesis altered the biological behaviour of vascular cells. Altering 
the fibre diameter had positive effects on both cell types, with the larger fibre diameter leading to 
increased cell viability and gene expression of key phenotypic genes in the seeded HUVECs and the 
smallest fibre diameter having similar effects in the seeded HUVSMCs. The addition of ECM into the 
fibres altered their mechanical properties and had beneficial effects for both cell types. Higher cell 
viability was noted for both cell types when the aortic ECM was incorporated into the fibres. 
Furthermore, these scaffolds have a range of different mechanical properties that closely mimic those 
of the ‘gold-standard’ treatment for bypass grafting. These novel electrospun polymer sheets put us 
one step closer to finding a realistic solution to the gap between synthetic bypass grafts and the ‘gold-











1.1 Heart Anatomy 
The heart muscle is composed of four main muscular chambers, two of which are associated with the 
pulmonary circuit and two with the systemic circuit 1. Blood comes into the right atrium from the 
vena cava (systemic circuit). It is then passed on to the right ventricle through the tricuspid valve. This 
blood is then pumped into the pulmonary artery (pulmonary circuit) where it makes its way to the 
lungs, collecting oxygen to feed the organs. The blood comes back into the left atrium via the 
pulmonary veins. The blood then passes through the mitral valve into the left ventricle, before being 
pumped out via the aorta (systemic system). The heart is surrounded by the pericardial sac, which acts 
to stabilize the heart muscle within the body. It is composed of a network of collagen fibres and filled 
with approximately 20-60 ml of pericardial fluid in adult humans 2. This fluid acts as a lubricant 
between the two internal surfaces of the pericardial sac. 
The wall of the heart is made up of three distinct layers called the epicardium, the myocardium and 
the endocardium. The outer layer of the heart wall is called the epicardium and is composed of a 
mesothelium and areolar tissue 1. This is connected to the myocardium which makes up the majority 
of the heart wall. The myocardium is a dense network of cardiac cells and connective tissues. The 
final inner layer of the heart wall is called the endocardium and is composed of areolar tissue and an 
endothelium lining the inner walls of the heart muscle 1. The heart wall is supplied with blood from 
the coronary artery. 
There are several different valves located within the heart muscle, all whose main purpose is to 
prevent the backflow of blood. The right atrioventricular (AV) tricuspid valve and left AV bicuspid 
valve are located between the right atrium and ventricle; and the left atrium and ventricle, 
respectively 3. They are designed to prevent backflow form the ventricles to the atriums during 
ventricular contraction. These two valves are closed using the papillary muscles which connect the 
two valves to the inside wall of the ventricles 4. The pulmonary valve and aortic valves are found 
between the right ventricle and the pulmonary artery and the left ventricle and aorta. Both of these 
valves are called semilunar valves and are designed to prevent the backflow of blood from the 
pulmonary artery and the aorta into the right and left ventricles, respectively 5.  
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1.2 Arterial Anatomy 
1.2.1 Human Arterial Anatomy 
Arteries are blood vessels within the body that take blood away from the heart to various parts of the 
body, such as organs and limbs. They are part of the circulatory system which is responsible for both 
carrying oxygenated nutrient filled blood to the cells, as well as removing carbon dioxide and waste 6. 
As well as performing this transportation function, they also act as dampers to ensure the organs and 
tissues are receiving a steady flow and pressure of blood 6. The pulmonary artery carries non-
oxygenated blood to the lungs, whereby a network of bronchioles and capillaries transfers oxygen 
from the lung into the blood 7. This oxygenated blood is then returned to the heart where it is pumped 
out of the aorta to all the subsequent arteries in the body. Major arteries that carry oxygenated blood 
are the coronary artery that supplies the heart muscle; the carotid artery that supplies the head and 
brain; the axillary arteries that supply the arms; the femoral artery that supplies the legs; the renal 
artery that supplies the kidneys; and the hepatic artery that supplies the liver 8. There are many more 
arteries that supply other organs with oxygenated blood 8. 
The walls of vessels consist of three distinct layers that all serve a unique function, as seen in Figure 
1 8. Firstly, the inner most layer is called the tunica intima. This is the location of the blood wall 
barrier and consists of a thin layer called the endothelium that is made up of a monolayer of 
endothelial cells. Outside that (moving away from the central lumen of the vessel) there is a layer of 
elastic tissue called the internal elastic membrane, which separates the endothelial cells from the next 
core section of the vessel – the tunica media. Next, beyond the tunica intima is the tunica media which 
mostly consists of a dense network of smooth muscle cells interwoven amongst connective tissue. The 
tunica intima is bound to the tunica media by collagen fibres. The smooth muscle cells found in the 
tunica media are somewhat responsible for the contractile properties of the elastic arteries. Finally, at 
the outer extremity of the vessel there is the tunica externa. This region mostly consists of elastic 




Figure 1: Structure of the vessels of the body: (A) arteries and (B) veins. Arteries have a thicker tunica media 
than veins, which helps them retain their shape. 
 
Vessels and arteries may share a similar structure to each other but there are some clear differences 
between them, mostly due to the loading that they undergo 8.  Firstly, the vessel wall tends to be 
thicker in arteries, with the majority of this being in the tunica media, allowing the vessel to resist 
higher pressures (as seen in Figure 1). Secondly, the vessel lumen appears to be relatively smaller 
17 
 
compared to the vessel wall thickness due to the recoiling nature of the elastic fibres present in 
arteries. Finally, veins tend to contain valves, whereas arteries do not. This is because of the lower 
pressures associated with veins and the higher potential for backflow. Valves at regular intervals 
ensure the blood keeps flowing in the right direction 9. 
Elastin and collagen are two of the major proteins that make up the extracellular matrix of 
arteries 10,11. The quantity of each protein has a major effect on mechanical properties of the 
arteries 12,13. This is described in more depth later on. The aorta is the largest artery in the body – it 
transports blood out of the heart to the entire body. The magnitude of the forces seen in the aorta 
change as you move down away from the heart 14. The extracellular matrix (ECM) of the aorta 
changes in composition along its length to accommodate these differences in force.  
Elastin and collagen have interesting mechanical properties that render them mechanically suitable for 
vascular tissue 12,13. The major role of elastin is to allow the vessel to undergo repeated extension 
without resulting in tissue deformation 12. As previously mentioned, elastin is found in higher quantity 
at the upper end of the aorta where pulsatile pressures are at their highest. This is because elastin is 
designed to maintain tissue shape under high repetitive forces 15. During aging, the quantity of elastin 
within the arteries decreases significantly, resulting in an increase in arterial stiffness 16. Elastin has a 
low propensity for turnover, therefore, the elastic fibres that were laid down during foetal 
development have to undergo large numbers of cyclic deformation without failure 17. Like elastin, 
collagen does also offer a degree of elasticity 18. However, its major role in the mechanical properties 
of vessels is to provide tensile strength. This stiffness comes from the intermolecular cross-links 
between each collagen molecule 13. 
1.2.2 Animal Arterial Anatomy 
The major animal of focus in this thesis is the Bovinae (cow). They were used as a source of vascular 
ECMs - aorta and myocardium to be precise. Interestingly, it was found that the aortic arch in young 
cows (similar in age to the cows used for ECM in this thesis) had elastin contents of 46.6% and 
collagen contents of 16.7% - a ratio of 2.79, which is lower than that found in the human aortic 
arch 19. These elastin and collagen contents are similar to that found in pigs, goats and sheep 20. 
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1.3 Resident Cells of the Vasculature 
1.3.1 Endothelial cells 
1.3.1.1 Umbilical Vein Endothelial Cells 
Human umbilical vein endothelial cells (HUVECs) are an endothelial cell line that is commonly used 
in vascular research as it is considered to be a robust cell line for the study of cell pathology and 
function 21. They were first isolated from the umbilical cord in the early 1970s by Jaffe, et al. using a 
simple collagenase digestion method 22. Since then, they have become a popular cell line for a variety 
of reasons including their low cost; simple isolation techniques; and their robustness during cell 
culture 23.  
HUVECs have been widely used in vascular tissue engineering with a range of different studies being 
carried out 24–27. Furthermore, Liao, et al. looked into the effect of passaging on HUVEC performance 
and whether or not any functionality losses were noted 28. Their results suggest that P10 is the 
approximate point where functionality of the HUVECs is altered. Briefly, cell spreading percentage 
and actin filament length were both seen to drop after P10 and cell surface roughness (especially in 
the region around the nucleus) was seen to increase after P15 28. As changes were noted between 
different passage numbers, it is of crucial importance to use the same passage number between 
different studies. 
1.3.1.2 Aortic Endothelial Cells 
Human aortic endothelial cells (HAECs) are an endothelial cell line that is isolated from a segment of 
the ascending aorta 29. This is a primary cell line that is directly obtained ex vivo through the use of 
endovascular surgery. HAECs have become more popular in recent times as they more accurately 
mimic the native vascular environment and are capable of substantially more doublings in vitro before 
undergoing senescence 29. They have since been used in a variety of tissue engineering settings 30–32. 
1.3.1.3 Coronary Artery Endothelial Cells 
Human coronary artery endothelial cells (HCAECs) are a cell line that is isolated from a segment of 
the coronary artery. They can be isolated during angioplasty and stent surgery to open up a blocked 
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coronary artery 33. They have been used for a range of tissue engineering applications and have shown 
positive results when cultured on 3D scaffolds 34–36. 
1.3.2 Smooth Muscle Cells 
Vascular smooth muscle cells (VSMCs) are an important component of vessel walls and are 
predominantly found in the tunica media  37. Depending on the size of the vessel, the thickness in cell 
number of the tunica media can range from around 40 layers of VSMCs up to around 60 layers 37. 
VSMCs differ slightly from other smooth muscle cell types that are often found in the walls of organs 
including the stomach, bladder and uterus, amongst others. Firstly, VSMCs have been found to 
contain high quantities of vimentin and low quantities of desmin, which is the opposite of the other 
conventional smooth muscle cell types 38. Vimentin and desmin are both intermediate sized filament 
proteins that play crucial roles in supporting and anchoring various cell constituents such as the 
nucleus, mitochondria and endoplasmic reticulum 39,40. A study by Schwartz et al. found that rat aortic 
smooth muscle cells contain 51% vimentin alone-positive cells, 48% positive for both vimentin and 
desmin, and 1% desmin alone-positive 41. Both proteins differ in molecular weight but share similar 
biochemical properties such as low solubility 42. In addition, VSMCs are predominantly composed of 
α-actin, whereas conventional smooth muscle cells are mostly made up of γ-actin 38,43. Interestingly, 
the expression of α-actin is one of the earliest markers for VSMC differentiation 44. 
1.3.3 Cardiomyocytes 
Cardiomyocytes are the most abundant cell type found within the heart and are predominantly 
responsible for providing the contractile force necessary to pump the heart muscle and provide blood 
perfusion to the body 45. Interestingly, once birth has occurred, cardiomyocytes reach maturity and 
lose their ability to divide 46. At this point, any cardiac muscle growth is associated with the individual 
myocytes increasing in size and not due to proliferation and increase in cell number 45. Therefore, any 
loss in cardiomyocyte number through adulthood has to be compensated for with increased workload 
from the remaining cardiomyocytes 45. Cardiomyocytes for cell-study can be isolated from a variety 
of sources including rats, humans, and other animal sources. Furthermore, they can be isolated from 
neonatal sources or matured adult sources, providing a range of possibilities for the study of 
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cardiomyocytes 45. Cardiomyocytes have been extensively used in tissue engineering, with work also 
being done on electrospun scaffolds 47–49.  
1.3.4 Cardiac Pacemaker Cells 
Cardiac pacemaker cells are responsible for creating the rhythmic electrical impulses that control the 
contraction of the cardiomyocytes, allowing for blood to be perfused around the body 50. Without a 
controlled set of impulses, the heart would lose functionality, eventually leading to heart failure 51. In 
this case, an artificial pacemaker can be used to synthetically produce the impulses required for heart 
muscle contraction 51. These cells have not been extensively studied in tissue engineering, however, 
some work has been done on generating them from stem cell sources as a means of treating heart 
failure 50,52. 
1.4 Growth Factors 
Vascular endothelial growth factor (VEGF) is a major growth factor responsible for stimulating the 
formation of new vasculature, also known as angiogenesis 53. The importance of VEGF in 
angiogenesis was discovered in 1983 by Senger et al. who originally called it vascular permeability 
factor 54. They found that tumours from various rodents secreted VEGF, ultimately leading to 
increased cell permeability 54. They noted similar findings with in vitro cell cultures 54. Interestingly, 
it has since been suggested that the VEGF may in fact protect the tumour cells from chemotherapy 
and radiotherapy, ultimately hindering the effect of these treatments 55. Furthermore, chemotherapy 
and radiotherapy have both been shown to increase the quantity of VEGF within the tumour cells 56. 
While this suggests that increased VEGF expression is solely negative, there are situations where 
VEGF is required, most notably in the cardiovascular system. It has been shown that VEGF acts on 
the site of infarction, promoting tissue remodelling 57.  
Fibroblast Growth Factor (FGF) is another growth factor responsible for angiogenesis and wound 
healing 58,59. A lot of work has shown that FGF stimulates VEGF expression in both endothelial cells 
and stromal cells, along with accelerating tumour formation 60–62. Likewise, increased FGF expression 
has been shown to synthesise hepatocyte growth factor (HGF), another angiogenic growth factor 63. 
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1.5 Vascular Extracellular Matrices 
The ECM is a 3-dimensional network of proteins, cytokines and enzymes, that provide the structural 
support for surrounding cells to attach and grow into specific tissues 64. Beyond its evident structural 
supporting functions, the ECM also provides cells with biochemical cues that can control the 
functionality of the local cells 64. It has slightly different functions depending on the tissue type, but in 
most cases it is involved in cell adhesion and cell-cell communication that is crucial for successful 
proliferation and differentiation of local cells 65. In vascular tissue, the ECM has the very important 
role of controlling the amount of stress and strain that the cells are exposed to, thus influencing cell 
metabolism 66. 
The aorta is the largest artery in the human body, with average diameters ranging from about 3cm at 
the aortic arch down to approximately 1.8 cm in the abdomen 67. As described in section 1.2.1, the 
arteries of the human body (including the aorta) are composed of various structural proteins that help 
give the artery its viscoelastic compliant properties 68. The two major components that make up the 
majority of the aorta’s ECM are collagen and elastin. The aortic arch (at the exit of the heart) is 
composed of approximately 38% elastin and 23% collagen (ratio of 1.65) 20. The elastin content drops 
as you go along the aorta to about 21% at the sub-renal level (below the abdomen). In contrast, 
collagen levels increase to about 28% at this point along the aorta leading to a ratio of 
approximately 0.7, which is less than half of the ratio found at the artic arch 20. Interestingly, the 
hydroxyproline content of the elastin was found to increase as the aorta descended 20. A higher 
quantity of hydroxyproline is associated with increase elasticity 69. 
In contrast to the aorta, the myocardium has a much lower collagen and elastin content. It has been 
found that the human left ventricle is composed of approximately 5% collagen, of which 85% is 
collagen type 1 and 11% collagen type 3 70,71. No values for human myocardium could be found in 
relation to elastin content, however, the ventricles of a rat were found to be composed of 3% collagen 




Collagen is composed of a hierarchical structure which is somewhat responsible for its mechanical 
properties 67. It is made of collagen fibrils that are approximately 50-200 nm in diameter that form the 
backbone of all collagenous tissues 72. These collagen fibrils are formed of interlinked collagen triple 
helical molecules 73. The fibrils are interlinked to each other by proteoglycan bridges (at 60 nm 
intervals along the fibrils) that allow for load transition between sequential fibrils 74. Next in the 
hierarchical composition of collagen comes the collagen fibres that are made up of several collagen 
fibrils. Work by O’Connell et al. found that the average collagen fibre was made up of a bundle of 
approximately 24 parallel collagen fibrils, tightly enveloping the smooth muscle cells 75. They also 
found that the fibrils run in parallel and were not woven together, and concluded that this was 
probably to improve its mechanical properties 75. The hierarchical structure of collagen can be seen in 
Figure 2. Furthermore, collagen has a half-life of around 2 months meaning that it is constantly being 
turned over and deposited by the local cells 11. The degradation of collagen is controlled by matrix 
metalloproteinase enzymes 11. 
The collagen supplies strength and stiffness (bulk Young’s moduli of approximately 3-10 GPa have 
been noted 69,76) to the aorta wall, allowing it to resist the force of the blood being pumped around the 
body. Aortic stiffness increases as you descend from the aortic arch to the abdominal aorta, which 
correlates with an increasing quantity of collagen 77. Furthermore, the spatial organisation of the 
collagen fibres has also been shown to greatly influence the mechanical properties of the aorta wall 72. 
Collagen is described as having viscoelastic properties and this can be explained by the load sharing 
capabilities of collagen fibrils through the proteoglycan bridges 74. More specifically, as the fibrils 
slide against each other the proteoglycan bridges deform allowing for the relative movement of each 




Figure 2: Hierarchical structure of collagen 
 
1.5.1.2 Elastin 
Elastin is one of the key proteins that makes up vascular ECM, especially in the case of arterial ECM 
where elastin can make upwards of 35% of the dry weight 20. An elastic fibre is composed of both 
elastin and microfibrils – each making up around 90% and 10% of the elastic fibres weight, 
respectively 78. The elastin forms the internal core of the elastic fibre, which is surrounded by a thin 
sheath of microfibrils. This elastic fibre has a diameter of approximately 10-12 nm 79. These fibres 
align themselves along the axis of strain within the artery’s wall, helping to counteract the effect of 
the pulsating blood, in turn protecting the organs downstream from the pulsating effect 6.  
Elastin is an insoluble biopolymer with an estimate half-life of around 70 years 10. Due to its inability 
to turn over, the total quantity of elastin in the human body drops over time 10. Elastin is formed 
through the crosslinking of tropoelastin, a 60 kDa protein. Tropoelastin is found as a monomer in 






of collagen molecules 
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microfibril appears first and acts as a scaffold for the deposition of elastin 81. It is mostly composed of 
two large (350 kDa) glycoproteins called fibrillins 1 and 2 82,83.  
The major property of elastin that makes it so prevalent in the body is its ability to extend and return 
to its original shape even after billions of cycles 17. These fibres are capable of extensions in the range 
of 150% before fibre failure 84. Furthermore, the Young’s modulus of elastin has been found to be 
between 300 kPa and 1.2 MPa 84,85 
1.6 Cardiovascular Disease 
1.6.1 Atherosclerosis 
Atherosclerosis is a type of cardiovascular disease that narrows the arteries, restricting the amount of 
oxygenated blood that can reach beyond the narrowing 86. Damage to the endothelium leads to a 
build-up of fat/cholesterol/calcium that over time expands causing a restriction in the vessel, as seen 
in Figure 3 87. This restriction itself causes issues as oxygenated nutrient filled blood can now no 
longer reach its destination, leading to diseases such as coronary artery disease and peripheral artery 
disease. Furthermore, if the blockage breaks away it can cause serious issues downstream as it can get 
stuck in narrower vessels leading to strokes and heart attacks 86. 
 
Figure 3: Coronary artery atherosclerosis in 11 month old pigs stained with haematoxylin, eosin and Verhoeff-
van Gieson. (A) Overall image. (B) represents a zoomed in image of the black rectangle in image (A). Black = 
cell nuclei, purple = cell cytoplasm, red = elastic tissue. Image adapted from 87. 
 
Interestingly, atherosclerosis first appears in childhood, whereby a small layer of plaque will line the 
endothelium of arteries 88. From here on, atherosclerosis progresses into adulthood where the build-up 
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of plaque will become more pronounced in areas of damage. Treatment options for atherosclerosis 
vary depending on the severity of the blockage. For example, in cases where urgent intervention is not 
required the usual treatment options include lifestyle changes (weight management, physical activity, 
diet and reduction in smoking) or the use of antiplatelet medication and statins that prevent the build-
up of more plaque and allow for smoother passage of blood 88. In more serious cases where the 
blockage is deemed too severe for the aforementioned treatment options, surgery is often required 89. 
This includes bypass grafting (grafting in an alternative path for the blood to flow around the 
blockage) and angioplasty (expansion of the artery to allow for smoother passage of blood) 90,91. 
1.6.2 Fibromuscular Dysplasia 
Fibromuscular dysplasia, also known as hyperplasia, is described as a non-atherosclerotic, non-
inflammatory vascular disease that predominantly affects the renal and carotid arteries (60-75% and 
25-30% frequency of involvement, respectively) 92. The disease state is characterized by an increase 
in the number of cells within the organ or tissue beyond what is normal 93. The difference between 
hyperplasia and dysplasia is that in hyperplasia the increased number of cells appear normal, whereas 
in dysplasia the cells appear abnormal. It can occur in any of the three layers of the vessel: intima, 
media and adventia; with medial dysplasia representing the most common type 92. It is typically 
characterized as having the appearance of a “string of beads” 94. These lesions can either present 
themselves as focal lesions (a single lesion) or multifocal lesions (several lesions), as seen in Figure 4. 
Briefly, Figure 4 shows an angiography of the affected vessel. Angiography is an imaging technique 
used to view the lumen of a vessel, so a narrowing in the lumen indicates hyperplasia may be 




Figure 4: Angiographic subtypes: (A) Multifocal lesions in the carotid artery and (B) focal lesions in the carotid 
artery. Adapted from 96. (C) Diagram showing the “string of beads” appearance adopted by the artery due to 
fibromuscular dysplasia. 
1.6.3 Thrombosis 
Thrombosis is a type of vascular disease that affects both arteries and veins. It occurs when a blood 
clot is formed inside the blood vessel, thus obstructing the flow of blood through the body 97. When 
the vessel endothelium is breached/disrupted, the underlying ECM becomes exposed to the blood 
initiating the formation of a thrombus. The exposed ECM triggers an accumulation of platelets at the 
site of damage, and the exposed tissue factor signals for the creation of thrombin. These two 
signalling pathways occurring simultaneously lead to the creation of a solid thrombus 97. Thrombosis 
can occur in almost every artery and vein in the body, with its location being a key factor in the 
severity of the disease 98. When a thrombus breaks away from the endothelium it becomes an embolus 
that can now freely travel through the circulatory system 99.  
1.6.4 Embolism 
An embolism is a blockage caused by an embolus, which is a piece of material that has freely 
travelled around the circulatory system and lodged itself into a narrow vessel 99. The embolus can 
come from a variety of sources: a dislodged blood clot called a thrombus 97; a fat globule called a fat 
embolism 100; a bubble of gas called a gas embolism 101; and a foreign body/material 102.  
(A) (B) 
Thickened arterial wall 
“String of beads” appearance 




There are two types of embolism: an arterial embolism and venous embolism. Arterial embolisms can 
occur anywhere in the body and often results in infarction, which is localised tissue death arising from 
a lack of oxygenated blood reaching that particular area 103. A venous embolism will usually form 
inside the lungs (pulmonary embolism) after passing through the right side of the heart 104. 
The most common treatment method employed for small scale embolisms is the use of an 
anticoagulant that stops blood from clotting, allowing time for the body to absorb the clot that has 
caused the embolism 105. If the embolism is deemed to be more serious, the doctor might go in with a 
catheter to either remove the embolism directly or try to dissolve it 106. Alternatively, a filter can be 
surgically placed into the Vena Cava, catching any embolus before it makes its way to the lungs 107. 
1.6.5 Coronary Artery Disease 
Coronary artery disease (CAD) starts to develop when the coronary artery that feeds the heart muscle 
with oxygen and nutrients starts to become blocked up due to atherosclerosis, thrombosis and 
hyperplasia, amongst other diseases 108. This decrease in oxygenated blood flow to the heart muscle 
leads to angina (chest pain) and shortness in breath, and in serious cases, will lead to a heart attack 
(myocardial infarction). The severity of CAD is made evident by the fact that 45.7% of all UK 
cardiovascular disease related deaths in 2012 and 44% of all European cardiovascular disease related 
deaths in 2017 were attributed to CAD 109,110.  
CAD treatments depend on what has actually caused the development of the disease. Once this has 
been concluded, a variety of treatment options are available. Briefly, if the CAD is in its early stages 
then a lifestyle change is the most common treatment method. This included changes in diet, reducing 
in alcohol intake and smoking, and more regular exercise 110. In addition to this, a variety of drugs are 
available including: cholesterol-modifying medications (decreases low density/bad cholesterol); blood 
thinners such as aspirin; beta blockers (slow down heart rate, thus reducing oxygen demand from the 
heart muscle); and pain killers to help with angina 109. If the CAD is deemed to be too severe and 
urgent intervention is required then angioplasty and stent placement or coronary artery bypass surgery 
are two options 111,112. 
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1.6.6 Myocardial Infarction 
A myocardial infarction, more commonly known as a heart attack, is when blood flow is restricted or 
completely stopped to a particular part of the heart, causing damage to the heart muscle and reducing 
its functionality 113. They are usually caused by a blockage in the coronary artery (atherosclerosis and 
hyperplasia) 113. A myocardial infarction is often the first indicator of other vascular diseases, most 
often coronary artery disease. It can have a variety of effects on the patient, ranging from going 
unnoticed with no symptoms to sudden death 113. Interestingly, myocardial infarctions can be 
predicted through the appearance of various proteins in the blood (myoglobin and cardiac troponin 
being examples) which are released by the dying myocardial cell population 114. The favoured 
biomarkers for the assessment of myocardial infarction is troponin I or troponin T due to their high 
specificity to cardiac cells and their high sensitivity during testing 114. 
1.6.7 Peripheral Artery Disease 
Much like coronary artery disease, peripheral artery disease (PAD) starts to develop when a peripheral 
artery (renal and brachial) becomes blocked up due to atherosclerosis, thrombosis and hyperplasia, 
amongst other diseases 108. These arteries feed the extremities with oxygen and nutrients. This can 
lead to a variety of issues such as numbness and weakness in the legs; blue/purple colouration of the 
legs; ulcers on the feet and hands; and muscle wastage 115. In serious cases, PAD can lead to critical 
limb ischemia, which will eventually lead to necrosis of the extremities 116. Treatment for PAD is very 
similar to CAD and includes the use of a variety of drugs, bypass surgery and angioplasty and stent 
placement 109.  
1.6.8 Stroke 
A stroke occurs when blood flow to the brain is restricted for various reasons, resulting in cell 
death 117. They will often lead to disability and sometimes death of the patient. The majority of strokes 
are caused by atherosclerotic thrombi in the cranial arteries 92. As the diameter of the artery decreases 
moving into the deeper parts of the brain, the thrombus (now called an embolus as it has broken away) 
can get stuck and block the artery, starving the downstream brain tissue of oxygen 118. The other major 
type of stroke is a haemorrhagic stroke, which is caused by bleeding, often due to a ruptured 
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aneurysm 119. Interestingly, the haemorrhagic stroke is usually more serious that the conventional 
ischemic stroke, with a significantly higher mortality noted (49.2% died during follow-up, compared 
to just 25.9%) 119.  
1.6.9 Arterial Aneurysms 
An arterial aneurysm is the dilatation of the artery to 50% larger than its normal size 120. This 50% 
guideline is a loose definition as arteries will naturally change in size over the patient’s lifetime 120. 
They can be located in any artery, however, the most common and severe location is in the aorta, both 
abdominal and thoracic 121. Aneurysms cause weaknesses in the arterial wall and create points of 
stress which increase the patient’s risk of arterial rupture 122. When a rupture does occur, large 
amounts of internal bleeding occur, often leading to death 121. The mortality rate for patients whose 
abdominal aortic aneurysm has ruptures is as high as 85%, with half of deaths occurring before 
surgery was attempted 123,124. In most cases, repair of large or symptomatic aneurysms (endovascular 
grafts) is recommended due to the higher risk associated with this type of aneurysm 121.   
1.6.10 Heart Failure 
Heart failure occurs when the heart muscle stops pumping blood efficiently, resulting in the muscle 
over working and ultimately leading to lower quantities of blood reaching the organs and limbs 125. 
Heart failure can appear as either chronic or acute heart failure. Chronic heart failure is the more 
common of the two and presents itself with bouts of worsening symptoms (shortness of breath and 
fatigue, amongst many others) that may require hospitalisation 126. In contrast to this, acute heart 
failure usually presents itself with severe symptoms (pulmonary oedema, cardiogenic shock and 
decompensation) and requires immediate attention 126. Unfortunately, heart failure is hard to reverse, 
therefore most treatments focus on preventing the progression of the disease. The main methods of 
treatment are lifestyle changes (increased exercise, reduced smoking, etc.) and the use of beta-
blockers and diuretics 127,128. 
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1.7 Treatment Options for Cardiovascular Disease 
1.7.1 Bypass Grafting 
Bypass grafting is a commonly used vascular intervention, whereby an alternative path is grafted onto 
a vessel to allow for oxygenated blood to travel around a damage or blockage in the vessel, as seen in 
Figure 5 91. This damage or blockage can be caused for a variety of reasons including, but not limited 
to, atherosclerosis and thrombosis, as mentioned above 86. Bypass grafting is usually split into two 
different categories: small diameter grafts (< 6 mm) and large diameter grafts (> 6 mm). Small 
diameter grafts include the coronary arteries, infrainguinal arteries and infrageniculate arteries 129. 
Large diameter grafts include aortoiliac substitutes (> 8 mm), carotid and femoral artery replacements 
(6 – 8 mm) 130,131.  
The difference between the small and large diameter bypass grafts becomes stark when the type of 
graft being used is looked at 129. Bypass grafting can be further subdivided into two more categories: 
synthetic grafts and vessel grafts (autologous vs allograft vs xenograft ) 129. Synthetic grafts are made 
from polymers such as Polytetrafluoroethylene (PTFE) and Polyethylene terephthalate (PET), also 
known as DACRON. They have shown very high patency (degree of openness) in large diameter 
bypass grafting, with values as high as 90% 130. However, in small diameter vessels, they have shown 
to be fairly unsuccessful, with patency rates ranging from 32-75% after only 2 years depending on 
which vessel was being operated on, as seen in Figure 6 111,132. One of the major advantages of 
synthetic bypass grafts is the ability to bond medication to the surface of the polymer graft. Heparin is 
often bound to the inside layer of a graft, giving it direct contact with the flowing blood 133. A study 
by Devin et al. found that 1, 2 and 3 year above-knee femoropopliteal bypass graft patency was 




Figure 5: Schematic of how a bypass graft works. Bypass grafting allows for blood flow to be deviated around a 
blockage within an artery, allowing oxygenated blood to reach beyond the blockage. 
 
The current ‘gold standard’ for bypass grafting is the use of an autologous vessel (one of the patients 
own vessels), in particular, the saphenous vein, internal thoracic artery and radial artery 134. The use of 
autologous vessels is especially desirable in small diameter bypass graft where huge improvements in 
patency rates have been noted compared to their synthetic alternatives 129,135. 5 year patency rates of 
approximately 75-85% have been noted in coronary artery bypass grafts, above-knee femoropopliteal 
bypass grafts and femoral popliteal distal bypass grafts, as seen in Figure 6 129,136. However, there is a 
limited availability of autologous vessels in the body due to there being a finite amount of vessels that 
can be used, and in some cases, the quality of the vessel is too low for transplantation, which means 
autologous vessel bypass grafting is not available for all patients 137,138. Furthermore, in some cases 
the extraction of autologous vessels can be deemed to be too dangerous and can cause donor site 




Figure 6: Patency rates for small diameter bypass grafts using the saphenous vein (SV) (gold standard) and 
PTFE conduits for three different surgeries. Patency rate is higher in all cases when using an SV conduit. 
CABG (coronary artery bypass grafts), Fem-pop above knee (above-knee femoropopliteal bypass grafts) and 
Fem-distal artery (femoral popliteal distal bypass grafts) 129. 
 
Vessel bypass grafts can be further subdivided into three different categories: autologous grafts 
(patient and donor are the same); allograft (patient and donor are different) vs xenograft (patient and 
donor are different species) 139. Autologous grafts and allografts are limited by the availability of the 
vessels within the body of the donor. The difference between the two is there is a higher chance of 
rejection in an allograft due to poor immune response 140. Xenografts are the least desirable of the 
three as they suffer from much shorter lifespans depending on the source of the graft. For example, 
when using a xenograft sourced from a pig, the graft would have to be replaced approximately every 
10-15 years 139. 
1.7.2 Angioplasty and Stenting 
Angioplasty and stenting are endovascular procedures designed to open up narrowed/obstructed 
vessels to allow for the free flow of blood 141. They are often used to treat atherosclerosis and 
fibromuscular dysplasia 142,143. An uninflated balloon carrying a stent is inserted into the blockage 
using a catheter before being inflated, causing the blockage to be opened up. This allows for the stent 
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(usually made of metal) to be placed into the now opened up blockage, ensuring it stays open and 
allows for the free passing of blood, as seen in Figure 7 142,144. The stent prevents arterial recoil and 
restenosis (the recurrence of arterial narrowing) after the balloon dilation 112.  
Original stent designs were fairly simple and were usually manufactured from bare metal 112. These 
devices successfully reduced restenosis compared to simple balloon angioplasty alone – mostly due to 
preventing arterial recoil 112. However, a study by Fischman, et al. found that, even though rates of 
restenosis were lower than angioplasty alone, 31.6% of patients (67 of 159) who received stents still 
suffered from restenosis 145. The next development in stent technology came in the early 2000s when 
the metallic stent was combined with a drug eluting polymer, allowing for pharmacological agents to 
be administered directly at the site of blockage 146. The drugs used in these stents include 
immunosuppressants (stops stent rejection) and anti-proliferative agents (stops unwanted cell growth 
at the site of stenting 146,147. As expected, the inclusion of these pharmacological agents had the effect 
of reducing restenosis rates down to approximately 5-8% (rate of restenosis reduced from 21% to 
8.6% (N = 533 and 525) in the study by Moses, et al. and from 12% to 4.7% (N = 652 and 662) in the 
study by Stone, et al.) 146,147. 
One of the common reasons for stent failure is a phenomenon called in-stent restenosis 148. This can 
occur for a variety of reasons: firstly, there may be a hyperplasic response to the stent, resulting in 
excessive tissue proliferation causing the lumen of the vessel to grow over the stent causing a 
narrowing of the artery to reoccur 148. Secondly, there may be neoatherosclerosis occurring which is 
the formation of a new fatty blockage within the stent 149,150. Interestingly, the occurrence of 
neoatherosclerosis was significantly higher in drug-eluting stents than in simple bare metal stents 
(31% vs 16% (N = 81 and 76) beyond the 5 year mark) 150.  
Stent technology is now moving towards the use of bioresorbable materials, whereby the stent still 
offers mechanical support for the artery in the short run (when arterial recoil is a key factor to 
consider) but can later be absorbed, thus avoiding the long run concerns of in-stent restenosis 151. 
Materials used in bioresorbable drug eluting polymer stents include polylactic acid (PLA) and 
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polylactic-co-glycolic acid (PLGA), made by a variety of companies including Axxess®, 
BioMatrix®, MiStent® and SYNERGY®. 
 
Figure 7: Schematic showing how angioplasty and stenting works. Blockage is opened up with an angioplasty 
balloon before a stent is placed to keep the blockage open. 
 
1.7.3 Medication 
Beta-blockers (medication that blocks the adrenergic β-receptors) are widely used in the treatment of 
different types of cardiovascular disease 152. They act by blocking the binding of adrenaline and other 
stress hormones to these receptors, reducing the effect these stress hormones have on the 
cardiovascular system. They have been used to treat hypertension, abnormal heart rhythms and to 
protect the heart following myocardial infarction 153. Interestingly, studies have shown that beta-
blockers lead to lower negative outcomes in hypertensive patients compared to a placebo 154.  
Diuretics are extensively used in the treatment and management of cardiovascular disease, most 
notably in the treatment of hypertension and heart failure 155,156. Diuretics act on the kidney and inhibit 
the reabsorption of salts (chloride, sodium, potassium, etc.), increasing the amount of water taken out 
of your blood to increase the volume of urine. This in turn reduces the total volume of blood, helping 
reduce blood pressure and alleviate the symptoms of heart failure 155.  
35 
 
Immunosuppressants are drugs used during allograft transplantations to inhibit the activity of the 
immune system on what it deems as being a foreign body 157. While immunosuppressants are a 
necessity for any patient undergoing a transplantation, they are associated with a variety of deleterious 
side effects 158. For example, many have shown to increase the development of atherosclerosis and 
increased hypertension 159. 
Anti-proliferative drugs are designed to prevent restenosis (narrowing of the blood vessel) after an 
endovascular medical procedure has been undertaken 160. These drugs have been widely used in a 
range of different endovascular devices such as bioresorbable scaffolds, where they are grafted into 
the device and designed to elute out over time. This mechanism allows for the slow release of the 
drug, with the aim of preventing restenosis whilst the stent is in place 146,147. 
Vasodilators are drugs designed to help widen the blood vessel, easing the perfusion of blood through 
the vascular system. They have been widely used to treat hypertension and heart failure 161,162. The 
aim of vasodilators is to help reduce the pressure on the arteries and heart muscle without depressing 
the cardiac output 162. Similarly, in heart failure, the most common symptom is an increased left 
ventricular filling pressure, which is alleviated through aortic dilation, in turn reducing the required 
pumping force 161. Vasodilators are usually used in tandem with diuretics to treat hypertension and 
heart failure 155,161.  
1.8 Cell Based Approaches for the Treatment of Vascular Disease 
Cell based therapies for the treatment and management of cardiovascular disease are on the increase, 
with a particular focus on stem cell-based therapies 163–165. Mesenchymal stem cell (MSC) localization 
in diseased hearts has been shown to improve cardiac function, reduce scar size and increase left 
ventricular ejection fraction 166,167. This is achieved through the stimulation of a variety of repair 
mechanisms designed to either upregulate or downregulate abnormally expressed genes 168,169. It is 
believed that the paracrinal secretion coming from the injected cells is providing growth factors and 
cytokines to the native cells 170. Furthermore, umbilical cord MSCs have been shown to improve 
cardiac function in patients with heart failure and managed to increase the left ventricular ejection 
fraction 171. The upside to using umbilical cord MSCs is they are easily obtained and cultured in vitro. 
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While stem cells alone have shown good results when used in cardiovascular therapies; the 
combination of two or more cell types has gained traction 172. A study by Patel, et al. looking at the 
combination of MSCs and activated macrophages showed a significant reduction in negative cardiac 
events 172.  
One of the major downfalls of conventional injection of cells is their poor engraftment 173. To combat 
this, many studies have looked at cell seeded tissue engineered patches to ensure the cells are acting 
directly at the point where tissue regeneration is required 174. 
1.9 Scaffolding Technologies for Vascular Tissue Engineering 
A tissue engineering scaffold is a material that has been designed to promote a particular cellular 
response 175. In many cases the scaffold is designed to mimic the native ECM, oftentimes proving to 
be the best structure for optimized cell growth 176. Many different manufacturing methods exist and 
are listed in Table 1. 
 
Table 1: Different techniques used to manufacture scaffolds for tissue engineering purposes. 

















 Nanofiber fabrication  
 Anisotropic or isotropic 
properties achievable 
 Good mechanical properties 
 Use of hazardous solvents  
 Pore size can be too small for 
cell infiltration 
 Issues with repeatability 
177–180 
Hydrogels 
 Cell encapsulation 
 Easy inclusion of bioactive 
properties 




 Anisotropic properties 
 Large pores and high porosity 
 Dense base layer 




 High porosity 
 Cheap manufacturing technique 
 Can be used solvent free 




 Carrier of cells and biologicals 
 Patient specific properties 
 Limited by printer quality 
189–191 
Gas foaming  High porosity 

















 High resolution 
 Uniform pores with a high 






 The use of ultra-high molecular 
weight polyethylene 
 High resolution and wide range 
of scaffolds can be manufactured 
 Hard to remove the injected 
powder 





 Ceramics and metals can be 
manufactured 
 Micron level resolution 




 Ability to print encapsulated 
cells 
 Wide range of scaffold 
architectures achievable 



















 Incorporation of native ECM 
components  
 Good use for unused tissue 
samples 
 Decellularizing methods can 
damage ECM components 




 Mimic the native ECM 
 Easier to handle than 
decellularized ECM 





 Functionalize a scaffold with a 
large range of cytokines 




 Large range of mechanical 
stimuli 
 Bulky 





Electrospinning is a method of fibre production that is widely used for a variety of applications 
including filtration, protective clothing, sensor, wound dressing and scaffolds for tissue 
engineering 207. The technique works by applying a high voltage to a polymer/solvent solution. This 
increase in voltage charges the surface of the liquid solution droplet causing the droplet to stretch 
across from the spinning nozzle to the mandrel, as seen in Figure 8. The droplet at the spinning nozzle 
forms a Taylor cone before it starts stretching out. Once the critical point is reached, the droplet fires 
across towards the mandrel. This part of the flow is called Ohmic flow and is reliant on the difference 
in charge. Between the spinning nozzle and the mandrel the solvent phase of the solution evaporates 
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leaving behind thin fibres of polymer that are subsequently deposited onto the mandrel. This part of 
the flow is called convective flow and happens due to the charge within the fibre migrating towards 
the surface, as seen in Figure 8 208.  
 
Figure 8: Electrospinning process. The high voltage charges the polymer/solvent solution causing it to fire 
across and deposit polymer fibres onto the mandrel. The transition from Ohmic flow to convective flow causes 
the solvent to evaporate from the solvent/polymer solution. 
 
Electrospinning is a versatile technique that can manufacture a range of fibre morphologies and can 
use a variety of different polymers, proteins and solvents 177,209–211. One of the major benefits of 
electrospinning is the ability to manufacture fibres in an array of sizes ranging from the nanoscale 
(30 nm) up to the micron scale (> 10 μm) 177,212–216. This characteristic of electrospinning gives it the 
flexibility to be used for a variety of tissue engineering applications where local ECM morphologies 
may differ 217. Beyond the control of the diameter of individual fibres, the orientation of the fibres can 
also be controlled by altering the rotational speed of the mandrel on which the fibres are collected 218. 
This is only achievable using a rotating mandrel where the speed can be modified allowing the fibrous 
sheet to have anisotropic properties that may more closely mimic the properties of the tissue being 
studied 219. Studies have also shown that certain cell types prefer aligned fibres where they can stretch 
out along the fibre 177. Furthermore, the process of electrospinning can accommodate a variety of 
polymers, solvents and organic proteins allowing for a range of applications 217,220,221. Polymers that 
have been widely researched in tissue engineering include polycaprolactone (PCL), polylactic acid 
(PLA), polylactic-co-glycolic acid (PLGA), Polyvinyl alcohol (PVA), amongst many other that will 
be discussed later 221. Equally, the range of solvents/liquid phases that can be electrospun is large and 
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offers an assortment of possibilities. These include solvents such as hexafluoroisopropanol (HFIP), 
chloroform, dimethyl formamide (DMF), methanol and acetic acid, and in some cases deionised 
water 220,221. Finally, a variety of other substances can be added to the electrospinning solution such as 
proteins, antibiotics/medication, growth factors, genes and cells 202,217,222,223. The versatility in the 
substances used and different morphologies that can be created means electrospinning can be used for 
a large range of purposes.  
1.9.2 Directional Freezing/Phase Separation 
Phase separation, also known as directional freezing, is a scaffold manufacturing technique that relies 
on the liquid phase of the polymer/solvent solution freezing along a temperature gradient. During the 
controlled freezing process, the liquid phase solidifies into columnar structures pushing the polymer 
into the gaps between the ice crystals, as seen in Figure 9 224. Once the solution is frozen the liquid 
phase can be sublimated away in a freeze dryer leaving behind a scaffold with a distinct columnar 
structure 184. A variety of parameters can be altered in the manufacturing process, allowing for a range 
of structures to be manufactured. These include the temperature at each end of the gradient; the 
polymers and solvents used; the polymer concentration; and the direction of the temperature gradient. 
Furthermore, this technique can incorporate a multitude of different proteins, growth factors and 
cells 184,186,225–227. 
 
Figure 9: Schematic representation of the directional freezing process. Crystals form along the axis of 
temperature gradient. Once sublimated, a columnar structure is left behind 184. 
 
1.9.3 Salt Leaching 
Salt leaching is a sacrificial scaffold manufacturing technique that is used to create highly porous 
scaffolds 187. The salt crystals are poured into a mold whereby the polymer solution is poured on top, 
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filling the voids left behind between the salt crystals (in some cases the salt can be mixed in with the 
polymer solution before being poured into the mold). Once the polymer solution has hardened, the salt 
particles are leached out through dissolution into a solvent, water often being the one used 228. One of 
the major advantages of this technique is that it is easily used without cariogenic solvents, which are 
often the downfall of other techniques 187. Furthermore, the scaffolds created can have large open 
pores that may be desirable for certain cell types 187. Additionally, a variety of different salt crystals 
can be utilised allowing this method to generate an array of different porous structures, both in shape, 
regularity and size 188.  
1.9.4 Gas Foaming 
Gas foaming is a widely used technique in large scale industry that has moved its way towards the 
production of micro scale scaffolds for tissue engineering 192. Examples of industrial uses include the 
manufacture of expanded polystyrene and various polymer based foams, where porosity and/or 
enclosed gases are desirable 192. This method can be split up into two types of gas foaming structures: 
closed-cell and open-cell. Closed-cell structures do not have pore interconnectivity (gas bubbles) and 
tend to possess stronger mechanical properties; these structures are not common in tissue engineering. 
On the other hand, open-cell structures do have pore interconnectivity (gas tunnels) and allow for cell 
and nutrient transfer throughout the thickness of the structure 192. Furthermore, these structures allow 
for vascularization, which is a key desirable feature for tissue engineering scaffolds 229.  
The method works by gasifying a liquid phase through chemical decomposition or a thermal reaction.  
For example, an effervescent salt particle (ammonium bicarbonate) can be combined into a polymer 
gel and cast in a mold. The solution is heated up releasing ammonia and carbon dioxide gas resulting 
in the formation of pores (gas bubbles or gas tunnels) 230. This technique has a range of applications in 
tissue engineering due to the different polymers, gases and proteins that can be developed into porous 
scaffolds 231. 
1.9.5 Hydrogels 
Hydrogels are a widely used scaffold manufacturing technique in tissue engineering; especially in soft 
tissues where the mechanical performance of the scaffold is not as important. They are a 3D structure 
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composed of a network of hydrophilic polymers cross-linked together via either covalent bonding or 
physical interactions 232. They get their hydrophilicity from the presence of hydrophilic moieties 
(amine groups, carboxyl groups, etc.) along the backbone of the polymer chain 232. Their highly 
porous structures combined with the high hydrophilicity of the polymers allow these hydrogel 
structures to absorb a large amount of fluid, often several times more mass than the polymer itself 232. 
Furthermore, this methods lends itself to the use of a wide range of biocompatible polymers such as 
the natural polymers chitosan, alginate and collagen; and the synthetic polymers Polyethylene oxide 
(PEO), Polyvinyl acetate and Polyacrylic acid (PAA). In addition to this, a wide array of proteins, 
growth factors and cell types have been encapsulated into the hydrogel structure as a means of 
improving the bioactivity of the scaffold 181,182,232–234.  
The encapsulation of native ECMs has gained traction in recent years due to the improving methods 
of decellularization along with the bioactive potential associated with these materials 235. Retaining 
the full biochemical complexity of the native ECM is of crucial importance and has been done with a 
variety of different decellularized tissue types 235–237.  
1.9.6 Rapid Prototyping 
Rapid prototyping is a blanket term used to describe a range of manufacturing techniques that use 
models made from 3D computer aided design or computed tomography (CT). The scaffold is 
designed on a computer and then manufactured using 3D printing or additive layer manufacturing 196. 
While this method is heavily used in industry for manufacturing objects from metals and polymers, it 
has only recently started being used to design scaffolds for tissue engineering applications. One of the 
major advantages of rapid prototyping is the ability to accurately tailor the morphology of the 
scaffold 238. Bioprinting is a new rapid prototyping method which uses bioinks (see section 1.9.6) to 
create 3D scaffolds 197. The method combines biomaterials with cells and growth factors to fabricate 
scaffolds which maximise mimicry with the native tissues. These rapid prototyping techniques have 
shown success in the tissue engineering realm 239,240. Studies by Bibb, et al. and Liew, et al. have 
demonstrated the efficacy of bioprinting at developing 3D scaffolds with predefined vascular 
networks. Furthermore, selective laser sintering (another rapid prototyping method) has been used to 
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develop scaffolds for ‘soft tissue’ engineering 194. They manufactured a scaffold with optimized 
mechanical properties capable of maintaining cell viability. 
1.9.7 Bioinks 
A bioink is a substance that carries cells and other bioactive substances and can be printed into a 3D 
scaffold for tissue engineering purposes 241. These bioinks are the major component of bioprinting and 
need to carry the correct characteristics in order to function properly during the printing process and 
once the structure is complete. They are designed to mimic the native ECM structure in order to create 
a habitable environment for the support of cells at all developmental stages (adhesion, proliferation 
and differentiation) 191. Due to the presence of biological components and cells within the bioinks, 
they tend to be processed and printed under very mild conditions to preserve the living cells and 
ensure no degradation of bioactive molecules occurs 242. Bioinks have a huge potential in tissue 
engineering due to the wide array of cells and biological components that can be incorporated into the 
ink 243. These include natural polymers such as collagen, chitosan, gelatin, or in some cases native 
ECMs that are made up of a mixture of different natural polymers 189,243,244. Furthermore, these 
bioinks can be tailored for each individual patient through the use of autologous cells and tissues 190.  
Printability is the major characteristic of the bioink that requires intricate design and study. They need 
to form filaments when they are deposited allowing the bioink to be printed into the desired shape 244. 
A variety of bioink and printer characteristics can be altered to allow for the successful printing of the 
bioink. These include the print pressure and velocity; volume flow rate; viscosity; and bioink 
concentration 242. Furthermore, flow rate needs to be kept minimal to ensure the cells undergo low 
shear stress as this can induce apoptosis 245. The mechanical properties of bioprinted bioinks are often 
too low for most tissues 244. Recent advancement of the field of bioinks has led to a combinational 
approach to bioprinting, whereby the mechanical properties are increased by embedding the bioink 
around a polymer lattice 244.  
1.9.8 Decellularized Tissues 
Decellularization is the process by which a tissue is stripped of its cellular population leaving behind 
the tissue’s ECM 200. This ECM is composed of a variety of different proteins and enzymes that are 
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tissue specific and is responsible for cell adhesion, cell-to-cell communication and cell differentiation 
into new functional tissue 64. These decellularized ECMs can either be used as scaffolds or can be 
combined with other manufacturing techniques to create composite scaffolds 235,246. They provide the 
new seeded cells with a native biochemical environment and therefore have the effect of increasing 
the bioactivity of the scaffold 217. 
There are a variety of different decellularization methods which tend to fall under three different 
categories including physical methods, chemical methods and enzymatic methods, as seen in Table 
2 200. Physical methods tend to rely on mechanical force or external environmental change. These 
include snap freezing, pressurization, sonication, agitation and shear stress via perfusion and have 
been successfully applied to a variety of tissues including vascular tissues 247–251. Snap freezing relies 
on ice crystal formation causing cell lysis, however, this needs to be highly controlled as the ice can 
damage the ECM, rendering it unusable 252. Furthermore, while this method does cause cell lysis, it 
doesn’t remove the cells from the tissue, therefore a further cell removal method is required 253. The 
pressurization method is a fairly simple method that relies on mechanical force to burst and remove 
the cells. It is an effective method when trying to decellularize a loosely packed tissue such as liver 
tissue, and has also been successfully implemented for decellularization of vessels 254,255. 
Pressurization, agitation and sonication are methods that are often combined with chemical and 
enzymatic methods 256. 
There are a wide range of different chemical methods that are used for decellularization 257. One 
chemical method is the use of detergents such as sodium dodecyl sulfate (SDS) and Triton X-100. 
These detergents solubilize the cell’s membranes and separate DNA from the cell’s proteins allowing 
the cellular material to be removed from the tissue 258,259. These methods are very effective at 
removing cellular material from the tissue and their efficacy increases with exposure time 260. 
However, with increasing exposure time and detergent concentration, increased ECM protein 
degradation is also noted 246. Over-exposure has been shown to decrease the ECM’s GAG content and 
also leads to a reduced quantity of native growth factors within the decellularized tissue, therefore, 
finding a fine balance between concentration, exposure time and final DNA content is of crucial 
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importance 261,262. As previously mentioned, combining physical methods and chemicals methods is 
fairly common practice when decellularizing tissues. An example of this is combining an SDS 
chemical method with a perfusion based pressurization method. By holding a pressure through the 
tissue, quicker and more effective decellularization is achieved 256.  
Finally, enzymatic methods are available for decellularization and rely on the breakdown of the bonds 
holding the nucleic acids onto their neighbouring proteins 263. Enzymes that have been widely used in 
literature for the purpose of vascular decellularization include collagenase, nuclease and 
trypsin 250,259,264. Nucleases, for example, are designed to cleave onto the nucleic acid sequence after 
cell lysis, facilitating the removal of nucleic material from the tissue being decellularized 265. While 
collagenase is an effective means of decellularization, it has a major drawback due to its collagen 
digesting properties, one of the major components of most ECMs. This means that collagenase can 
only be used when the collagen structure of the ECM is not required post-decellularization 266. 
Finally, trypsin acts by breaking down the cell-matrix bonds and is often used to facilitate 
decellularization 267. It has been shown to accelerate the decellularization process when used 
alongside other methods but can also damage the ECM 267,268. 
 
Table 2: Different decellularization techniques used in tissue engineering. 
Decellularization 
technique 















 Ice crystal formation disrupts 
cell membrane  
 Damage to the local ECM due to 
freezing  
 Lysed cells need to be removed 




 High pressure can burst the 
cells  
 High pressure used to strip 
cells away from the ECM  
 Effective with loosely packed 
ECM  
 Over-pressurization can damage 




 Shear stress facilitates the 
removal of cellular material 
from the tissue  
 Helps disrupt the cells  
















 Detergent solubilizes the cell’s 
membrane and separates DNA 
from protein  
 Over-exposure can damage the 
ECM  
 Lysed cells need to be removed 
from the tissue using an 
alternative method  
256,258,261 
Acids and bases 
 Solubilizes the cytoplasm and 
disrupts the DNA  
 Damages the ECM and removes 
GAG  
 Alters mechanical properties  
268,271,272 
Alcohols 
 Dehydration of cells causing 
lysis  













 Cleave onto nucleic acid post-
lysis  
 Lysed cellular content needs to 




 Breaks down the cell-matrix 
bonds  
 Speeds up the decellularization 
process  
 Damages the ECM  
267,268,275 
Collagenase 
 Digests collagen which breaks 
down bonds with cells  
 Damages the ECM’s collagen  266 
 
1.10 Summary 
To summarise, cardiovascular disease is the leading cause of death globally and can present itself in 
many different ways, requiring a range of different treatment options. While great progress is being 
made to find novel solutions, there is still a shortfall in the quality of treatment available. Patients 
requiring small diameter bypass grafts still find themselves without long-term solutions due to the 
inadequacies of the current materials being used. Tissue engineering is presenting itself as a promising 
avenue for the development of new treatments to treat cardiovascular disease. This project aims to 
look at novel biomaterials as a means of influencing the behaviour of two vascular cell types: 




Aims and Objectives 
The hypothesis of this thesis is that the morphology and composition of electrospun scaffolds can 
influence vascular cells – human umbilical vein endothelial cells (HUVECs) and human umbilical 
vein smooth muscle cells (HUVSMCs). Many studies have shown that vascular cells can be 
influenced by their environment, therefore there is rationale to studying scaffold morphology and 
composition.  
The aims of this thesis are: 
I. Manufacture electrospun scaffolds with differing morphologies and assess their impact on 
HUVECs and HUVSMCs. The morphological characteristic focussed on in this thesis is fibre 
diameter, which has been shown in past literature to affect other cell types. 
II. Incorporate decellularized vascular ECMs (aortic and myocardial ECM) into polymer 
scaffolds and assess their impact on HUVECs and HUVSMCs. Aortic and myocardial ECM 
from a bovine source were used as these two ECMs are physiologically relevant to the two 
cell types being studies. Past literature has shown that ECMs from other tissue types can be 
incorporated into polymer scaffold and do have beneficial effects on other cell types.  
III. Bind vascular cell secretome to polymer scaffolds to further biofunctionalized them and 
assess their impact on HUVECs and HUVSMCs. The pre-functionalization of scaffolds using 
proteins has shown promise in the field of tissue engineering. Therefore, there is rationale in 
trying to create a scaffold that is functionalized with proteins that have been directly secreted 
by vascular cells. 
IV. Use physiologically relevant environmental conditions to alter cell secretome and cell 
functionality. Hydrostatic pressure was used to try and create an altered secretome profile for 
binding onto the scaffold and hypoxia was used to assess the ECM scaffolds in an in vitro 

















The electrospinning set up used during this thesis is an EC-DIG electrospinning platform from IME 
Technologies (Netherlands). The electrospinner had a wide range of settings allowing from a variety 
of solutions to be used and morphologies to be created 1. Briefly, the range of potential set ups are: 
needle to mandrel distances ranging from 0 to 23 cm; mandrel rotational velocities ranging from 0 to 
2500 RPM; needle bore sizes ranging from 0.1 to 0.9 mm; positive voltages ranging from 0 to 25 kV; 
negative voltages ranging from -4 to 0 kV; and a range of different needle motions. 
All fibres during this study were collected on a rotating mandrel covered in aluminium foil at room 
temperature. The rotational velocity of the mandrel can be altered depending on the alignment being 
sought from the fibres. This thesis predominantly uses randomly orientated fibres which were 
collected at 150-250 RPM depending the solution being used. Polycaprolactone (PCL) (Mn=80000 
Da) (Sigma-Aldrich, UK) was either dissolved into 1,1,1,3,3,3-hexafluoro-2-isopropanol (HFIP) 
(Manchester Organics, UK) or a 5:1 ratio solution of chloroform to methanol (both Sigma-Aldrich, 
UK), or a 10:1 ratio of the same two solvents. Solutions were mixed at 30 RPM overnight at room 
temperature using an SRT9D roller mixer (Stuart, UK). The finalised electrospun scaffold sheet was 
left overnight to dry in a fume hood before being removed for use as a scaffold. Electrospinning of 
ECM-PCL blends was achieved using the same protocol. Individual electrospinning protocols for 
each study are listed in their respective chapters. All scaffolds were punched out from the sheet using 
a 10 mm diameter punch. 
2.2 Decellularization 
Decellularization was achieved with a closed-loop perfusion based chemical detergent protocol using 
a bespoke decellularization device 2. Bovine aorta and heart tissue samples were harvested from a 
2 year old cows and frozen within 4 hours. First, approximately 2 g of native tissue was chopped up 
into 5x5x5 mm pieces to create a larger surface area for decellularization as this has been shown to 
facilitate the process 3. The pieces were then placed into the device and perfusion decellularized using 
0.5% w/v sodium dodecyl sulfate (SDS) (Sigma-Aldrich, UK) in 1 L of ultrapure deionised water 
(diH2O). The SDS solution was swapped over to a new batch after 12 h of decellularization. In total, 
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decellularization lasted approximately 36 h. Subsequently, the SDS was flushed out of the 
decellularized tissue using 10 L of deionised water for a total of 1 h in the same system with the 
device exit attached to separate vessel to ensure flushed out SDS is not put back into the tissue. It is 
imperative that SDS is removed from the tissue as SDS residue has been shown to lead to several 
unwanted outcomes including foreign body response in vivo 4. The decellularized tissue was then 
frozen and lyophilized to remove all liquid for the milling process.  
2.2.1 Milling 
Milling of decellularized tissue was achieved using a PM100 plenary ball mill (Retsch, Germany) 
with approximately 300 stainless steel balls with a diameter of 2 mm. Pieces of lyophilized 
decellularized tissue were cut up to be smaller than the individual balls before being placed into the 
ball mill. Milling was achieved using a 4 minute 500 RPM protocol (3min clockwise, 1min counter-
clockwise). The protocol was run 8 times to achieve full milling. Between each run the set up was put 
on dry ice to make sure the decellularized tissue was kept as cold as possible, simulating cryomilling. 
This increases the brittleness of the ECM, leading to the creation of a finer powder and ensures the 
ECM does not overheat during the process 5–7. Milled ECM was collected in water, frozen and then 
lyophilized leaving behind a fine powder.  
2.3 Cell culture 
2.3.1 Culture of Human Umbilical Vein Endothelial Cells 
The human umbilical vein endothelial cell (HUVEC) line is a primary cell line that was first isolated 
in the 1970s by Jaffe, et al. using a collagenase digestion method 8. They are widely used to study the 
pathology and functionality of endothelial cells, and have shown to be robust, cheap and easy to 
isolate, making them an ideal cell type for preliminary in vitro cell studies 9. 
The HUVECs used were isolated from the umbilical cord of an infant male Caucasian donor 
(PromoCell GmbH). This study abides by all criteria of the UK Human Tissue Act. The HUVECs 
arrived at P1 and were cultured to P7 in a humidified atmosphere of 5% CO2 and 37°C. HUVECs 
were cultured in MCDB131 medium (Life Technologies™) supplemented with 5% v/v FBS 
(ThermoFisher Scientific) + 1% v/v L-glutamine + 100 U/mL penicillin + 100 μg/mL streptomycin 
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(all Gibco) + 1 mg/L hydrocortisone + 50 mg/L of ascorbic acid (Sigma) + 2 mg/L fibroblast growth 
factor + 10 mg/L epidermal growth factor + 2 mg/L insulin-like growth factor + and 1 mg/L VEGF 
(all PeproTech). Cells were passaged once 80% confluency was reached using Trypsin-EDTA 
(Gibco). All cell studies were run with HUVECs at either passage 7 or 8. 
2.3.2 Culture of Human Umbilical Vein Smooth Muscle Cells 
The human umbilical vein smooth muscle cell (HUVSMC) line is a primary cell line that is isolated 
from one or two of the arteries found within the human umbilical cord 10. They are usually isolated in 
a similar manner to HUVECs, often using a form of enzymatic digestion that was first introduced by 
Jaffe, et al. in the 1970s 8. They are a robust cell line for the study of vascular diseases and have been 
widely used in tissue engineering for preliminary in vitro and in vivo studies 11–13.  
The HUVSMCs used were isolated from the umbilicus of a neonatal Caucasian male (Merck). 
Briefly, the HUVSMCs arrived at P1 and were cultured to P5 in a humidified atmosphere of 5% CO2 
and 37°C. Cells were cultured and banked using smooth muscle cell culture medium (Merck) up to 
P4. Cells were passaged at 80% confluence using Trypsin-EDTA (Gibco) at room temperature and 
were split 1:3. Subsequent cell studies were run using P5 HUVSMCs and cultured using DMEM 
supplemented with 10% v/v FBS + 100 U/mL penicillin + 100 μg/mL streptomycin + 1% Non-
essential amino acids. 
2.4 Histology 
2.4.1 Paraffin Wax Embedding and Sample Processing 
All tissue samples undergoing immune histological staining were fixed and embedded into paraffin 
wax before being cut down using a microtome for staining. Firstly, the tissue sample was cut down to 
approximately 5 mm of thickness and then fixed in 10% v/v formalin for 24 h. This ensured that the 
samples were thoroughly fixed but not damaged due to over-fixation. Formalin fixation followed by 
paraffin wax embedding has been shown to lead to sample shrinkage by up to 30%, therefore, it is 
imperative that the sample is adequately processed 14. The sample was then moved over to 70% v/v 
ethanol before the next step is performed. 
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Once fixed, the sample went through a series of ethanol based dehydration steps and xylene washes to 
displace the water and subsequently allow for paraffin wax infiltration. Once the tissue sample had 
been completely cleared with xylene, the sample was placed into paraffin to allow for the paraffin 
wax to infiltrate the tissue. The paraffin used had a melting point of 54-58°C, therefore the oven 
should be set at no more than 60°C. This melted the wax whilst limiting any damage that overheating 
may cause on the fixed tissue. Over-exposure to hot wax can lead to brittle samples 14. The tissue goes 
through two soakings in paraffin lasting 1-2 h each. This ensures that the paraffin has fully penetrated 
the fixed sample. 
The sample was then ready to be embedded into solid paraffin wax in a microtome cassette. This was 
all done at 60°C to ensure the wax does not solidify during processing. Approximately 1-2 mm of 
molten wax was placed onto the base of the cassette. The sample was then placed on top of this wax 
in the desired orientation for trimming. The cassette backing was then added before the whole cassette 
was filled with paraffin wax. Once the wax had solidified the whole embedded block could be placed 
into the freezer for later use. 
The embedded blocks were then be sectioned into thin slices for staining using a microtome. Before 
sectioning, the blocks were placed on ice to keep the paraffin wax cold as this facilities the sectioning 
process 15. The microtome blade was set at approximately 5° and the slice thickness was set to 
anywhere between 3-10 μm. The sections were sliced and floated in 37°C water before being picked 
up by glass slides. The slides were then heated up to 60°C (slightly above the wax’s melting 
temperature) to allow for the tissue slices to bond onto the glass slide. Samples were then stored at 
room temperature. 
Once the sample had been sectioned and bound onto a glass slide, they were read to undergo 
dewaxing so they could be stained. First, the samples was thoroughly dewaxed using three 2 min 




2.4.2 Haematoxylin and Eosin 
The haematoxylin and eosin (H&E) stains are commonly used stains for microscopic examination of 
cellular based tissues and are widely used in medical diagnosis, where they are regarded as the gold 
standard 16. Examples of this include the diagnosis of many cancers that can be easily identified using 
H&E staining 17. Likewise, H&E staining are widely used in tissue engineering for a variety of reason. 
For example, the stain is often used to confirm decellularization or to evaluate the success of in vivo 
experiments 18,19. Haematoxylin has a dark blue/black colour that stains anything that can be 
considered basophilic (anything with an affinity for the base dye). In this case that includes the cell 
nuclei, rough endoplasmic reticulum and the ribosomes20. In contrast, the eosin stain has a light pink 
colour that stains anything that can be considered to be eosinophilic. This includes the cell membrane, 
cell cytoplasm and most ECM proteins such as collagen, elastin and many more 20. It is imperative 
that the protocol used is tailored to each tissue type as overstaining and understaining can be 
misleading. Both haematoxylin and eosin are light sensitive stains and require varying exposure times 
to different tissues 21.   
Once the tissue had been dewaxed and rehydrated it can be stained with H&E. Briefly, the sample was 
placed in haematoxylin solution for 6min, allowing enough time for the haematoxylin stain to 
penetrate the cell nucleus. This was followed by a 5 min rinse under tap water to ensure the 
haematoxylin is completely removed. At this point the sample will darken in colour as the 
haematoxylin starts to bind to the basophilic substances. The sample was then placed in eosin for 90 s 
allowing enough time for the eosin to penetrate. The eosin was then removed using 95% ethanol. The 
sample was placed in acidified water (0.5% v/v acetic acid in diH2O) for 15 s before undergoing a 
series of dehydration steps. 
2.4.3 Picrosirius Red 
The picrosirius red stain is a widely used stain for the characterisation of collagen I and III fibres 
within embedded tissue samples 22,23. The stain possess a red colour and reacts with the sulfonic acid 
and base groups present in collagen molecules and can easily be visualized under conventional light 
microscopy, although cross-polarized light has also been used 24. Furthermore, the cell substances 
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such as the nucleus and cytoplasm are stained a dull yellow colour, helping to create contrast between 
the cellular material and the collagenous substances 23.   
Once the tissue had been dewaxed and rehydrated it could be stained with Picrosirius red. Briefly, the 
sample was placed into the 0.1% w/v Picrosirius red stain (Sirius red in saturated aqueous picric acid) 
for 1 h. This gave near equilibrium staining which does not increase over time. Shorter times should 
be avoided as this may lead to incomplete staining. Sample was then washed in two changes of 
acidified water (0.5% v/v acetic acid in diH2O) for 1 min. The sample was then dehydrated through a 
series of ethanol washes and cleared: 
2.5 Plasma Coating 
Plasma coating is a surface modification technique that is often used in biomaterials engineering as a 
means of altering the hydrophilicity of a material 25,26. The process is usually performed under a low 
pressure oxygen environment, however, argon and conventional air compositions can also be used. 
Ionization of these elements is achieved by applying a high frequency voltage to the central coil of the 
chamber containing the gas. This creates highly reactive free radicals that will bind themselves to the 
material within the chamber. In an oxygen environment, this leads to the formation of oxygen 
containing groups on the surface of the material, increasing its hydrophilicity 27. Furthermore, the 
process of plasma coating has the additional benefit of sterilizing the material 27.   
Polymer scaffolds were plasma coated directly before use to avoid the effect of hydrophobic recovery 
taking place 28. Briefly, a Harrick Plasma cleaner and a PPC-FMG-2 PlasmaFlo gas flow mixer 
(Harrick Plasma) were used to plasma coat the scaffolds before cell seeding. This process was done 
after the scaffolds were punched out of their respective electrospun sheets. Oxygen was introduced 
into the system and the pressure was stabilised at approximately 500mTorr. Plasma coating was 
undertaken at 10.2 W for 60 s. Scaffolds were immediately removed and placed into sterilized PBS 
containing antibiotic/antimycotic treatment solution. 
54 
 
2.6 Mechanical Testing 
The mechanical properties of the scaffolds in this thesis were undertaken in tension, the predominant 
direction of force observed by vascular tissue 29. Studying and understanding the mechanical 
properties of any scaffold or device that is designed for implantation is of crucial importance. The 
mechanical properties of the host and implant need to fall within a tight band or else the unmatched 
loads can lead to complications down the line, and ultimately, failure of the implant and further 
damage to the native tissue 30,31. Synthetic materials have great difficulty in matching the mechanical 
properties of native vessels due to the native tissue’s unique mechanical features including non-
linearity (steep increase in Young’s modulus as pressure is increased), viscoelasticity (viscous time-
dependent strain response) and compliance (ability of the vessel to extend under pressure) 32. 
Compliance is of particular interest as this mechanical feature is very hard to mimic with synthetic 
materials. In clinical practice, arterial compliance is defined as how much the cross-sectional area of 
the artery distends when internal blood pressure increases 33. Designing scaffolds with mechanical 
properties that fall within the realm of native tissues is the first step to designing a successful scaffold. 
In vascular tissue engineering, this involves designing scaffolds with properties similar to the arteries 
that are either being healed or replaced. Strekelenburg et al. found that the saphenous vein has 
longitudinal and circumferential elastic moduli of 23.7 MPa and 4.2 MPa, and longitudinal and 
circumferential ultimate tensile strengths of 6.3 MPa and 1.8 MPa 34.Similarly, Soletti et al. noted a 
circumferential elastic modulus of 2.25 MPa for the saphenous vein 35.   
An Instron 3367 tensile testing machine (Instron, UK) was used for all mechanical characterization. 
The device was set up with a 50 N load cell. For the majority of studies a gauge length of 20 mm was 
used with an extension rate of 10 mm/min (50% strain per minute was always used to ensure 
consistency between studies and to ensure high resolution of data capture). Samples were fixed to a 
‘C’ shaped paper template to improve handleability of the samples and ensure the same gauge length 
was used every time. The width of each sample was measured using digital callipers and the thickness 
measured using a DMK 41 AU02 monochrome 1280 x 960 camera. 
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An incremental Young’s modulus method was used 1,36,37. Young’s modulus is a measure of the 
materials ability to withstand deformation when under tension or compression. Briefly, incremental 








where 𝐸𝑖𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙  is the Young’s modulus between two strain bands (denoted as 1 and 0 in the 
subscripts), 𝜎 is stress, 𝜀 is strain, 𝐹1 is the applied force at the upper strain band, 𝐹0 is the applied 
force at the lower strain band, 𝐴 is the cross-sectional area of the scaffold perpendicular to the 
direction of elongation, 𝐿0 is the original length at the lower strain band, and 𝐿1 is the final length at 
the upper strain band. Young’s modulus is calculated over a range of strains to show the evolving 
properties of the scaffold under extension. 
The ultimate tensile strength was calculated as the highest stress withstood by the scaffold. This was 
also used as the point at which the scaffold was deemed to have failed (failure strain). 
An incremental compliance method was used to characterise the different ECM concentration blended 
scaffolds. Compliance was measured using the following equation 




where 𝐶 is the compliance, ∆𝑉 is the change in volume and ∆𝑃 is the change in pressure. Values for 
∆𝑃 and ∆𝑉 between 0 and 5% strain were deduced from thin-wall pressure vessel theory. Briefly, the 
equation for circumferential stress was reorganized to give an equation that told us the representative 











where 𝜎𝑛 is stress, 𝑑𝑛 is the diameter of the representative cylinder, and 𝑡 is the thickness of the 
scaffold. Representative volume (𝑉𝑛) was calculated by treating the strip of scaffold as a cylinder and 
the strain as a volume increase to this cylinder (subscript n denoting that the value is at n% strain) 






where 𝑑𝑛 is the diameter of the representative cylinder and 𝑤 is the width of the scaffold.  
2.7 Contact Angle Measurement 
The term wettability refers to the ease at which a liquid will spread itself across or through a solid 
substrate and how easily it will adhere itself to the substrate 38. Water contact angle measurement is a 
common method of assessing the wettability of a material 39. The water contact angle is defined as the 
angle formed at the intersection of the liquid–solid interface. In this case, the liquid is a water droplet 
and the solid is the polymer scaffold being tested. A lower contact angle is indicative of a more 
hydrophilic substrate, whereas a higher contact angle is indicative of a hydrophobic substrate  40,41. 
Furthermore, studies have shown that altering the contact angle of a scaffold can have interesting 
effects on cell adhesion 25,42. 
Briefly, all contact angles were measured using the sessile drop method. This is the most commonly 
used method and relies on measuring the advancing contact angle between a water droplet and the 
substrate 43,44. All contact angles were measured on dry scaffolds. A 5 μL droplet of water was placed 
onto the scaffold using a pipette tip, and images were captured using a DMK 41 AU02 monochrome 
camera at a frequency of 5 Hz. Analysis of the scaffolds was done on ImageJ (NIH) using the 
LBADSA plugin at varying times after the water droplet made contact with the scaffold, as seen in 




Figure 10: LBASDA plugin for ImageJ measuring the contact angle of a hydrophobic and a hydrophilic 
substrate. The contact angle being measured is denoted by 𝜃𝐶𝐴. 
 
2.8 Scaffold Fibre Alignment/Orientation 
The fibre alignment and orientation of various biological substrates have been shown to have a drastic 
effect on cell survival, performance and morphology for a range of cell types 1,46–49. Furthermore, a 
scaffolds mechanical properties can be altered through the modulation of fibre orientation 50. Aligning 
fibres in parallel leads to a highly anisotropic scaffold with high stiffness along the axis of its fibres 
and low stiffness perpendicularly. On the contrary, a highly random fibre orientation will lead to an 
isotropic scaffold with similar mechanical properties along all its axes 1.  
The alignment/orientation of the fibres within each scaffold were assessed using the OrientationJ 
plugin for ImageJ 51. Briefly, SEM images of the scaffold’s fibres were imported into ImageJ and 
thresholded for analysis.  
2.9 Scaffold Porosity 
Scaffold porosity is a measure of the amount of empty space found within the scaffold. A high 
porosity suggests that there is a lot of empty space within the scaffold, and vice versa for a low 
porosity. In some cases the pores are highly interconnected (often the case with electrospun 
scaffolds), whereas sometimes the pore interconnectivity will be low even with a high porosity 
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(occurs more often in directional freezing). Studies have suggested that there is a connection between 
the scaffolds porosity and pore interconnectivity with overall cell survival, proliferation and 
migration 36,52–54. These studies tend to follow the trend that high pore interconnectivity and porosity 
are beneficial for cellular performance 55. In addition, the size of each pore is also very important, 
with most cells and tissue types having an optimal middle ground. Pores that are too small don’t allow 
for sufficient cell infiltration and nutrient transfer, whereas pores that are too large do not allow for 
adequate cell-cell interactions 54. Therefore it is very important to modulate the scaffold’s porosity for 
the particular cell type being studied.  
Scaffold porosity (%) was calculated using a DMK 41AU02 monochrome camera with the following 
equation: 






where V is volume, m is mass and ρ is density.  
2.10 Fourier Transform Infrared Spectroscopy 
Fourier Transform Infrared spectroscopy (FTIR) is a commonly used technique that obtains either an 
absorbance or emission spectrum from a substance 56. This method allows for the collection of a range 
of data over a wide spectral range, which is advantageous compared to traditional dispersive 
spectrometers as they only measure the intensity of a narrow range of wavelengths. FTIR has been 
widely used in tissue engineering to confirm the presence of various substances within biomaterials 
and tissues 42,57–60. They have been used to show that decellularization techniques do not destroy the 
native components of the tissue 61; ECM has been incorporated into polymeric scaffolds 42,60; and that 
specific substances have been successfully grafted onto polymeric scaffolds 58,59. The absorbance 
spectrum collected for a particular material can give a wide range of information regarding the types 
of bonds and substances present. Each peak along the spectrum is associated to a particular bond type 
which in turn is associated to a particular substance 62. For example, the peaks at 1655 cm-1 and 
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1550 cm-1 are associated with the amide I and amide II bonds, respectively 63. These bonds are found 
with collagen I and other ECM related proteins 63. 
FTIR spectra were recorded using a Nicolet iS10 spectrometer with a Smart iTX diamond attenuated 
total reflector (all from Thermo Fisher Scientific). Measurements were taken over a wave range of 
400-4000 cm-1 at a 1 cm-1 resolution using the OMNIC Spectra software (Thermo Fisher Scientific). 
FTIR spectra were used to ensure the integrity of the ECM was maintained during decellularization 
and to ensure the ECM was properly integrated into the electrospun fibres.  
2.11 Scaffold Seeding 
Scaffolds used for experiments were punched out using a 10 mm punch and soaked in 70% ethanol to 
remove them from the aluminium foil that they were collected on and to sterilize the scaffolds. 
Scaffolds are then transferred to a bio hood to ensure they remain sterilized. Scaffolds that were 
treated with plasma are soaked in PBS + 1% antibiotic/antimycotic before being transferred across to 
the bio hood. The scaffolds were then placed into a 48 well plate and soaked in serum free medium 
overnight to help with hydrophilicity. The medium was then removed prior to cell seeding. 
Cells were drip seeded at the required cell density in 20 μL of medium. This medium volume was 
kept as small as possible as it has been shown that scaffold seeding efficiency is increased when the 
seeding volume to scaffold volume ratio is kept as small as possible 64. The drop of medium was 
placed in the middle of the scaffold and allowed to soak through the scaffold for 30 mins. This 
ensures the cells are caught within the fibrous structure of the scaffold. An additional 30 μL of 
medium was added after 30 mins to ensure the cells are provided with sufficient medium. The volume 
of media is kept minimal and the incubation time until topping of up of media is kept long enough to 
help with cell binding as this has shown to lead to more efficient cell seeding 64. After another 90 
mins, the medium was topped up to 500 μL. Seeded scaffolds were fed every 48 hours. 
2.12 CellTiter-Blue Assay 
The CellTiter-Blue® (Promega, UK) assay is a fluorescence based method for measuring cell 
metabolic activity and thus cell viability. The assay works by the living cells converting a redox dye 
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called resazurin into a fluorescent end product called resorufin 65. Any non-viable cell will rapidly 
lose metabolic capacity and will therefore not produce a fluorescent signal 65. The resazurin is dark 
blue in colour and has very little fluorescence until it is changed to resorufin, which is pink and highly 
fluorescent at 579/584 nm. For most cells, there is a highly linear correlation between cell number and 
fluorescence, meaning that changes in cell viability can be considered as the same percentage change 
in cell number 65. 
The assay was run as per manufacturer’s protocol. Briefly, scaffolds were removed from their well-
plates, were washed thrice in PBS and then placed in new well-plates. A 1:4 ratio of CellTiter-Blue 
assay to cell culture medium was mixed together. This solution was added to the cell seeded scaffold 
and cultured for between 3 and 3.5 hours (this time should not be exceeded as it leads to assay 
saturation 65) . The reduced solution was then added to a black microplate in 100 μL samplings. 
Measurements were taken using a Modulus™ II microplate reader at excitation wavelength of 525 nm 
and emission wavelength of 580-640 nm. 
2.13 BCA Assay – Protein Quantification 
The Pierce™ BCA Protein Assay (Thermo Scientific) is a quantification method for measuring the 
total protein content of a solution. The assay works by the peptide bonds found within the protein 
reducing the cupric ions from the copper sulfate down to copper 66,67. There is a direct correlation 
between the amount of reduced copper ions and the amount of protein present. These copper ions then 
bind to the bicinchonic acid forming a purple complex that absorbs light at the 562 nm wavelength 66. 
The assay works through absorption and quantification is achieved by comparing the results with 
known protein standards. This assay has been widely used in tissue engineering, where it can be used 
to confirm the successful engraftment of proteins onto a polymeric scaffold and the rate of release of a 
protein from a scaffold 68–71.  
This assay was used to quantify the amount of protein being released during the media functionalizing 
experiments and the amount of protein being bound to the scaffolds during the soaking phase that 
followed on after the EDC/NHS treatment of scaffolds. All experiments were run as per 
manufacturers’ protocol. Briefly, 25 μL of unknown protein solution is pipetted into a clear bottomed 
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96-well plate along with 200 μL of BCA assay working reagent. This is done alongside known 
standards ranging from 0 to 2000 μg/mL. The well plate is mixed on shaking plate for 30 s before 
being incubated at 37°C for 30 mins. Absorbance is then measured at 560 nm using a Modulus™ II 
microplate reader.   
2.14 EDC/NHS Binding Method 
The EDC NHS surface activation method is an effective technique of activating the surface of a 
polymer to aide with the immobilisation of biomolecules 68. The method works by the 1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) activating the carboxyl groups on the polymer for 
reaction with the primary amines 72. This creates an unstable intermediate that can react with another 
amine. The N-hydroxysuccinimide (NHS) is then added to stabilize this intermediate by converting 
the unstable amine-reactive O-acylurea into a stable amine-reactive NHS ester. This process allows 
one side of the carboxyl group to be free for coupling with a ligand that already contains a free 
aldehyde group 68. The process is shown in Figure 11 68. The EDC/NHS surface activation method has 
been widely used to help with the grafting of proteins onto various different surfaces 73–75. 
The EDC/NHS method was used to help with the binding of proteins and cytokines found in the cell-
secretome functionalized media. Briefly, 5 mM of EDC and 5 mM of NHS were dissolved into 0.5 M 
of MES buffer at a pH of 5.7. The pH of the solution and the molarity of the EDC and NHS are both 
critical. The pH directly affects the half-life of the activation period of the EDC and NHS and the 
molarity of the solution affects whether or not complete activation of the surface is achieved or if by-
products are left on the scaffold 73. A lower pH (< 6.5) has been shown to drastically reduce the 
activity half-life of EDC and NHS from above 4 hours to below 30 minutes 76. Furthermore, it has 
also been found that over-treatment in EDC/NHS can lead to lower quantity of amide bonds being 
formed and that a pH of approximately 5-6 leads to a higher rate of amide bond formation 76. 
Therefore, selecting an appropriate pH is of crucial importance when trying to ensure an optimal 
amount of amide bonds are formed to increase the quantity of protein binding. On that note, scaffolds 
were bathed in the EDC/NHS solution for 30mins and were then washed thrice in PBS to remove all 
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remnant EDC/NHS. The scaffolds were then bathed in the protein solution (media in this instance) for 
4h to maximise the quantity of protein being bound to the scaffold. 
 
 
Figure 11: Schematic of how the 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/ N-
hydroxysuccinimide (NHS) process creates binding opportunities for proteins. In this case the protein is 
albumin. The EDC activates the carboxyl group for a reaction with a primary amine. This creates an unstable 
intermediate which is stabilized using the NHS. This process creates a stable amide bond for binding with a free 
aldehyde group  68. 
 
2.15 DNA Quantification 
DNA quantification was performed using the Quant-IT™ Picogreen® dsDNA assay (Promega). The 
assay has become popular for biological applications as it about 1000 times more sensitive than 
traditional absorbance methods 77. For most biological applications where sample sizes are quite 
small, a more sensitive method is required that can read below 250 ng/mL. This fluorescent nucleic 
acid stain is used to quantify double-stranded DNA and has a sensitivity as low as 0.25 ng/mL. All 
unknowns were compared to known DNA standards to give a numerical quantity of DNA in each 
sample 78.   
Samples were lyophilized and then digested in a papain solution containing 2.5 U of papain, 5 mM 
cysteine HCL and 5 mM EDTA in DNA free water (all Sigma-Aldrich, UK). Digestion lasted 24 h at 
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60°C with periodic vortexing to disrupt the samples to aide with digestion. The assay was run as per 
manufacturer’s protocol. Samples were measured for fluorescent intensity in a Modulus™ II 
microplate reader at an excitation wavelength of 490 nm and emission of 510-570 nm. 
2.16 Cell Staining 
2.16.1 Fluorescence Staining 
Fluorescence staining is a technique used with a fluorescent microscope to visualize particular 
biomolecules within the cell. The process works by targeting the antigens of these specific 
biomolecules with antibodies that bind to them at specific sites called epitopes. These antibodies are 
then targeted by specific fluorescent dyes that allow for the specific biomolecule to be visualized 
using a fluorescence microscope. Phalloidin is used to visualize the F-actin filaments found with the 
cell cytoplasm 79. Phalloidin-iFluor™ 514 Conjugate was purchased from Sigma and used on all cell 
types in this thesis. (The Phalloidin comes conjugated with a fluorescent dye meaning that the 
antibody has already been dyed and no second step of attaching a dye to the antibody is required). 
Likewise, 4’,6-diamidino-2-phenylindole (DAPI) was purchased from Sigma and used to areas within 
the cell that contain DNA. Specifically, DAPI binds to the AT regions of dsDNA and notes a 20 fold 
increase in fluorescence upon binding 80. DAPI (blue) is excited at 405 nm making it an ideal 
counterstain for phalloidin (green) or anything stained with a yellow, orange or red stain. Other 
fluorescently conjugated antibodies were used to visualize parts of the cell specific to the particular 
cell line. 
Briefly, cell seeded scaffolds were removed from their media and washed thrice in PBS, before being 
fixed in 10% v/v formalin solution in PBS for 30 mins. This was followed by three further PBS 
washes. Cells were then permeabilized in a 0.2% v/v Triton X-100 solution in PBS for 5 mins and 
then washed thrice in PBS. Cells were then placed in 1 µL/Ll of primary antibody in 1% v/v BSA in 
PBS overnight at 4ºC to allow for the antibodies to bind to the targeted antigens. This was followed 
by three PBS washes. Cells were then placed in 1 µL/mL of secondary fluorescent conjugate in 1% 
v/v BSA in PBS for 30 mins to allow the fluorescent dye to bind to the antibody. This was followed 
by a further three washes in PBS. 
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Cells were then stained with conjugated phalloidin at 1 µL/mL in 1% v/v BSA in PBS for 30 mins at 
room temperature. This was followed by three 5 min PBS washes to ensure no phalloidin remains 
unbound. Cells were then stained with conjugated DAPI at 300 nM in deionized water for 20 mins, 
then washed thrice in PBS for 5 mins per wash. Scaffolds were then imaged using a Coherent Anti-
Stokes Raman scattering microscope. 
2.16.2 Fluorescence Imaging 
Cell seeded fluorescently stained scaffolds were visualized using one of two microscopes. 
The first set up was a custom built multiphoton microscope 81. Coherent anti-stokes Raman scattering 
(CARS) imaging at 2911cm-1 was used to image the PCL scaffold fibres, whilst simultaneously 
exciting two photon fluorescence (TPEF) from Phalloidin and DAPI stained cells. CARS excitation 
was performed by overlapping the 1064 nm stokes beam with the 812.6 nm pump beam on to the 
sample using excitation power of 85 mW and 110 mW respectively. The 812.6 nm beam 
simultaneously excited TPEF, the signals were collected in the backscattered detection and spectrally 
separated using custom filter cubes. For CARS and Phalloidin a 649 nm long pass (LP) dichroic cube 
with a 660/13 nm and 542/50 nm bandpass filter was used. The DAPI signal was acquired 
consecutively using a 454/50 nm bandpass filter and a 570 nm Dichroic. All images were acquired 
using a 25x/1.05 N.A water immersion lens (XLPlanN, Olympus), providing a maximum field of 
view of 509 µm on the sample.   
The second set up is a Zeiss Axio Imager fluorescent microscope. This was used to image 
fluorescently stained cells through a variety of different filters. While this set up doesn’t allow for 
visualization of the scaffold fibres, it does allow for the several different fluorescent wavelengths to 
be imaged simultaneously. Images were processed using ICY or ImageJ. 
2.16.3 Osmium Staining for SEM 
Osmium staining is used to condition the cells so that they can be visualized using SEM. Osmium 
staining follows directly on from glutaraldehyde fixation. This allows for clear viewing of the cellular 
membrane and ECM components on the scaffold. Glutaraldehyde fixation causes rapid crosslinking of 
the proteins within the cells 82. Osmium tetroxide is then used as a lipid stain by embedding a heavy 
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metal directly into the cell membrane, thus creating a high electron scattering rate allowing for clear 
visualization of the cell membrane 83. Interestingly, osmium staining has been widely used to visualize 
cells in many tissue engineering applications 8,84–86. 
Briefly, cell seeded scaffolds were fixed overnight in 4% glutaraldehyde. A 1% osmium solution was 
diluted into deionised water and cell seeded scaffolds were stained for 30mins. The samples were then 
rinsed thrice in deionised water and then put through a set of dehydration steps and then left overnight 
in Hexamethyldisilazane (HDMS). The cell seeded scaffolds are now ready to be sputter coated and 
visualized using SEM. 
2.17 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) is a method of microscopy that produces an image by scanning 
the surface of an object with a beam of electrons. The electrons interact with the atoms located on the 
surface of the object which releases various signals that can be picked up by a detector. This allows 
for nanoscale topographies to be imaged 87. Many materials, such as polymers, absorb electrons which 
can change the trajectory of the electrons that are being sent towards the specimen. This can create 
blurred images, therefore, most objects need to be sputter coated in order to visualize them using 
SEM. 
Briefly, two different SEM set ups were used for this thesis. The first set up used was a Hitachi S4700 
fuelled emission scanning electron microscope (SEM, Hitachi) with a 5 kV accelerating voltage and a 
working distance of 12 mm. This set up was used for the ECM blended scaffold studies utilising 
endothelial cells. The second set up used was a Hitachi TM4000 tabletop SEM (Hitachi) with a 15 kV 
accelerating voltage and a 10 mm working distance. This set up was used for the remainder of the 
studies. 
2.17.1 Sputter Coating 
Sputter coating is a sample preparation method employed to improve the quality of the information 
gathered by the SEM 88. Many materials, such as a range of non-conductive polymers and biological 
materials will lead to charging in certain areas of the sample, influencing the image information. 
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Therefore, applying a thin layer (< 10 nm) of conductive material such as gold, platinum or palladium 
reduces the effect of charging and increases the quality of information captured by the SEM. 
Two different sputter coating methods were used. One method used an Elmscope SC500A splutter 
coater with gold–palladium (60:40). The second method used an Elmscope FLM-007 with gold. 
2.18 Reverse Transcription Polymerase Chain Reaction 
Reverse transcription polymerase chain reaction (RT-qPCR) is a method used to quantify the genes 
expressed by cells. Firstly, the RNA is extracted from the cells using standard Tri-Reagent 
(Invitrogen, ThermoFisher) methods and purified using a Qiagen RNeasy spin column system 
(Qiagen). This RNA is then reverse-transcribed into complementary DNA (cDNA) using a reaction 
based around reverse transcriptase (Promega). The cDNA is then used with real-time polymerase 
chain reaction using a LightCycler® 480 Instrument II (Roche Life Science) and Sensifast™ SYBR® 
High-ROX system (Bioline). This final step uses a specific primer sequence to target a particular area 
along the DNA strand associated with that primer. As each cycle passes, the quantity of DNA 
associated to that particular primer is doubled, binding itself to SybrGreen. This continues until the 
fluorescence reaches a threshold value, whereby the number of cycles required to reach this value is 
recorded (Ct). This Ct value is then used to quantify the amount of RNA present in the original sample 
using the 2−∆∆𝐶𝑡 method 89,90. This method is a means of relative quantification of a target gene in the 
group of interest to that of the same gene in a control group, whilst normalizing it to a housekeeping 
reference gene, in this case GAPDH. 
Briefly, 
∆∆𝐶𝑡 = ∆𝐶𝑡𝑆 − 𝐶𝑡𝑅 = (𝑆𝑇𝐺𝐶𝑡 − 𝑆𝑇𝐻𝐾𝐺𝐶𝑡) − (𝑅𝑇𝐺𝐶𝑡 − 𝑅𝑇𝐻𝐾𝐺𝐶𝑡) 
where 𝑆𝑇𝐺𝐶𝑡 is the is the Ct value of the subject target gene, 𝑆𝑇𝐻𝐾𝐺𝐶𝑡 is the Ct value of the subject 
housekeeping gene, 𝑅𝑇𝐺𝐶𝑡 is the is the Ct value of the reference target gene, and 𝑅𝑇𝐻𝐾𝐺𝐶𝑡 is the Ct 




This value for ∆∆𝐶𝑡 is then used to find the fold difference in gene expression between the two 
samples: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  2−∆∆𝐶𝑡 
This works out as any value below 1 representing a relative downregulation of that gene and anything 
above 1 a relative upregulation. All RT-qPCR data is plotted on a log axis as to ensure all 
downregulations are represented equally in size to upregulations.  
A variety of different primer sequences were used to target specific genes in both endothelial cells and smooth 
muscle cells. In all studies, gene expression levels were normalised to the expression of the housekeeping gene 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). These primer sequences can be seen in  
Table 3. 
 
Table 3: Primer sequences used for gene analysis of HUVECs and HUVSMCs. 
Gene Primer Sequence 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Matrix metalloproteinase-1 
MMP1 (forward) CGGTTTTTCAAAGGGAATAAGTACT 
MMP1 (reverse) TCAGAAAGAGCAGCATCGATATG 
Matrix metalloproteinase-2 
MMP2 (forward) CGCTCAGATCCGTGGTGAG 
MMP2 (reverse) TGTCACGTGGCGTCACAGT 
Tissue inhibitor of 
metalloproteinases-2 
TIMP2 (forward) AATGCAGATGTAGTGATCAGG 
TIMP2 (reverse) TCTATATCCTTCTCAGGCCC 
Vascular endothelial growth 
factor 
VEGF (forward) AGACCAAAGAAAGATAGAGCAAGACAAG 
VEGF (reverse) GGCAGCGTGGTTTCTGTATCG 
Platelet endothelial cell 
adhesion molecule 
CD31 (forward) ACTGGACAAGAAAGAGGCCATCCA 
CD31 (reverse) TCCTTCTGGATGGTGAAGTTGGCT 
Actin alpha 1 
α-actin1 (forward) CCGCCCAGAAACTAGACACA 
α-actin1 (reverse) CAGCGATCCCAGGGTACATC 
Myocardin 
Myocardin (forward) GGGTCTGAGCATTCCTTGCT 
Myocardin (reverse) CTGGACGTTTCAGTGGTGGT 
Mesenchyme homeobox 2 MEOX-2 (forward) AAAAGCGACAGCTCAGACTC 
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MEOX-2 (reverse) TTGCTGTCCACCCTTTACCC 
Interleukin 1 alpha 
IL1-α (forward) GCGTTTGAGTCAGCAAAGAAG 
IL1-α (reverse) GCCGTGAGTTTCCCAGAAGA 
Intercellular Adhesion 
Molecule 1 
ICAM1 (forward) CCTTCCTCACCGTGTACTGG 
ICAM1 (reverse) AGCGTAGGGTAAGGTTCTTGC 
Basic Fibroblast Growth Factor 
FGF2 (forward) CACCTATAATTGGTCAAAGTGGTTG 
FGF2 (reverse) AAACGAGGGAGAAAGGATGGA 
Hypoxia-inducible factor 1-
alpha 
HIF1-α (forward) ACTTGGCAACCTTGGATTGG 
HIF1-α (reverse) GTGCAGTGCAATACCTTCCA 
Nitric Oxide Synthase 3 
eNOS (forward) AGATGTTCCAGGCTACAATCCGCT 
eNOS (reverse) TGTATGCCAGCACAGCTACAGTGA 
 
2.19 Statistical Analysis 
Statistical analysis was performed using Minitab software. For all data sets, the mean and standard 
deviation were calculated. The number of biological replicates are displayed under the graphs in each 
individual chapter, with a minimum of 3 biological replicates being used for statistical analysis. The 
tests used in this thesis include the one-way analysis of variance (ANOVA) with Tukey’s or Fisher’s 






















Currently, vascular diseases (a subcategory of cardiovascular disease which looks at the vessels) such 
as coronary heart disease, peripheral arterial disease and strokes account for upwards of 30% of all 
deaths in Europe 1. To treat this, approaches such as bypass grafting are implemented. Bypass grafting 
is a surgery that involves diverting flow around an arterial blockage by grafting in an alternative path 
for the blood to flow  2. This surgery is often used in the treatment of coronary heart disease (blockage 
in the coronary artery) and peripheral arterial disease (blockage in arteries in the arms and legs). This 
is either done with a synthetic material, such as PTFE, or by using an autologous vessel such as the 
saphenous vein or the internal thoracic artery 3. These autologous vessels represent the gold standard 
for bypass grafting, especially for smaller vessel bypasses (< 6mm), as they are associated with much 
higher patency rates compared to their synthetic counterparts (80-90% for the saphenous vein after 5 
years compared to 20-70% for the PTFE conduit) 3. However, there are only a finite amount of vessels 
that can be harvested for bypass grafting, and patients who are in need of a bypass graft will often 
have damaged autologous vessels that are not of the standard required for surgery 4. Therefore, there 
is a clear need for an easily manufacturable synthetic alternative that can achieve higher patency rates. 
Currently, a wide array of strategies are being investigated to come up with novel treatment methods 
for vascular disease. These include mechanical cues, biochemical cues (incorporation of native ECM, 
protein binding, etc.) and bioelectric cues (electrical stimulation) 3,5–10. An optimized environment can 
be created by providing the correct physical cues to the cells through altering the topographical 
features of the scaffold 11,12. For example, it has been shown with a human kidney primary epithelial 
cell line that fibre diameter and fibre orientation have dramatic effects on cell morphology and the 
expression of key genes 13. Likewise, a study looking at the effect of fibre diameter on seeded 
chondrocytes found that a reduction in fibre diameter increased collagen II and integrin expression, 
two key phenotypic markers 14. Furthermore, recent work has shown that including nano-
topographical features onto a PCL mesh had the effect of promoting endothelial cell proliferation and 
adhesion compared to the smooth PCL mesh 15. 
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Electrospinning is an exciting avenue that allows for a wide range of scaffold morphologies to be 
created 13,16. This method has been used in many aspects of tissue engineering to mimic the structure 
of the native ECM, providing the cells with the correct mechanical cues, allowing for improved 
environments for cell adhesion, migration and proliferation 17. Herein, the present study proposes 
altering the fibre size of PCL electrospun scaffolds to study how this aspect of the scaffold 
morphology affects the performance of two vascular cell types: human umbilical vein endothelial 




Part A: Optimizing Scaffold Morphology for Endothelial Cells 
3A.1 Introduction 
Angiogenesis is a process by which endothelial cell proliferation and remodelling leads to the 
formation of new blood vessels 18. This is the aim of vascular tissue engineering, whereby an area of 
damaged or degenerated tissue can be healed through vascularization. One of the major components 
of the vessel is the endothelium, which is made up of a monolayer of endothelial cells 19. This is one 
of the main constituents of the vessel that affects bypass graft patency due to its direct contact with 
the flowing blood. This is where thrombosis, blood clotting and hyperplasia occur, and to some extent 
infection as well 19. Therefore, one of the major aims when developing new bypass grafts is to create a 
healthy layer of endothelial cells organized into a tubular network 20. This can happen under the 
correct environmental conditions, whereby endothelial cells communicate with each other through the 
release of angiogenic paracrinal factors 21. 
As previously mentioned, it has been shown that adding topographical features of the nanometre scale 
onto smooth electrospun PCL fibres had the effect of increasing endothelial cell adhesion and 
proliferation 17. This suggests that endothelial cells are very sensitive to their local topographical 
features and strengthens the case for studying the effect that scaffold fibre diameter has on seeded 
endothelial cells. Therefore, the present study has looked at how altering the diameter of the 
individual fibres within an electrospun scaffold affects seeded endothelial cells.   
3A.2 Methods and Materials 
3A.2.1 Electrospinning 
Polycaprolactone (Mn = 80,000 Da) was either dissolved into HFIP or a 5:1 mixture of 
Chlorofrom:Methanol (C:M) (Sigma Aldrich) at varying concentrations to achieve four different 
solutions (Table 4). Briefly, the electrospun fibres were spun as one continuous fibre onto an 
aluminium foil covered 8 cm diameter rotating mandrel. Scaffolds were subsequently stored at 4°C. 
All scaffold analysis was performed on ImageJ. A schematic of the experimental process is shown in 
Figure 12. More details can be seen in Section 2.1. 
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S – 1.64 µm 8 HFIP 0.4 1 6 11 +10.6 -2 250 
M – 2.95 µm 12 HFIP 0.4 1.7 8.5 15 +14 0 250 
L – 3.37 µm 14 5:1 C:M 0.8 3 18 19 +15 -4 250 
XL – 4.83 µm 19 5:1 C:M 0.8 4 20 23 +18 -4 250 
 
 
Figure 12: Schematic representation of the electrospinning process with increasing fibre diameters. Four 
different electrospinning set-ups were used to achieve the four different fibre diameters. 
 
3A.2.2 Scanning Electron Microscopy 
Scaffolds were imaged using a Hitachi TM4000 tabletop SEM (Hitachi) with a 15 kV accelerating 
voltage and a 10 mm working distance. These scaffolds were sputter coated with an Elmscope FLM-
007 using gold. More details can be found in Section 2.5. 
PCL/solvent 
electrospinning solution 
PCL fibres electrospun 
onto a rotating mandrel 
Four different scaffolds with increasing fibre diameter 
74 
 
3A.2.3 Fibre and Pore Properties 
Scanning electron images were analysed using ImageJ software (NIH). Images were imported into the 
software and thresholded. They were then analysed using the DiameterJ plugin (fibre diameter 
analysis) and the OrientationJ plugin (fibre orientation analysis) 22. More details can be found in 
Section 2.9. 
3A.2.4 Mechanical Testing 
Tensile properties were measured using an Instron 3367 testing rig. Measurements were performed on 
40 x 5 mm strips of electrospun scaffold with a starting gauge length of 20 mm. Scaffolds were 
stretched at 10 mm/min until failure. Incremental Young’s moduli were calculated. More details can 
be found in Section 2.7. 
3A.2.5 Contact Angle Measurement 
Contact angle was measured on each scaffold using a DMK 41AU02 monochrome camera at a 
frequency of 5 Hz. Briefly, a 5 µL droplet of water was placed on the scaffold whilst images were 
being taken. Analysis was performed on ImageJ using the LBADSA plugin 23. More details can be 
found in Section 2.8. 
3A.2.6 Scaffold Porosity 
Scaffold porosity was calculated using the density of PCL, weight of the scaffold and volume of the 
scaffold. Volume was measured using a DMK 41AU02 monochrome camera. All scaffolds were 
punched out using a 10 mm diameter punch. More details can be found in Section 2.10. 
3A.2.7 Cell Culture and Scaffold Seeding 
HUVECs were expanded to passage 7 in a 5% CO2/37°C atmosphere. HUVECs were expanded using 
MCBD 131 medium supplemented with 5% v/v FBS; 1% v/v L-glutamine; 1% v/v 
penicillin/streptomycin; 1 mg/L hydrocortisone; 50 mg/L ascorbic acid; 2 μg/L fibroblast growth 
factor; 10 μg/L epidermal growth factor; 2 μg/L insulin-like growth factor; and 1 μg/L vascular 
endothelial growth factor. HUVECs were lifted for scaffold seeding at 80% confluence. Briefly, 
10 mm diameter scaffolds were punched out and sterilized in 70% ethanol before being soaked in 
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basal medium overnight. Scaffolds were then placed in a 48-well plate. 20,000 cells/cm2 were drip 
seeded in 30 µL of medium onto the middle of the scaffold. After 30 mins a further 20µL of medium 
was added to stop the cells from drying out. After a further 30mins, medium in each well was topped 
up to 500 µL. Medium was replaced every 48 h. More details can be found in Sections 2.3 and 2.12. 
3A.2.8 CellTiter-Blue® Cell Viability Assay 
The assay was performed at 1, 6 and 12 days as per manufacturer’s instructions. Measurements were 
taken at ex: 525 nm and em: 580-640 nm. More details can be found in Section 2.13. 
3A.2.9 Cell Staining 
Scaffolds used for cell staining were washed thrice in PBS and fixed in 10% v/v formalin solution in 
PBS overnight. Cells were permeabilized in 0.2% v/v TritonX-100 solution in PBS for 5mins, 
followed by three PBS washes. Scaffolds were then stained in 0.1% v/v 1000X Phalloidin-iFluor-
TM514 conjugate and in DAPI. More details can be found in Section 2.17. 
Cell seeded scaffolds were visualized after 12 days using a previously described osmium based 
method 24. Briefly, samples were stained in 0.1% osmium tetroxide and visualized using a Hitachi 
TM4000 tabletop SEM with a 15 kV accelerating voltage and a 10 mm working distance. More 
details can be found in Section 2.17. 
3A.2.10 Measuring Cell Infiltration 
Cell infiltration was measured using DAPI and phalloidin stained Z-stack images on ImageJ (NIH) 
whereby depth of cell intravasasion was measured.  
3A.2.11 Reverse Transcription Quantative Polymerase Chain Reaction (RT-qPCR) 
RNA was extracted from the cell seeded scaffolds using a Tri-Reagent method and purified using 
Qiagen’s RNeasy spin colum system. Real-time polymerase chain reaction was performed using a 
LightCycler® 480 Instrument II and Sensifast™ SYBR® High-ROX system. Forward and reverse 
sequences were taken from literature and are displayed in Table 5. Relative quantification of RT-PCR 
results was carried out using the 2−∆∆𝑐𝑡 method 25. Gene expression levels were expressed relative to 
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GAPDH (housekeeping gene) and normalised to 70% confluent HUVECs on tissue culture plastic. 
More details can be found in Section 2.18. 
Table 5: Primer sequences used for RT-qPCR to measure gene expression from the seeded HUVECs 
Gene Primer Sequence Reference 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
20 
GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Matrix metalloproteinase-1 
MMP1 (forward) CGGTTTTTCAAAGGGAATAAGTACT 
20 
MMP1 (reverse) TCAGAAAGAGCAGCATCGATATG 
matrix metalloproteinase-2 
MMP2 (forward) CGCTCAGATCCGTGGTGAG 
20 
MMP2 (reverse) TGTCACGTGGCGTCACAGT 
Tissue inhibitor of 
metalloproteinases-2 
TIMP2 (forward) AATGCAGATGTAGTGATCAGG 
20 
TIMP2 (reverse) TCTATATCCTTCTCAGGCCC 
Vascular endothelial growth 
factor 
VEGF (forward) AGACCAAAGAAAGATAGAGCAAGACAAG 
20 
VEGF (reverse) GGCAGCGTGGTTTCTGTATCG 
Platelet endothelial cell 
adhesion molecule 
CD31 (forward) ACTGGACAAGAAAGAGGCCATCCA 
26 
CD31 (reverse) TCCTTCTGGATGGTGAAGTTGGCT 
 
3A.2.12 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 











3A.3.1 Scaffold Properties 
By altering the electrospinning parameters, four different fibre morphologies were achieved. Firstly, 
increasing fibre diameters of 1.64 ± 0.18 µm, 2.95 ± 0.16 µm, 3.37 ± 0.27 µm and 4.83 ± 0.49 µm 
were noted across the four scaffolds (p < 0.001 between each group). This meant that all the 
morphologies could be considered as being different. The four different fibre morphologies can be 
seen in Figure 13. 
 
Figure 13: The four different scaffold morphologies with increasing fibre diameters. Scaffold thickness ranged 
from approximately 0.2 mm in the small fibre diameter to 0.5 mm in the extra-large fibre diameter. 
 
Secondly, the fibre orientation of all four scaffolds appeared to be very similar. Likewise all four 
scaffolds had a uniform random alignment. These can be seen in Figure 14. The electrospinning 
parameters were set up so that the mandrel rotational speed was low enough to ensure that the fibres 




Figure 14: Fibre orientation of all four scaffold morphologies. All four scaffolds appear to have a random 
orientation with no clear peaks at any angle. 
 
Finally, a very strong correlation between fibre diameter and pore width was noted between the four 
scaffold morphologies (R2 =0.9997). These can be seen in Figure 15. Pore diameter ranged from 
79 
 
8.4 ± 3.7µm in the small fibre scaffold up to 23.3 ± 9.0µm in the extra-large fibre scaffold (Table 6). 
This high correlation between fibre diameter and pore width was expected. 
 
Figure 15: Correlation between fibre diameter and pore width. A strong correlation with an R2 = 0.9997 noted. 
Error bars = SD. 
 
Furthermore, it was noted that scaffold porosity decreased as fibre diameter increased. The small fibre 
had a porosity of 91.0 ± 1.6%, decreasing all the way down to 83.3 ± 0.9% in the extra-large fibre 
scaffold (Table 6). 
Table 6: Physical and tensile mechanical properties of the four different scaffold morphologies. 
*Results with matching symbols (# and &) are significantly different to each other (p<0.05). Results with the $ symbol are significantly 
different (p<0.05) to all other results. 
3A.3.2 Scaffold Mechanical Properties 
Mechanical characterization of the scaffolds led to some interesting results. Firstly, the ultimate 




















S 1.64 ± 0.18 1.08 ± 0.17&# 843 ± 143&# 91.0 ± 1.6 110.8 ± 7.7$ 8.4 ± 3.7 4.10 ± 0.33$ 2.17 ± 0.25$ 
M 2.95 ± 0.16 1.50 ± 0.09# 1202 ± 62# 89.6 ± 2.4 128.2 ± 4.0 14.7 ± 4.8 6.50 ± 0.72 2.99 ± 0.46 
L 3.37 ± 0.27 1.55 ± 0.16& 1071 ± 21& 83.9 ± 1.1 129.1 ± 2.5 16.4 ± 6.7 5.80 ± 0.36 3.16 ± 0.48 
XL 4.83 ± 0.49 1.26 ± 0.06&# 855 ± 120&# 83.3 ± 0.9 131.5 ± 1.1 23.3 ± 9.0 5.77 ± 0.39 3.66 ± 0.28 
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dropped in the small fibre and extra-large fibre (p values ranging from 0.001 to 0.068) (as seen in 
Table 6). Representative stress-strain curves can be seen in Figure 16. 
Similarly, scaffold failure strain was highest in the medium and large fibre scaffold, but dropped 
significantly in the small and extra-large scaffold (p values ranging from 0.001 to 0.019) (as seen in 
Table 6).  
 
Figure 16: Representative stress vs strain curves for all four scaffold morphologies. Failure strain and ultimate 
tensile strength were highest in the medium and large fibre diameters.  
 
The stiffnesses at the 5-10% strain band were 2.17 ± 0.25, 2.99 ± 0.46, 3.16 ± 0.48 and 
3.66 ± 0.28 MPa for the small, medium, large and extra-large scaffolds, respectively. This represents 
an increase in stiffness at each subsequently larger fibre diameter with a strong correlation between 
the two results (R2 = 0.9667). Furthermore, the small fibre scaffold had significantly lower stiffness at 
both the 0-5% (p < 0.001) and 5-10% (p < 0.017) strain bands compared to the three other fibre 
diameters. Interestingly, the larger the fibre diameter, the more stiffness/elasticity the scaffold 
maintained as the strain band was increased (Table 6). For example, the relative drop in stiffness 




Contact angle measurements lead to some interesting findings. There was a general trend in increasing 
contact angle as fibre size increased – ranging from 110.8 ± 7.7° in the small fibre up to 131.5 ± 1.1° 
in the extra-large fibre. A significant difference was noted between the contact angles on the small 
fibre scaffold compared to the three other scaffolds (p < 0.001) (as seen in Table 6). 
3A.3.3 Cell Imaging 
SEM images of osmium stained HUVECs growing on all four scaffold morphologies showed that the 
cells were spreading across the fibres and had several binding sites (as seen in Figure 17). The images 
also show that the cells were starting to adopt a slightly more elongated HUVEC like morphology 
when bound onto the largest fibre diameter scaffold.  
 
Figure 17: SEM images of osmium stained HUVECs bound to the four scaffold morphologies. HUVECs have 




Likewise, nuclei and f-actin staining (Figure 18) showed that the larger fibres led to the HUVECs 
spreading out across the fibre, adopting a more desirable elongated shape. This spreading became 
more evident in the later time points. In contrast, the small fibre showed a more rounded cell shape, 
which may indicate apoptosis 28.  
 
Figure 18: DAPI (nuclei) and phalloidin (f-actin) stained HUVECs on all four scaffolds after 1, 6 and 12 days 
of culture. HUVECs appear more elongated (phenotypic morphology) on the Extra-large fibre scaffold. 
 
Further analysis of nuclei and f-actin stained scaffolds was achieved using Z-stack imaging. This 
allowed for cell infiltration to be assessed. The larger fibre scaffold with larger pores showed 
infiltration up to approximately 80 μm, compared to approximately 25-30 μm of infiltration for the 




Figure 19: Z-stack images of DAPI (nuclei) and phalloidin (f-actin) stained HUVECs on all four morphologies. 
The largest fibre diameter showed deeper cellular infiltration compared to three smaller fibre morphologies. 
Infiltration depths of approximately 80µm were noted for the extra-large fibre scaffold compared to 25-30 µm 
for the three smaller fibre diameter scaffolds. 
 
3A.3.4 Cell Viability 
Results showed that the extra-large fibre led to significantly higher cell viability after 12 days 
compared to the three other scaffolds (p < 0.001). Relative fluorescence units (RFU) values were 
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approximately 200% to 300% higher (Figure 20). Furthermore, higher viabilities were also noted in 
the medium and extra-large scaffolds after 24h compared to the small scaffold. 
 
Figure 20: Cell viability of HUVECs on all four scaffolds after 1, 6 and 12 days of culture. Significantly higher 
cell viability was noted in the XL scaffold after 12 days compared to the three other fibre diameters. S=small, 
M=medium, L=large and XL=extra-large. N=4, error bars = SD. *p < 0.05, **p < 0.01 
 
3A.3.5 Reverse Transcription Quantitative Polymerase Chain Reaction 
Interesting trends in gene expression were noted across the four scaffold morphologies (Figure 21). 
Most notably, CD31 expression was significantly higher in the extra-large fibre scaffold after 6 days 
compared to the medium fibre diameter. While no other significance was noted in the CD31 
expression, there was an evident trend with the extra-large scaffold having higher relative expression 
than the three other fibre sizes at both 6 days and 12 days of culture. MMP1, MMP2 and TIMP2 all 
showed very similar results to each other. In all cases the small fibre diameter showed a significantly 
lower relative expression at 12 days compared to 6 days. Furthermore, MMP1 expression at 12 days 
on the small fibre scaffold was significantly lower than the 3 other fibre diameters. The other three 
morphologies did show downregulations between 6 and 12 days, however, none of these were 





Figure 21: RT-qPCR results for five different genes on all four scaffold morphologies. All results were 
normalised to 70% confluent HUVECs on tissue culture plastic. The expression of CD31 was significantly 
higher in the XL scaffold after 6 and 12 days compared to the three other morphologies. N=5, error bars = SD. 
*p < 0.05, **p < 0.01, ***p < 0.001. 
 
3A.4 Discussion 
When studying endothelial cells in combination with novel materials for vascular tissue engineering, 
it is of crucial importance that the concept of angiogenesis is considered. As previously mentioned, 
angiogenesis is a process by which endothelial cell proliferation and remodelling leads to the 
formation of new blood vessels 18. In this study, electrospinning was shown to offer a flexible solution 
for the manufacture of scaffolds for vascular tissue engineering. Four scaffold morphologies were 
created with increasing fibre diameters: 1.64 ± 0.18 µm, 2.95 ± 0.16 µm, 3.37 ± 0.27 µm and 4.83 ± 
0.49 µm, with significant differences noted between all four scaffolds. They were manufactured using 
PCL, which has FDA approval for various uses in vivo due to its biocompatibility and tailorable 
bioresorption properties 29,30. 
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Fluorescence imaging of cell seeded scaffolds led to some interesting results. Firstly, in the 
conventional fluorescence images (Figure 18), a clear cellular elongation and spreading of the cell’s 
morphology can be noted on the extra-large and large scaffolds, becoming more obvious after 6 and 
12 days. In contrast to this, the small fibre (and to some extent the medium fibre) appears to show 
more rounded cells, especially after 12 days, which may indicate apoptosis 28. This phenomenon may 
be caused by the fibre size and/or pore size, with evidence shown in other studies examining the effect 
of electrospun scaffold topography on cellular performance 13,15,31. Secondly, Z-stack imaging showed 
that the extra-large scaffold morphology aided cell infiltration after 12 days of culture. Cells were 
seen to at depths of approximately 80 µm, compared to 25 µm for the three other scaffolds. A 
HUVEC is approximately 20-30 µm in diameter, meaning that the extra-large scaffold is the only one 
with pore sizes ‘large enough’ to allow for a full sized HUVEC to pass through without altering its 
shape 32. Furthermore, a large fibre dimeter and pore size means the HUVEC can grow perpendicular 
to the top of the scaffold. While this may seem counterintuitive as previous studies have typically 
tried to grow a monolayer of endothelial cells on the surface; this infiltration and 3D cell culture could 
be helping with cell survival (higher cell viability, Figure 20) and with the quantity of angiogenic 
genes being actuated (PCR results, Figure 21). It has been shown in many cases that a 3D cell culture 
is favourable in relation to gene expression as it more accurately captures the morphological 
characteristics of the native ECM 33. This has also been shown when using human coronary artery 
endothelial cells, where 3D culture showed a significant increase in the expression of key proteins 
compared to 2D culture 34.  
On this note, gene expression results showed some interesting trends. While none of the VEGF gene 
expression results showed any significance, all four scaffold morphologies showed a relative increase 
in gene expression between 6 and 12 days, suggesting that VEGF expression is predominantly driven 
by the cell’s maturity, as opposed to scaffold morphology. This trend has been noted before when 
studying HUVECs. Zhang et al. noted a doubling in the relative gene expression of VEGF from 
HUVECs between 7 and 14 days, which falls within the values noted in this study 35. 
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The same applies for MMP1, MMP2 and TIMP2, whereby all four morphologies showed a relative 
decrease in gene expression after 12 days compared to 6 days. This, like the results for VEGF, suggest 
that the expression of these particular genes is mediated more by the cell’s maturity rather than the 
scaffold’s morphology. However, some trends were noted between the four scaffold morphologies. 
Most notably, all three genes were significantly downregulated in the small fibre scaffold between 6 
and 12 days, as opposed to the other morphologies whereby a relative downregulation was still noted, 
albeit without significance. This suggests that while cell maturity is playing a role in the expression of 
these genes, the smaller fibre morphology is also having an effect. MMP1 and MMP2 are two genes 
associated with the remodelling of ECM proteins (collagen and gelatin, respectively). Their 
downregulation means the cells are not trying to turnover ECM, suggesting homeostasis within the 
cell microenvironment 36. Furthermore, an upregulation of these genes is associated with a variety of 
degenerative diseases 37. 
Additionally, an upregulation in CD31 was noted in the extra-large scaffold compared to the three 
other scaffolds. CD31, also known as PECAM1 is an angiogenic gene that is heavily involved in 
endothelial cell motility and endothelial cell-cell association that is required for their reorganization 
into a tubular network 21. Therefore, a relative upregulation of this gene is desirable in the short run 
where cellular reorganization is one of the main aims. However, overexpression of this gene, like 
many other angiogenic genes, is associated with cancer and tumour formation 38,39. Therefore, finding 
a point whereby endothelial cell modulation leads to the creation of new vasculature without leading 
to tumour formation is of crucial importance. A significant relative upregulation in CD31 was noted 
in the extra-large scaffold after 6 days compared to the medium scaffold and the 70% confluent 
HUVECs on tissue culture plastic. Relative increases were also noted between the extra-large scaffold 
and the three other morphologies at both 6 and 12 days, albeit not significant. This can either be 
explained by the larger fibres creating a more favourable environment for the cells, or by the increase 
in pore size leading to infiltration of cells, creating a more ‘3D-like’ microenvironment. No trend in 
data could be noted between the three other morphologies suggesting that the increase from 3.37 µm 
to 4.83 µm (with an increase in pore size too) ultimately led to this increase in CD31 expression. 
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Therefore, with the final aim of creating an environment most suited for endothelial cells to 
proliferate into a healthy endothelium, the results suggest that a fibre and pore diameter similar to that 
of the extra-large scaffold is the best candidate. 
The tensile testing results exposed intriguing findings in how fibre diameter modified the mechanical 
properties of the four scaffolds. Firstly, the ultimate tensile strength (UTS) was found to be 
significantly lower in the small and extra-large scaffolds when compared to the medium and large 
scaffold. It is interesting to note that the middling fibre diameters had the effect of increasing UTS. 
Similarly, the failure strain was significantly higher in the medium and large fibre diameter compared 
to the small and extra-large fibre diameters. This finding may be linked to the increase in UTS noted 
in these same scaffolds and warrants further study. Furthermore, it was noted that the stiffness of the 
small diameter fibre was significantly lower than that of the three larger fibres for both the 0-5% and 
5-10% strain bands. Moreover, the larger the fibre diameter the more stiffness it maintained as it was 
stretched into the 5-10% strain band. This particular phenomena may be a result of the lower porosity, 
leading to increased bulk properties and therefore merits further research.  
Additionally, all four scaffolds had stiffnesses that were found to fall within the range of values noted 
in native vessels, such as the saphenous vein. For example, Stekelenburg et al. found that the 
saphenous vein had longitudinal and circumferential elastic moduli of 23.7 MPa and 4.2 MPa 40. 
Similarly, Soletti et al. noted a circumferential elastic modulus of 2.25 MPa for the saphenous vein 41. 
These circumferential elastic moduli are in a similar realm to the four elastic moduli noted in this 
study at the 0-5% and 5-10% strains; with values ranging from 2.17 ± 0.25 MPa up to 
6.50 ± 0.72 MPa depending on strain range and fibre diameter. 
A further interesting finding was that as fibre diameter was increased, the scaffold’s porosity 
decreased. This finding has been noted before when electrospinning PCL, Pham et al. noted that as 
fibre diameter increased from 2 μm to 8 μm, the porosity of the scaffold decreased from 
approximately 89% down to 83%, which is in line with the results found in this study 42. 
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One of the major limitations of this study is the inability to differentiate between whether fibre 
diameter or pore width was having the major effect on the seeded HUVECs. A very strong correlation 
between fibre diameter and pore width was noted (R2 = 0.9997). One issue with electrospinning is that 
these two morphological characteristics are somewhat interconnected, with a study by Pham et al. 
showing a linear correlation between the two characteristics 42. While this in itself is an interesting 
finding, it makes it difficult to distinguish between which aspect had the effect on cellular 
performance. A further limitation is that the full spectrum of fibre diameters was not analysed. Only a 
limited number of scaffold morphologies could be studied and the apparatus only allowed for fibre 
diameters of up to approximately 5 μm. While these limitations merit further study in an attempt to 
gain an overarching image of exactly how scaffold morphology is affecting the seeded endothelial 
cells; the present study has shown that cellular performance can be influenced through altering the 
scaffold’s fibre diameter. 
3A.5 Conclusions 
In this study, four different scaffolds with incrementally larger fibre diameters ranging from 1.64 μm 
to 4.83 μm were successfully manufactured. The largest fibre diameter led to greater HUVEC 
infiltration and significantly greater cell viability after 12 days of culture. Furthermore, the largest 
fibre diameter also had interesting effects on gene expression. Most notably, CD31 expression was 
higher in the largest fibre after 6 and 12 days compared to the three other fibre diameters. CD31 is a 
gene associated with angiogenesis and is required for endothelial cell reorganization into vasculature, 
therefore and upregulation in the short run is desirable. These findings suggest that the largest fibre 
diameter (4.83 μm) is most suitable for the seeding of endothelial cells with the final aim of creating a 




Part B: Optimizing Scaffold Morphology for Smooth Muscle Cells 
3B.1 Introduction 
Vascular smooth muscle cells (VSMC) are an important component of the vessel wall and are 
predominantly located in the largest part of the vessel; the tunica media 43. The tunica media on 
average consists of between 40 and 60 layers of smooth muscle cells depending on the size and 
location of the vessel 43. This part of the vessel wall provides mechanical force and the vasoactive 
responsive properties that allow blood vessels to function effectively 44. Due to the thickness of the 
tunica media, it has been suggested that it would be beneficial to create a scaffold that allows for 
sufficient VSMC infiltration to mimic the functionality of the native tunica media 45. It has been well 
documented with several cell types that increasing infiltration can affect cell morphology and 
phenotype 16,46,47. Furthermore, work focussing on creating optimal environments for VSMCs has 
shown that both scaffold morphology and pore size can have a drastic effect on the performance of 
VSMCs 12,16,48,49. These studies suggest that there is merit to studying the effect of electrospun fibre 
diameter on VSMC performance. Therefore, the present study has looked at how fibre diameter of an 
electrospun polymer scaffold affects seeded VSMCs. 
3B.2 Methods and Materials 
3B.2.1 Electrospinning 
PCL was either dissolved into HFIP; a 5:1 mixture of Chlorofrom:Methanol (C:M) or a 10:1 mixture 
of C:M at varying concentrations to achieve four different solutions (Table 7). Briefly, the electrospun 
fibres were spun as one continuous fibre onto an aluminium foil covered 8 cm diameter rotating 
mandrel. All scaffold analysis was performed on ImageJ. A schematic of the experimental process is 







































S 8 HFIP 0.4 1.2 8 12 +12 0 250 
M 12 HFIP 0.4 1.7 8.5 15 +12 0 250 
L 20 5:1 C:M 0.8 5 18 23 +15 -4 250 
XL 20 10:1 C:M 0.8 6 18 21 +23.5 0 250 
 
3B.2.2 Scanning Electron Microscopy 
Scaffolds were imaged using a Hitachi TM4000 tabletop SEM. More detail can be found in Section 
2.5. 
3B.2.3 Fibre and Pore Properties 
Scanning electron images were analysed using ImageJ software. Images were imported into the 
software and thresholded. They were then analysed using the DiameterJ plugin (fibre diameter 
analysis) and the OrientationJ plugin (fibre orientation analysis) 22. More details can be found in 
Section 2.9. 
3B.2.4 Mechanical Testing 
Tensile properties were measured using an Instron 3367 testing rig. Measurements were performed on 
40 x 5 mm strips of electrospun scaffold with a starting gauge length of 20 mm. Scaffolds were 
stretched at 10mm/min until failure. The incremental Young’s Moduli were calculated using the stress 
strain curve. More details can be found in Section 2.7. 
3B.2.5 Contact Angle Measurement 
Contact angle was measured on each scaffold using a DMK 41AU02 monochrome camera at a 
frequency of 5 Hz. Briefly, a 5 µL droplet of water was placed on the scaffold whilst images were 
being taken. Analysis was performed on ImageJ using the LBADSA plugin 23. More details can be 
found in Section 2.8. 
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3B.2.6 Scaffold Porosity 
Scaffold porosity (%) was calculated using the density of PCL, weight of the scaffold and volume of 
the scaffold. The thickness of the scaffold was measured in order to calculate the volume of the 
scaffold. This was done using a DMK 41AU02 monochrome camera. All scaffolds were punched out 
using a 10 mm diameter punch. More details can be found in Section 2.10. 
3B.2.7 Cell Culture and Scaffold Seeding 
HUVSMCs were expanded to passage 4 in a 5% CO2/37°C atmosphere. HUVSMCs were expanded 
using smooth muscle cell growth medium and then cultured using DMEM supplemented with 10% 
v/v FBS; 1% v/v penicillin/streptomycin; and 1% v/v non-essential amino acids. HUVSMCs were 
lifted for scaffold seeding at 80% confluence. Briefly, 10 mm diameter scaffolds were punched out 
and sterilized in 70% ethanol before being soaked in basal medium overnight (non-supplemented 
DMEM). Scaffolds were then seeded in a 48-well plate. 25,500 cells/cm2 were drip seeded in 20 µL 
of culture medium (supplemented DMEM) onto the middle of the scaffold. After 30 mins a further 
30 µL of medium was added to stop the cells from drying out. After a further 30 mins, medium in 
each well was topped up to 500 µL. Medium was replaced every 48 h. More details can be found in 
Section 2.3 and Section 2.11. 
3B.2.8 CellTiter-Blue® Cell Viability Assay 
The assay was performed at 1, 6 and 12 days as per manufacturer’s instructions (Promega). Briefly, 
cell seeded scaffolds were removed and placed in new wells. Each well was topped up with 300 μL of 
media and 75 μL of CellTiter-Blue assay (4:1 ratio). The plate was lightly shaken for 1 min and then 
wrapped in aluminium foil and incubated for 3.5 h. After incubation, 100 μL samples (x3) of the 
media/assay were taken from each scaffold and pipetted into a black well plate. The plate was 
measured in a Modulus™ II microplate reader at excitation: 525 nm and emission: 580-640 nm. 
3B.2.9 Cell Staining 
Scaffolds used for cell staining were washed thrice in phosphate buffer saline (PBS) and fixed in 10% 
v/v formalin solution in PBS overnight. Cells were permeabilized in 0.2% v/v TritonX-100 solution 
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then stained in 0.1% v/v 1000X Phalloidin-iFluorTM514 conjugate and in DAPI. Fluorescent images 
were taken using a bespoke coherent anti-stokes Raman (CARS) system. More details can be found in 
Section 2.17. 
SEM images were taken of cell seeded scaffolds after 12 days using a previously described osmium 
based method 24. Briefly, samples were stained in 0.1% osmium tetroxide and visualized using a 
Hitachi TM4000 tabletop SEM. More details can found in Section 2.17. 
3B.2.10 Measuring Cell Infiltration 
Cell infiltration was measured using DAPI and phalloidin stained Z-stack images on ImageJ (NIH) 
whereby depth of cell intravasation was measured. 
3B.2.11 Reverse Transcription Quantative Polymerase Chain Reaction (RT-qPCR) 
RNA was extracted from the cell seeded scaffolds using a Tri-Reagent method and purified using 
Qiagen’s RNeasy spin colum system. Real-time polymerase chain reaction was performed using a 
LightCycler® 480 Instrument II and Sensifast™ SYBR® High-ROX system. Forward and reverse 
sequences were either designed or used from literature and are displayed in Table 8. Relative 
quantification of RT-PCR results was carried out using the 2−∆∆𝑐𝑡 method 25. Gene expression levels 
were expressed relative to GAPDH (housekeeping gene) and normalised to 70% confluent HUVECs 










Table 8: Primer sequences used for RT-qPCR to analyse gene expression from the seeded HUVSMCs. 
Gene Primer Sequence Reference 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
20 
GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Smooth muscle actin alpha 1 
Α-actin1 (forward) CCGACCGAATGCAGAAGGA 
50 
Α-actin1 (reverse) ACAGAGTATTTGCGCTCCGAA 
Myocardin 
Myocardin (forward) GGGTCTGAGCATTCCTTGCT Self-
designed Myocardin (reverse) CTGGACGTTTCAGTGGTGGT 
Mesenchyme homeobox 2 
MEOX-2 (forward) AAAAGCGACAGCTCAGACTC 
51 
MEOX-2 (reverse) TTGCTGTCCACCCTTTACCC 
Interleukin 1 alpha 
IL1-α (forward) GCGTTTGAGTCAGCAAAGAAG Self-
designed IL1-α (reverse) GCCGTGAGTTTCCCAGAAGA 
 
3B.2.12 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 
ANOVA with post-hoc Tukey test. 
3B.3 Results 
3B.3.1 Scaffold Properties 
Four different fibre morphologies were achieved through altering the electrospinning parameters. 
Firstly, increasing fibre diameters of 0.77 ± 0.14 µm, 2.06 ± 0.26 µm, 3.91 ± 0.40 µm and 
5.91 ± 0.56 µm were noted for the four scaffolds (p < 0.001 between each group) (Figure 22 and 
Figure 23). This significance between each scaffold means that all the morphologies can be 




Figure 22: Representative SEM images of four different PCL scaffold morphologies with increasing fibre 
diameters for seeding with HUVSMCs. Fibre diameters ranged from 0.77 µm in the smallest fibre scaffold to 





Figure 23: Fibre diameter histograms showing frequency of sizes for each scaffold. All four scaffolds show a 
peak in frequency of fibre diameter at different values. 
Additionally, the fibre alignment of each scaffold appeared to be fairly random and displayed no 
alignment in a particular direction. This can be seen in the SEM images in Figure 22 and the fibre 




Figure 24: Fibre orientations for all four scaffold morphologies showing no clear sharp peak at any angle. 
 
Furthermore, a very strong correlation between fibre diameter and pore width was noted for all four 
scaffold morphologies, with an R2 value of 0.9918. Pore widths ranged from 4.37 ± 1.29 μm for the 
small fibre morphology up to 33.41 ± 13.37 μm for the largest fibre diameter. These correlations can 




Figure 25: Correlation between fibre diameter and pore width of all four scaffold morphologies. A strong 
correlation was noted (R2 = 0.9918). 
 
3B.3.2 Scaffold Mechanical Properties 
Firstly, it was noted that the medium scaffold morphology has the highest ultimate tensile strength 
(UTS), highest failure strain and the highest stiffness at all 5 strain bands measured (Table 9). The 
UTS for these scaffolds dropped either side of the medium sized fibre diameter with the medium fibre 
diameter showing a significantly higher UTS (p < 0.012 for all 3 comparisons). While the failure 
strain was higher in the medium fibre diameter compared to the three other morphologies, it was only 
significantly higher than the small fibre diameter (p = 0.000 for the small, p = 0.164 and 0.168 for the 
large and extra-large, respectively). Furthermore, the small scaffold morphology not only had a 
significantly lower failure strain than the medium fibre diameter, as previously mentioned, it also had 
significantly lower failure strains than the large and extra-large fibre diameters (p = 0.011 for both). 
These values can all be seen in Table 9. 
Likewise, the stiffness of each scaffold at the five different strain bands followed a similar pattern. 
The medium scaffold morphology showed a higher stiffness at all five strain bands (see Table 9) 
compared to the three other fibre diameters, and the extra-large fibre diameter showed a lower 
stiffness at all five strain bands. Significance was noted at all 5 strain bands between the medium fibre 
diameter and the large and extra-large fibre diameters (p < 0.05 in all cases) and in some cases 
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significance between the medium fibre and small fibre (p = 0.053 for the 0-1% strain band; p = 0.042 
for the 1-2% strain band).  















Stiffness (MPa) at given strain bands 
0-1 % 1-2 % 2-3 % 3-4 % 4-5 % 













































3B.3.3 Cell Imaging 
Conventional 2D epifluorescence imaging showed that on the smaller fibre diameter a layer of SMCs 
were formed showing the phenotypic characteristics of healthy SMCs. Furthermore, while no clear 
monolayer could be noted on the three other morphologies, they were all able to maintain the 




Figure 26: Representative DAPI (nuclei) and phalloidin (f-actin) stained HUVSMCs seeded onto all three 
scaffold morphologies. HUVSMCS showed a phenotypic morphology on all four fibre diameters.  
 
Z-stacks of phalloidin stained SMCs showed how increasing fibre diameter had the effect of 
increasing cell infiltration into the scaffold. Cell infiltrations of approximately 40 µm, 42 µm, 61 µm 




Figure 27: Representative Z-stacks of phalloidin (f-actin) stained HUVSMCs showing depth of cell infiltration 
into the scaffold. As expected, infiltration was deepest on the extra-large scaffold. HUVSMCs spread and 




Figure 28: Representative SEM image of the HUVSMCs on the small fibre scaffold showing the hill and valley 
cell morphology. 
 
3B.3.4 Cell Viability 
Cell viability was measured using a CellTiter-Blue® Cell Viability Assay and showed some 
interesting results, as seen in Figure 29. Firstly, cell viability in the small electrospun fibre 
morphology after 12 days of culture was significantly higher than in the three other morphologies, 
suggesting that a smaller fibre morphology may be more suited for the growth of SMCs. On the 
contrary, the medium fibre diameter and XL fibre diameter both had reductions in cell viability, 




Figure 29: Cell viability of HUVSMCs on all four scaffolds after 1, 6 and 12 days of culture. Cell viability was 
significantly higher in the smallest fibre morphology compared to the three larger fibre morphologies. N=4, 
error bars = SD. ***p < 0.001 
 
3A.3.5 Reverse Transcription Quantitative Polymerase Chain Reaction 
RT-PCR results showed some interesting trends in HUVSMC gene expression between the four 
scaffold morphologies over the 12 days of culture, as seen in Figure 30. Myocardin is a key 
phenotypic gene in smooth muscle cells and is heavily involved in their contractile functionality, with 
upregulations being associated with cell maturity 52–55. In this study, the smallest fibre diameter lead to 
an upregulation in myocardin between 6 and 12 days of culture, whereas in the three larger fibre 
diameters, a downregulation was noted between the same two timepoints. Likewise, smooth muscle 
alpha actin 1 is associated with maturing smooth muscle cells and their contractile functionality 50. 
This study found an upregulation of smooth muscle alpha actin 1 on the small fibre between 24 h and 




Figure 30: RT-qPCR results for three different genes on all four scaffolds. All results were normalised to 70% 
confluent HUVSMCs on tissue culture plastic. N=4, error bars = SD. *p < 0.05. 
 
3B.4 Discussion 
In this study PCL was used as the polymer source for electrospinning. PCL is a widely used polymer 
in tissue engineering applications due to its versatility and its FDA approval for certain applications in 
vivo 15,56. It has been extensively used to manufacture different types of scaffolds, especially 
electrospun fibrous scaffolds which require a polymer that can be easily used with different 
solvents 11,57–59. Electrospinning is a flexible scaffold manufacturing technique that allows for a range 
of different morphologies to be created 13. Four different scaffolds were manufactured with increasing 
fibre diameters ranging from 0.77 ± 0.14 µm to 5.91 ± 0.56 µm with relatively equal increments 
between each scaffold. Interestingly, a very strong correlation was noted between the fibre diameter 
and the average pore width found on all four scaffolds (R2 = 0.9918). This allowed for the effect of 
fibre diameter/pore width and cellular infiltration on seeded SMCs to be studied in an attempt to find 
an optimum fibre diameter for the culture of SMCs. 
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As expected, an increase in infiltration depth was noted as fibre diameter and pore width were 
increased. Depths of approximately 40 µm, 42 µm, 61 µm and 82 µm for the small, medium, large 
and extra-large scaffolds, respectively. This phenomena is expected and has been seen in previous 
studies where increasing the pore size of a scaffold has led to increased cellular infiltration 60,61. 
Phipps et al. noted a 6 to 7 fold increase in mean cellular infiltration of mesenchymal stem cells when 
average pore area was increased from approximately 400 µm2 to 1800 µm2 61. Likewise, Whited et al. 
found that increasing pore diameter from less than 10 µm to 89 µm lead to significant increases in 
osteoblasts infiltrating to depths greater than 600 µm after 6 days of culture 60. While these cell types 
are different to the ones used in this study, the same principle applies whereby a larger pore size offers 
more space for cell infiltration. 
Fluorescence images of nuclei and f-actin stained cells showed a monolayer of SMCs on the small 
and large fibre scaffolds. In contrast, the extra-large scaffold appears to show cells infiltrating into 
pores and growing into the scaffold. While the medium fibre diameter scaffold may not have a full 
monolayer of cells growing, it does show cells growing along the same plane of the scaffold, which 
suggests that no infiltration is occurring. In vivo, VSMCs adopt an elongated morphology and are 
found interwoven around the ECM in thick layers of 40 to 60 cells 44. This would suggest that the 
extra-large scaffold would be optimal for the growth of VSMCs. However, the results suggest that the 
smallest fibre scaffold lead to increased cell performance. VSMCs tend to grow in very compact 
formations in vivo and therefore the extra-large fibre scaffold may not have allowed for adequate cell-
cell interactions due to the increase in space on offer for cell growth. This in turn may have decreased 
the amount of paracrine communication between the cells, reducing their proliferative performance. 
Studies have shown that decreased cell-cell communication in seeded scaffolds can lead to reduced 
cell growth and altered phenotypic gene expression in various cell types 62,63. 
The small scaffold morphology lead to the formation of VSMC bundles, whereby the cells realign 
themselves and adopt the phenotypic ‘hill and valley’ morphology commonly seen in in vitro 2D 
cultures 64,65. While this shows that the scaffold is well suited to the culture of VSMCs, it does not 
necessarily mean that this scaffold is optimal for the long-term 3D culture of VSMCs.  
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A relative upregulation of myocardin was noted in the smallest fibre diameter scaffold compared to 
the three larger fibre diameter scaffolds between 6 and 12 days of culture. Myocardin is a major 
phenotypic gene present in SMCs and is responsible for their contractile functionality 52–55. As SMCs 
proliferate and mature, an upregulation of myocardin would be expected. Furthermore, smooth muscle 
alpha actin 1 is associated with maturing smooth muscle cells and their contractile functionality 50. 
This study found that the small fibre diameter increased the expression of this gene over a 12 day 
culture period, whereas the three other scaffolds lead to a decrease in the expression of this gene over 
12 days. These results would suggest that the smallest fibre diameter scaffold helped facilitate SMC 
maturing and improved their functionality compared to the larger fibre diameters.  
3B.5 Conclusions 
In conclusion, four different electrospun scaffolds were manufactured with increasing fibre diameters 
ranging from 0.77 µm to 5.91 µm. The largest fibre diameter led to increased cell infiltration 
compared to the three other morphologies. However, the smallest diameter fibre lead to a monolayer 
of HUVSMCs growing, showing significantly higher cell viability after 12 days of culture compared 
to the three other morphologies. Furthermore, altering the fibre diameter had the effect of changing 
the levels of gene expression from the HUVSMCs. Most notably, the cells seeded onto the smallest 
fibre had elevated expressions of myocardin and smooth muscle actin-α 1 (two genes associated with 
mature SMCs) compared to the three other morphologies. These results show how altering the fibre 
diameter of the scaffold has clear effects on the seeded HUVSMCs. These findings suggest that the 

















In 2015 cardiovascular disease killed around 630,000 people in the United States, accounting for 
23.4% of all deaths 391. Approximately 80% of those deaths fell in the category of over 65 year olds 
391. One of the major reasons for the increase in people requiring sophisticated and complex cardiac 
interventions is the ever increasing average life expectancy across the world’s population 392. 
There are currently a variety of tissue engineering strategies utilized in the treatment of arterial 
disease, including scaffold materials that mimic the native ECM 393,394. Materials used in vascular 
tissue engineering include decellularized extracellular matrices, biopolymers, bioabsorbable polymers 
and collagen 200,394–399. There are many scaffold manufacturing methods utilised in vascular tissue 
engineering including electrospinning, which has been widely used due to its ability to mimic the 
nano and micro scale structure of tissues 214,338,375,400.  While utilising polymers does give good control 
over architecture, they lack some of the unique biomolecular cues found in native tissue, which is why 
in recent years there has been an increase in demand for utilising decellularized ECMs in tissue 
engineering 24,246,401,402. The ECM is the pivotal factor in the intracellular microenvironment, thus it 
plays a major role in maintaining and regulating tissue function 403. Therefore, incorporating 
components of the ECM into a scaffold to more closely mimic the native environment is an effective 
way to promote tissue regeneration 404. On this note, hybrid electrospun scaffolds that incorporate 
ECM into a spun fibre have shown improved cellular performance when using meniscus and cartilage 
198,199. 
Herein, the present study proposes electrospinning PCL/ECM composites with two different ECM 
sources: bovine aorta and bovine myocardium, to study how the inclusion of these biological 




Part A: Vascular ECMs and Endothelial Cells 
4A.1 Introduction 
One of the major aims of vascular tissue engineering is to create a functional layer of endothelial 
cells, which can happen under the correct environmental conditions 359. Current treatments are not 
keeping up with the increased demand for surgery and transplantation 392,405, therefore it is imperative 
that new treatments are developed. 
It has been shown that the inclusion of native biochemical factors can have beneficial effects on a 
variety of different cell types, including endothelial cells 199,394. Herein, the present study proposes 
incorporating the native vascular ECM into the electrospun polymer fibres via solubilisation of the 
ECM. By combining heart and aorta ECM with PCL, the aim is to manufacture an improved platform 
for the attachment and growth of endothelial cells, with the goal of improving vascular regeneration 
4A.2 Methods and Materials 
4A.2.1 ECM Production 
Bovine aorta and heart were collected from a 2 year old female cow. Samples were frozen at -80ºC 
upon collection. The heart tissue was sliced into 5 mm thick slices, whilst the aorta was cut open and 
laid flat. Samples approximately 40 mm in diameter were punched out and cut up into 2x2x2 mm 
cubes to aide with decellularization. Samples were perfusion decellularized with 0.5% w/v SDS in 
deionised water for 36 h, before being washed out with 10 L of water to ensure all the remnant SDS 
and DNA was removed from the sample. Decellularized samples were then frozen at -80°C before 
being lyophilized and milled into a fine powder. More detail on decellularization and ECM processing 
can be seen in Section 2.2. 
4A.2.2 Histology 
Histology was performed on native and decellularized samples to confirm the decellularization 
process has been successful. Samples were fixed in 10% v/v formalin for 24 h, and embedded in 
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paraffin wax, before being trimmed down to 5 µm thicknesses and mounted onto glass slides. Before 
staining all samples were cleared with xylene to remove the paraffin wax.  
Haematoxylin and Eosin staining was performed to see the remnant DNA in the tissue. Briefly, 
samples were cleared and then rehydrated before being stained in haematoxylin for 6 mins and eosin 
for 90 s. This lead to a vivid pink colour for all eosinophilic substances such as the cell cytoplasm and 
all ECM proteins; and a dark blue colour for the nuclear substances such as the cell nucleus. 
Picrosirius Red staining was performed to ensure the collagenous structure of the tissue had not been 
damaged during decellularization. Briefly, samples were cleared and then rehydrated before being 
stained in 0.1% w/v Sirius Red for 1h, leading to a red colour for the collagen fibres and a dull yellow 
colour for the cellular substances 293. 
More detail on histology can be seen in Section 2.4. 
4A.2.3 Electrospinning 
Powdered ECM (either heart or aorta) was dissolved into HFIP at 0.25% w/v. PCL was then added to 
this same solution at 8% w/v and dissolved overnight on a roller, resulting in ECM and PCL in 
solution with HFIP. A PCL only electrospun scaffold was used as a control. The solutions were 
electrospun using an EC-DIG electrospinning system. The parameters used for all three spins are seen 
in Table 10. Once finished, the electrospun sheet was left to dry overnight in the hood before being 
stored at 4°C. Scaffolds were punched out with a diameter of 10 mm and left in ethanol for 30 mins to 
sterilise. This resulted in two different ECM:PCL scaffolds with ECM:PCL ratios of approximately 
3:97 and a pure PCL control. More information on the electrospinning process can be seen in Section 
2.1. 





















4A.2.4 Scanning Electron Microscopy 
Scaffolds were visualized before and after cell seeding using a Hitachi S4700 fuelled emission 
scanning electron microscope (SEM (Hitachi) with a 5 kV accelerating voltage and a working 
distance of 12 mm. Scaffolds after 10 days of cell culture were stained with osmium tetroxide to allow 
for clear viewing of the cellular membrane and ECM components. Briefly, scaffolds were fixed in 4% 
v/v glutaraldehyde overnight and then stained in 0.1% v/v osmium for 30 mins. More details on SEM 
imaging and osmium staining can be seen in Sections 2.5 and 2.17. 
4A.2.5 Mechanical Analysis 
The Young’s modulus of the scaffolds was assessed on unseeded scaffolds and on scaffolds after 10 
days of culture. Samples with a gauge length of 14 mm were tested until 200% strain was reached. 
Data was analysed using a previously described analysis method 31,177,184,406. More detail can be found 
in Section 2.7. 
4A.2.6 Contact Angle Measurement 
Contact angles were measured on dry scaffolds. A 5 µL droplet of deionised water was placed onto 
the scaffold and images were captured at 5Hz using a DMK 41AU02 monochrome 1280 x 960 
camera. Analysis was done using ImageJ software with a previously developed plugin: LBADSA 309. 
More detail can be found in Section 2.8. 
4A.2.7 Fourier Transform Infrared Spectroscopy 
Fourier transform infrared spectroscopy (FTIR) was used to confirm the successful inclusion of 
vascular ECMs into the electrospun PCL fibres. All spectra were obtained using a Nicolet™ iS™10 
spectrometer with a Smart™ iTX diamond attenuated total reflection (ATR) detector. Spectra were 
acquired between 4000 and 400 cm-1 with a resolution of 1 cm-1 using OMNIC™ Spectra software 
(Thermo Fisher Scientific). More details can be found in Section 2.11. 
4A.2.8 Cell Growth 
HUVECs from an infant male Caucasian donor were obtained cryopreserved at passage 1 and 
expanded to passage 7 in a 5% CO2/37°C atmosphere. This study abides by all criteria of the UK 
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Human Tissue Act. HUVECs were expanded using MCBD 131 medium supplemented with 5% v/v 
FBS; 1% v/v L-glutamine; 1% v/v penicillin/streptomycin; 1mg/L hydrocortisone; 50 mg/L ascorbic 
acid; 2 μg/L fibroblast growth factor; 10 μg/L epidermal growth factor; 2 μg/L insulin-like growth 
factor; and 1 μg/L vascular endothelial growth factor 31,407,408. More details can be found in Section 
2.3. 
4A.2.9 Cell Seeding and Culture 
Scaffolds were incubated in serum free MCDB 131 medium overnight to increase hydrophilicity and 
help with cell attachment. Cells were seeded at approximately 45,000 cells/cm2 in 20 µL of culture 
medium (MCDB 131 + supplements as mentioned in 4A.2.8) and left for 30 mins to allow for 
attachment. Another 30 µL of medium was added and left for a further 30 mins before total medium 
was increased to 500 µL. Medium was replaced every 2 days. More details can be found in Section 
2.3 and 2.12. 
4A.2.10 Cell Viability 
The CellTiter-Blue® assay was performed after 1, 5 and 10 days of culture as per the manufacturer’s 
instructions 328. Measurements were made with a Modulus™ II microplate reader at Excitation 
525 nm and Emission 580-640 nm. More details can be found in Section 2.13. 
4A.2.11 DNA Quantification 
Cell seeded scaffolds cultured for 1, 5 and 10 days were frozen and tested for total DNA content of 
using a Quant-iTTMPicoGreen® assay kit as per the manufacturers' instructions 341. Fluorescence was 
read using a Modulus™ II microplate reader at Excitation 490 nm and Emission 510–570 nm. More 
detail can be found in Section 2.14. 
4A.2.12 Cell Imaging 
Scaffolds for imaging were fixed in 4% v/v formalin in PBS for 24 h. Scaffolds were then washed and 
stored in PBS. Permeabilization for cell imaging was achieved using 0.2% v/v TritonX-100 in PBS 
for 5 mins. Scaffolds were stained with 0.1 mL of 0.1 μL 1000X Phalloidin-iFluorTM514 conjugate in 
0.1 mL PBS with 1% v/v bovine serum albumin for 60 min. Scaffolds were washed thrice in PBS for 
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10 mins. Scaffolds were then stained with 0.1 mL of 300 nM 4’,6-diamidino-2-phenylindole (DAPI) 
in PBS for 10 mins followed by three 10 min PBS washes. All scaffolds were imaged using a 
Coherent Anti-Stokes Raman scattering microscope. More details can be found in Section 2.17. 
4A.2.13 Reverse Transcription Quantative Polymerase Chain Reaction (RT-qPCR) 
RNA was extracted from the scaffolds using standard Tri-Reagent methods and purified using 
Qiagen’s RNeasy spin column system. Real-time polymerase chain reaction was performed using a 
LightCycler® 480 Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX system 
(Bioline). Forward and reverse sequences were designed with Sigma-Aldrich and are displayed in 
Table 11 31,361. Relative quantification of RT-PCR results was carried out using the 2−∆∆𝑐𝑡 method 350. 
Gene expression levels were expressed relative to GAPDH (housekeeping gene) and normalised to 
expression on the day 1 PCL control. More details can be found in Section 2.18. 
Table 11: Primer sequences used in RT-PCR amplification of genes from the seeded HUVECs. 






















































4A.2.14 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation, unless stated otherwise. Statistical analysis was 
preformed using one-way ANOVA with post-hoc Fisher test unless otherwise stated.  
4A.3 Results 
4A.3.1 Decellularization 
Bovine heart and aorta tissue were both successfully decellularized using 0.5% w/v SDS as seen in 
Figure 31. DNA content was significantly reduced in both tissues and the Haematoxylin and Eosin 
staining showed that the nuclear content of the cells had been removed from both tissues. 
Furthermore, Picrosirius Red staining showed that the collagenous composition of the tissue was 




Figure 31: Decellularization of bovine aorta and myocardium was successfully achieved using a 0.5% SDS 
protocol. (A) DNA content of tissue before and after decellularization. (B) H&E and Picrosirius red staining of 




Electrospun fibrous sheets were successfully manufactured, as seen in Figure 32. All three scaffolds 
are made up of randomly orientated fibres with fairly uniform fibre sizes. The three scaffolds have 
average fibre diameters of 0.97 ± 0.19 μm, 1.20 ± 0.09 μm and 0.94 ± 0.12 μm for the PCL control, 
heart ECM and aorta ECM scaffolds, respectively. The heart ECM and aorta ECM scaffolds comprise 
of 97% PCL and 3% ECM (aorta or heart depending on the scaffold), whereas the PCL control is 
100% PCL. 
 
Figure 32: SEM images of the three electrospun scaffolds for seeding with HUVECs. The heart ECM and aorta 
ECM scaffold comprise of approximately 97% PCL and 3% ECM. The PCL control is entirely made up of PCL 
(100%). 
 
4A.3.3 Mechanical Characterisation 
Mechanical testing performed using an Instron tensile tester showed no statistically significant 
difference between cell seeded and unseeded scaffolds for each scaffold at all the strain bands. 
However, the general trend for the PCL scaffold and the heart ECM scaffold (3% ECM) is a slightly 
higher Young’s modulus in the seeded scaffolds then the unseeded scaffold, as seen in Figure 33 and 
Table 12. Furthermore, it was noted that the two ECM scaffolds had consistently higher Young’s 
moduli at all strain brackets compared to the PCL only scaffold (Table 12), with significance noted at 
the 0-1% strain bracket between the ECM scaffolds and the PCL scaffold; and in the 1-2% strain 




Figure 33: Representative stress vs strain curves for each scaffold – seeded and unseeded and after 10 days of 
culture. The incorporation of ECM led to steeper curves. 
 
Table 12: The incremental Young’s moduli of all three scaffolds and different strain bands along the stress 
strain curve. Incremental Young’s moduli were taken on both unseeded scaffolds and seeded scaffold after 10 
days of culture. 
  Scaffold type 
  PCL Heart ECM Aorta ECM 
  Unseeded Seeded Unseeded Seeded Unseeded Seeded 
Young’s 
Modulus at % 
strain, MPa 
0-1 17.05 ± 1.81$ 19.48 ± 2.14 21.00 ± 1.87$ 22.58 ± 2.13 21.90 ± 2.93$ 21.60 ± 1.91 
1-2 16.80 ± 1.27& 18.10 ± 2.21 20.87 ± 2.60 20.68 ± 2.37 22.00 ± 3.11& 18.76 ± 1.95 
2-3 15.03 ± 1.89 15.25 ± 2.47 16.27 ± 2.22 18.18 ± 1.62 18.04 ± 2.29 15.82 ± 1.12 
3-4 13.93 ± 1.53 14.55 ± 3.00 15.96 ± 1.69 15.84 ± 1.60 17.34 ± 1.95 14.30 ± 0.85 
4-5 12.45 ± 1.75 13.08 ± 2.80 12.64 ± 1.40 14.16 ± 1.18 14.90 ± 1.76 12.92 ± 0.64 
0-5 15.05 ± 1.54 16.09 ± 2.49 17.35 ± 1.83 18.29 ± 1.72 18.84 ± 2.28 16.68 ± 1.26 
*Results with matching symbols (&) are significantly different to each other (p<0.05) across the same strain band. Results with the $ symbol 
are significantly different to all other results in that same strain band (p<0.05). 
4A.3.4 Fourier Transform Infrared Spectroscopy 
The FTIR results confirmed that the aorta ECM and heart ECM had both been successfully 
incorporated into the electrospun PCL scaffolds. A range of spectra were taken for PCL alone, 
PCL/ECM blended scaffolds and ECM alone. Figure 34 shows the peaks in intensity at 1720, 1654, 
and 1,541 cm−1 for both the aorta ECM and heart ECM. The peaks can be attributed to the stretching 
of the carbonyl in the PCL, the amide I bond in the ECM, and the amide II bond in the ECM, 
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respectively 326,409. The differences in intensities for each peak were quantified to show that the ECM 
has been integrated and can be seen in  
Table 13 and Table 14. Briefly, increases of 84.3 ± 8.0% (p < 0.01) and 109.2 ± 18.6% (p < 0.01) 
were seen at 1654 and 1,541 cm−1, respectively, for the aorta ECM, with a decrease of 19.4 ± 15.5% 
(p < 0.05) at 1720 cm−1. The heart ECM showed increases of 35.2 ± 6.7% (p < 0.01) and 




Figure 34: FTIR absorbance spectra for A) aorta ECM scaffolds and B) heart ECM scaffolds compared to PCL 
alone and ECM alone. Absorbance spectra show peaks in intensity at Amide I and Amide II bonds in both ECM 
blended scaffolds, suggesting that the ECM had been successfully incorporated into the fibre. N=5. Each 





Table 13: Absorbance values for each peak on all three scaffolds. 
Wavelength 
of peak (cm-1) 
Absorbance values 
PCL Aorta ECM Heart ECM 
1720 0.774 ± 0.110 0.624 ± 0.040 0.693 ± 0.039 
1654 0.025 ± 0.001 0.046 ± 0.004 0.034 ± 0.002 
1541 0.011 ± 0.001 0.023 ± 0.004 0.014 ± 0.001 
 
Table 14: Wavelengths of peaks noted in FTIR absorbance spectra and their associated intensity changes 
between each scaffold.  
Wavelength 
of peak (cm-1) 
Assignment Caused by 
Change in absorbance between PCL fibre 
and ECM/PCL fibre 
Aorta ECM Heart ECM 
1720 Carbonyl group stretching PCL - 19.4 ± 15.5% - 10.5 ± 15.2% 
1654 Amide I bond ECM (collagen and elastin) + 84.3 ± 8.0% + 35.2 ± 6.7% 
1541 Amide II bond ECM (collagen and elastin) + 109.2 ± 18.6% + 26.8 ± 10.7% 
 
4A.3.5 Contact Angle Measurement 
The addition of aorta ECM had the effect of increasing the hydrophilicity of the scaffold compared to 
the conventional PCL scaffold and heart ECM scaffold, as seen in Table 15. These results were 
significant when comparing the aorta ECM scaffold to the heart ECM scaffold: 26.9% lower 
(p < 0.05) after 0.2s and 38.7% lower (p < 0.05) after 1s, but not when comparing either to the PCL 
scaffold. Furthermore, the percentage drop in contact angle between 0.2 s post contact and 5 s post 







Table 15: Contact angle measurements for all three scaffolds after 0.2, 1 and 5 seconds. 
  Scaffold type 
  PCL Heart ECM Aorta ECM 
Contact angle after 0.2s, ° 114.4 ± 8.9 122.5 ± 3.5& 89.6 ± 37.7& 
Contact angle after 1s, ° 103.6 ± 19.6 118.8 ± 10.7# 72.8 ± 43.9# 
Contact angle after 5s, ° 98.7 ± 25.2 106.3 ± 27.2 68.8 ± 43.6 
Percentage drop in 
contact angle between 
0.2s and 1s 
9.44% 3.02% 18.75% 
Percentage drop in 
contact angle between 
0.2s and 5s 
13.7% 13.2% 23.2% 
*Results with matching symbols (& and #) are significantly different to each other (p<0.05). 
4A.3.6 Cell Viability  
Cell viability was assessed using a CellTitre-Blue® fluorescence assay. After 10 days, the aorta ECM 
scaffold and heart ECM scaffold both showed a significant increase in cell viability compared to their 
viabilities after 1 day (p < 0.05), as seen in Figure 35. Furthermore, the aorta ECM scaffold also 
showed a significant increase between 5 and 10 days of culture (p < 0.01). Conversely, the PCL 
scaffold showed no significant increase between all three timepoints, although an upward trend was 




Figure 35: Cell viability using the CellTitre-Blue assay for all three scaffolds after 1, 5 and 10 days of culture. 
HUVECs on the aorta ECM scaffold showed higher viability after 10 days compared to the heart ECM scaffold 
and PCL control. N=5, error bars = SD. *p < 0.05, **p < 0.01. 
 
4A.3.7 DNA Quantification 
DNA quantification was performed using a Picogreen assay. The DNA content of the aorta ECM 
scaffold was significantly higher after 10 days than all other scaffolds at all three timepoints, as seen 
in Figure 36. While this was the only significance noted, a trend of increasing DNA content was noted 




Figure 36: DNA quantification using the Picogreen assay for all three scaffolds. The aorta ECM blended 
scaffold showed significantly higher DNA content after 10 days of culture compared to the two other scaffolds. 
N=5, error bars = SD. *p<0.05. 
 
4A.3.8 Cell Imaging 
Representative SEM images taken using a scanning electron microscope show the functional cell 
layers on scaffolds after 10 days of culture (Figure 7A). Interestingly, the aorta ECM scaffold appears 
to be 100% confluent with HUVECs, compared to approximately 30% for the PCL scaffold and 50% 
for the heart ECM scaffold. These results validate the cell viability and DNA quantification results, 
suggesting that the incorporation of aorta ECM into the scaffold improved HUVEC proliferation. 
Furthermore, all three scaffolds show similar HUVEC morphology. 
Representative images taken using CARS further confirm that the incorporation of aorta ECM into the 
scaffold had a favourable effect on HUVECs (Figure 7B). After 1 day of growth, the cells on the aorta 
ECM scaffold already appear greater in number and have a higher quantity of visible actin filaments. 
The heart ECM scaffolds show very poor cell attachment after 1 day, which matches the cell viability 
and DNA quantification results. Furthermore, cell number appears to increase for all scaffolds 
between day 1 and day 10. Interestingly, the actin filaments appear more characterized after 10 days, 





Figure 37: A) Representative SEM images of osmium stained HUVECs on the three scaffolds after 10 days. B) 
Representative CARS images of HUVECs on all three scaffolds after 1 and 10 days of culture. Blue = cell 
nuclei, green = f-actin filaments. 
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4A.3.9 Gene Analysis 
Multiple genes associated with vascular function were assayed for their expression, including cluster 
of differentiation (CD31), matrix metalloproteinase-1 (MMP1), matrix metalloproteinase-2 (MMP2) 
and vascular endothelial growth factor (VEGF), as seen in Figure 38. All three scaffolds noted a 
downregulation in CD31 over the three timepoints. The day 1 heart ECM showed significantly higher 
expression compared to all other scaffolds at all timepoints. MMP1 expression showed 
downregulation over time for all three scaffolds, with the biggest reduction in expression seen for the 
aorta ECM scaffold. Significantly lower expressions were also noted for the aorta ECM scaffolds at 5 
and 10 days when compared to the two other scaffolds.  
Conversely, MMP2 expression was seen to increase over time, with significant increases for the PCL 
and heart ECM scaffolds. Furthermore, the aorta ECM scaffold had a significantly higher expression 
at day 1 compared to the PCL and heart ECM scaffolds. VEGF showed no real trend over time, with 
the only exception being that aorta ECM scaffold had a significantly higher expression than the heart 




Figure 38: RT-qPCR data showing the HUVEC gene expression of MMP1, MMP2, CD31 and VEGF relative to 
the house keeping gene: GAPDH. All results have been normalized to day 1 PCL. N=5, error bars = SD. *p < 
0.05, **p < 0.01. 
4A.4 Discussion 
Polymer scaffolds have long been utilised in tissue engineering as a platform for tissue 
regeneration 363,411,412. Physical characteristics can be designed into the scaffold to support cellular 
activity and promote differentiation, proliferation and deposition of new functional ECM 412. 
Furthermore, PCL offers a range of degradation profiles that can be tailored based on the tissue type 
its being designed for 413. PCL is widely used as the polymer component of electrospun bioscaffolds 
due to these properties 198,414,415. Alongside polymers, decellularized tissue has been used in tissue 
engineering due to its cell supporting physical and chemical characteristics 246,399. The aim when 
decellularizing is to maintain the physical and chemical characteristics of the remnant ECM 200. This 
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study utilized SDS, a commonly used ionic detergent for decellularizing tissues and successfully 
reduced the DNA content to below the 50ng/mg standard 249,257,271,416. SDS is a very effective means 
of decellularization and has been used at varying concentrations ranging from 0.1% to 4%, with DNA 
removal and maintenance of structural integrity observed 417–421. H&E staining confirmed the removal 
of the DNA content from the two tissue types after decellularization and the Picrosirius red staining 
confirmed that the collagenous structure of the ECM was maintained during decellularization. The 
FTIR results for the two ECMs showed peaks in the areas associated with structural proteins such as 
collagen and elastin, suggesting that the decellularizing process maintained the protein’s integrity 422.  
Polymers and ECM both have their advantages when used as scaffolds for tissue engineering 246,363. In 
this study, the two were combined in an attempt to harness the beneficial characteristics from each to 
create a bioscaffold more suited for vascular tissue engineering. Recently, work has focussed on 
combining the two to take advantage of these characteristics, in a similar vein to this 
study 198,394,396,397,423. For example, coating decellularized vascular ECMs with polymers has been 
implemented before, with the aim of improving biochemical and mechanical performance 396,423. 
These studies both noted improved mechanical properties. However, the final structure of the scaffold 
is limited by the size and architecture of the ECM. By integrating the ECM directly into the polymer 
fibres, as has been done in this study using electrospinning, highly tailored and physically repeatable 
structures were created that include both the biochemical cues found in native ECM; and have the 
mechanical strength of the electrospun polymer. Moreover, as found in this study and previous, there 
are mechanical and biochemical benefits to combining ECM with polymers 396,423. 
The method of solubilising ECMs into a PCL/HFIP solution has been used before with decellularized 
meniscus and cartilage ECM 198,199. Gao et al. found that the addition of meniscus ECM had a positive 
effect in reducing contact angle, a phenomena also noted with the inclusion of aorta ECM in this 
study 198. Similarly, Garrigues et al. dissolved decellularized cartilage ECM into a solution of PCL 
and HFIP and found gene expression changes, in similar vein to this study 199.  
A downward trend in CD31 expression was seen for all three scaffolds. CD31, also known as 
PECAM1 (platelet endothelial cell adhesion molecule 1) is a protein found on the surface of many 
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cells and is involved in angiogenesis and integrin activation. Over-expression of CD31 can inhibit 
morphogenesis in cells 424. Its downregulation suggests that: the HUVECs are struggling to adhere to 
each other 425, which SEM and fluorescence microscopy images disprove, or the HUVECs are not 
attempting to create new vasculature (angiogenesis) 426. This is the most likely reason that can be 
attributed to the issue of poor cellular infiltration which is required in order to achieve full tissue 
regeneration. A lack of infiltration in this study resulted in a monolayer of cells growing on the 
surface of the scaffold. Studies have shown the contribution of porosity and pore interconnectivity on 
cell survival and HUVEC angiogenesis, similar to the findings in the fibre diameter study with 
HUVECs (Chapter 3.1) 227,315. On the other hand, no real trend in VEGF expression was noted. VEGF 
is a signal protein that stimulates the formation of new blood vessels (angiogenesis) in tissue 
regeneration 53. Its overexpression is also associated with tumour growth and intraocular neovascular 
disorders 53. During cellular proliferation, an upregulation of VEGF would be expected 427. It has been 
suggested that HUVECs ‘overexpress’ VEGF in the first 24h, which may explain this down regulation 
over time compared to the day 1 scaffolds 26. 
A trend of decreasing MMP1 expression for all three scaffolds was noted. MMP1 is an enzyme 
involved in the breakdown and remodelling of collagen (one of the major components of vascular 
ECMs) 428. Its downregulation suggests the cells are not trying to breakdown the collagen within the 
ECM, suggesting they are in a position of homeostatic equilibrium with their scaffold. In contrast, a 
significant upregulation of MMP2 was noted in all three scaffolds after 5 and 10 days. Furthermore, 
after 1 day a significantly higher expression was seen in the aorta ECM scaffold compared to the two 
other scaffolds. This enzyme is involved in the breakdown and remodelling of gelatin (another major 
component of vascular ECMs) 429. Its upregulation suggests the presence of gelatin in the ECM 
scaffolds. An upregulation was noted across both ECM scaffolds, as well as the PCL only scaffold 
after 10 days of culture, with no significant differences noted between the three scaffolds. This 
suggests that this upregulation is unlikely to be caused by the presence of gelatin in the ECM 
scaffolds and is probably a result of something other than the constituents of the two native ECMs, 




This study showed that integrating two different sources of decellularized vascular ECMs into 
electrospun polymer scaffolds has promise for vascular tissue engineering. The ECMs were 
successfully decellularized and combined into the scaffolds. The inclusion of ECM had effects on the 
performance of seeded HUVECs and on the mechanical properties of the scaffold. Furthermore, the 
mechanical properties of the scaffold could easily be altered through including ECM into the scaffold. 
The inclusion of aorta ECM resulted in a stiffer scaffold that had improved biomechanical properties 
for the attachment of cells – leading to the increased cell adherence noted in this study. The method 
described combines the controllable physical properties of the polymer (PCL) with the biochemical 
and mechanical properties of the ECM (aorta and myocardium wall) to create a tailored hybrid 
bioscaffold. The combination of a natural ECM and a synthetic polymer to generate a hybrid 




Part B: Vascular ECMs and smooth muscle cells 
4B.1 Introduction 
Vascular smooth muscle cells (VSMCs) are an important component of the vessel, making up the 
bulk of the cells in the tunica media 37. They are responsible for the mechanical properties and 
vasoactive responsive properties that allow blood vessels to function properly 372. Vascular ECMs, 
especially aortic ECM contain a variety of different proteins and GAGs that have shown benefit to 
VSMCs. Furthermore, VSMCs are found integrated amongst a network of ECM, mostly made up of 
collagen and elastin and are strongly interconnected in their functions. Studies have looked at how 
smooth muscle cells interact with electrospun polymer/protein combinations 376, however, none have 
investigated the effect of electrospinning decellularized vascular ECMs on VSMCs.  
Herein, this study proposes incorporating decellularized vascular ECMs into electrospun polymer 
fibres to see how they affect the performance of seeded HUVSMCs. 
4B.2 Methods and Materials 
4B.2.1 ECM Production 
Aorta and heart samples were collected from a 2 year old female cow and decellularized using 
previously described methods. More detail on decellularization and ECM processing can be seen in 
Section 2.2. 
4B.2.2 Histology 
Histology was performed on native and decellularized samples. Samples were fixed in 10% v/v 
formalin for 24 h, embedded in paraffin wax and then trimmed down to 5 µm thicknesses and 
mounted onto glass slides. Before staining all samples were cleared with xylene to remove the 
paraffin wax.  
Haematoxylin and Eosin staining was performed to see the remnant DNA in the tissue.  




Powdered ECM was dissolved into HFIP at 0.25% w/v. PCL was added at 8% w/v and dissolved 
resulting in ECM and PCL in solution with HFIP. A PCL only electrospun scaffold was used as a 
control. Electrospinning parameters used for all three spins are seen in Table 16. Scaffolds were 
punched out with a diameter of 10mm and left in ethanol for 30 mins to sterilize. This resulted in two 
different ECM:PCL scaffolds with ECM:PCL ratios of approximately 3:97 and a pure PCL control. 
More information on the electrospinning process can be seen in Section 2.1. 
Table 16: Electrospinning parameters used to manufacture the three different scaffolds: PCL control; aorta 
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4B.2.4 Scanning Electron Microscopy 
Scaffolds were visualized before and after cell seeding using a scanning electron microscope. 
Scaffolds after 10 days of cell culture were stained with osmium tetroxide. Briefly, scaffolds were 
fixed in 4% v/v glutaraldehyde overnight and stained in 0.1% v/v osmium tetroxide for 30mins. More 
details on SEM imaging and osmium staining can be found in Sections 2.5 and 2.17. 
4B.2.5 Mechanical Analysis 
Samples were stretched using an Instron 3367 tensile testing machine with a 50 N load cell. Samples 
with a gauge length of 14mm were tested until failure. The incremental Young’s modulus was 





where 𝐸 is Young’s modulus, 𝐹 is the applied force, 𝐴 is the cross sectional area, ∆𝐿 is change in 
length and 𝐿0 is the original length. More details can be seen in Section 2.7. 
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4B.2.6 Contact Angle Measurement 
Contact angles were measured on dry scaffolds. A 5 µL droplet of deionised water was placed onto 
the scaffold and images were captured at 5 Hz using a DMK 41AU02 monochrome 1280 x 960 
camera. Analysis was done using ImageJ software with a previously developed plugin: LBADSA 309. 
More details can be found in Section 2.8. 
4B.2.7 Fourier Transform Infrared Spectroscopy 
FTIR was used to confirm the successful incorporation of vascular ECMs into the electrospun PCL 
fibres. All spectra were obtained using diamond attenuated total reflection detector. Spectra were 
acquired between 4000 and 400 cm-1 with a resolution of 1 cm-1. More details can be found in Section 
2.11. 
4B.2.8 Cell Growth 
HUVSMCs from an infant male Caucasian donor were obtained cryopreserved at passage 1 (Sigma 
Aldrich) and expanded to passage 4 in a 5% CO2/37°C atmosphere. HUVSMCs were expanded using 
Smooth Muscle Cell Growth Medium (Sigma Aldrich). More details can be found in Section 2.3. 
4B.2.9 Cell Seeding and Culture 
Scaffolds were soaked in serum free DMEM medium overnight to increase hydrophilicity and help 
with cell attachment. Cells were seeded at approximately 20,000 cells/cm2 in 20 µL of culture medium 
(Smooth Muscle Cell Growth Medium as mentioned in 4B.2.8) and left for 30 mins to allow for 
attachment. The medium was topped up with another 30 µL of medium and left for a further 90 mins 
before total medium was topped up to 500 µL. Medium was replaced every 2 days. More details can 
be found in Section 2.3 and 2.12. 
4B.2.10 Cell Viability 
The CellTiter-Blue® assay was performed after 1, 5 and 10 days of culture as per the manufacturer’s 
instructions 328. Measurements were made at Excitation 525 nm and Emission 580-640 nm. More 
details can be found in Section 2.13. 
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4B.2.11 DNA Quantification 
HUVSMC seeded scaffolds were cultured for 1, 5 and 10 days and tested for total DNA content using 
a Quant-iTTMPicoGreen® assay kit as per the manufacturers' instructions 341. Fluorescence was read at 
Excitation 490 nm and Emission 510–570 nm. More details can be found in Section 2.14. 
4B.2.12 Cell Imaging 
Scaffolds for imaging were fixed in 4%v/v formalin. Scaffolds were permeabilized using 0.2% v/v 
TritonX-100 in PBS for 5 mins. Scaffolds were stained with 0.1 mL of 0.1 μL 1000X Phalloidin-
iFluorTM514 conjugate and then stained with 0.1 mL of 300 nM DAPI in PBS for 10 mins. All 
scaffolds were imaged using a Coherent Anti-Stokes Raman scattering microscope. More details can 
be found in Section 2.17. 
4B.2.13 Reverse Transcription Quantative Polymerase Chain Reaction 
RNA was extracted from the scaffolds using standard Tri-Reagent methods and purified using 
Qiagen’s RNeasy spin column system. Real-time polymerase chain reaction was performed using a 
LightCycler® 480 Instrument II and Sensifast™ SYBR® High-ROX system. Forward and reverse 
sequences were designed with Sigma-Aldrich and are displayed in Table 17. Relative quantification 
of RT-PCR results was carried out using the 2−∆∆𝑐𝑡 method 350. Gene expression levels were 
expressed relative to GAPDH (housekeeping gene) and normalised to the expression of 70% 
confluent HUVSMCs. More details can be found in Section 2.18. 
Table 17: Primer sequences used in RT-PCR amplification 





GAPDH (forward) GTCTCCTCTGACTTCAACAG 20 
GAPDH (reverse) GTTGTCATACCAGGAAATGAG 21 
Myocardin 
Myocardin (forward) GGGTCTGAGCATTCCTTGCT 20 
Myocardin (reverse) CTGGACGTTTCAGTGGTGGT 20 
Interleukin 1 alpha 
IL1-α (forward) GCGTTTGAGTCAGCAAAGAAG 21 




4B.2.14 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation, unless stated otherwise. Statistical analysis was 
preformed using one-way ANOVA with post-hoc Fisher test unless otherwise stated.  
4B.3 Results 
4B.3.1 Decellularization 
To confirm the decellularization process, the DNA content of the decellularized tissue samples was 
assessed using a Picogreen DNA assay. Both tissues were found to have significant reductions in 
DNA content after decellularization, with the remnant values being lower than the 50 ng/mg standard 
257 (Figure 39A). Furthermore, decellularization efficacy was assessed using H&E staining as seen in 
Figure 39B. Nuclear content is stained in dark blue and in both the aorta and heart tissues the DNA 




Figure 39: Decellularization of bovine aorta and heart ECM was successfully achieved using a 0.5% SDS 
protocol. A) DNA content of the aorta and heart tissue before and after decellularization. B) H & E staining of 
the aorta and heart tissue before and after decellularization. N=4, error bars = SD. **p < 0.01, ***P < 0.001. 
 
4B.3.2 Electrospinning 
All three scaffolds were successfully electrospun and showed very similar randomly orientated 
morphologies, as seen in Figure 40. The three scaffolds showed similar fibre orientations and had 
fibre diameters of 0.77 ± 0.14 µm, 0.69 ± 0.26 µm and 0.73 ± 0.27 µm for the PCL scaffold, aorta 
ECM scaffold and heart ECM scaffold, respectively. These similarities in the morphology of the 
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scaffolds ensures that all results noted can be attributed to the inclusion of ECM and not due to 
differences in morphology. 
 
Figure 40: SEM images, fibre orientation and fibre diameter of all three scaffolds manufactured for seeding 
with HUVSMCs. SEM images show that the scaffold appear to all have uniform fibre morphologies. Fibre 
orientation shows similar peaks across all three scaffolds.  
 
4B.3.3 Mechanical Characterisation 
Mechanical characterisation led to some interesting results. Firstly, the PCL scaffolds were 
significantly stiffer than the two ECM scaffolds at all strain bands, as seen in Table 18. The ECM 
scaffolds were both relatively similar and were between 40 to 60% of the stiffnesses noted in the PCL 
scaffold, depending on the strain band measured. Secondly, the PCL scaffold had a significantly 
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higher failure strain than both ECM scaffolds: 159% higher than the heart ECM scaffold, and 55% 
higher than the aorta ECM scaffold. Moreover, the PCL scaffold also had a significantly higher 
ultimate tensile strength than the two ECM scaffolds: 27% and 34% higher than the heart ECM and 
aorta ECM scaffolds, respectively.   
Table 18: Mechanical properties (Incremental Young’s moduli, failure strain and ultimate tensile strength) of 
the three scaffolds (PCL, heart ECM and aorta ECM). The PCL scaffold had significantly higher values for all 
measured properties. 
  Scaffold type 
  PCL Heart ECM Aorta ECM 
Young’s 
Modulus at each 
strain band, 
MPa 
0-1% 3.78 ± 1.75* 1.42 ± 0.59 1.78 ± 0.73 
1-2% 6.49 ± 1.64* 2.57 ± 0.69 2.89 ± 0.75 
2-3% 7.35 ± 0.66* 3.40 ± 0.32 3.27 ± 0.68 
3-4% 7.09 ± 0.63* 3.70 ± 0.19 3.31 ± 0.59 
4-5% 6.31 ± 0.67* 3.55 ± 0.41 3.09 ± 0.44 
0-5% 6.20 ± 0.65* 2.93 ± 0.23 2.87 ± 0.58 
Failure strain (%) 357 ± 79* 138 ± 5 231 ± 44 
Ultimate tensile strength 
(MPa) 
1.41 ± 0.09* 1.11 ± 0.09 1.05 ± 0.18 
*The PCL scaffold showed significantly higher Young’s modulus at all strain bands, failure strain and ultimate tensile strength compared to 
the two blended ECM scaffolds. No significance was noted between the two aorta ECM and heart ECM scaffolds 
4B.3.4 Fourier Transform Infrared Spectroscopy 
The FTIR results showed that the aorta and heart ECMs were both successfully incorporated into the 
electrospun PCL scaffold. A range of spectra were taken from PCL and ECM samples alone, 
alongside the PCL/ECM scaffolds, as seen in Figure 41. The spectra showed that characteristic peaks 
from the ECM and PCL could be seen in the combined scaffold, showing that the electrospinning 
process did successfully integrate the ECM into the fibres. Peaks were observed at wavelengths of 
1720, 1654 and 1541cm-1 for both ECM scaffolds which can be attributed to the carbonyl bond in the 




Figure 41: Representative FTIR spectra for the two ECM scaffolds (aorta and heart ECM blended scaffolds) 
compared to the PCL control and the native decellularized ECM. FTIR spectra of the blended scaffolds show 
peaks at the Amide I and Amide II bonds which are indicative of ECM proteins. 
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4B.3.5 Contact Angle Measurement 
Contact angle measurements led to some interesting results as seen in Table 19. Firstly, the PCL had a 
significantly higher contact angle than the two ECM scaffolds after 0.2, 1 and 5 seconds of elapsed 
time. After 0.2 seconds, the PCL scaffold had a contact angle of 130.7 ± 0.9º, compared to 94.4 ± 
39.6º and 93.1 ± 39.6º for the heart ECM and aorta ECM scaffolds, respectively.  Interestingly, the 
PCL scaffold maintained its hydrophobicity over the 5 seconds, with a small reduction in contact 
angle of 2.59% noted. In contrast the heart ECM scaffold and aorta ECM scaffold had reductions in 
contact angle of 36.31% and 62.13% over the 5 seconds, respectively. This suggest that the two ECM 
scaffolds are much more hydrophilic than the PCL scaffold. 
Table 19: Contact angle measurements for all three scaffolds 
  Scaffold type 
  PCL Heart ECM Aorta ECM 
Contact angle after 0.2s, ° 130.7 ± 0.9* 94.4 ± 39.6 93.1 ± 39.6 
Contact angle after 1s, ° 131.3 ± 2.3* 85.3 ± 44.4 68.8 ± 33.4 
Contact angle after 5s, ° 127.3 ± 6.9* 60.1 ± 44.2 35.3 ± 7.4 
Percentage drop in 
contact angle between 
0.2s and 1s 
- 0.44% 9.72% 26.11% 
Percentage drop in 
contact angle between 
0.2s and 5s 
2.59% 36.31% 62.13% 
*The PCL scaffold showed significantly higher contact angles than both ECM scaffolds after 0.2, 1 and 5 seconds.  
4B.3.6 Cell Viability  
Cell viability was assessed using a CellTitre-Blue® fluorescence assay. Results are displayed in Figure 
42 and show a significant increase in HUVSMC cell viability on the two ECM scaffolds compared to 
the PCL scaffold after 10 days of culture. Furthermore, the two ECM scaffolds showed significantly 
higher cell viability after 10 days of culture compared to 1 and 5 days of culture, whereas the PCL 
only scaffold did not have a significant increase in cell viability over time. Interestingly, while the 
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PCL only scaffold did not show a significant increase in viability like the two ECM scaffolds, it did 
maintain cell viability over the 10 days of culture. 
 
Figure 42: Cell viability of HUVSMCs cultured on PCL, aorta ECM and heart ECM scaffolds after 1, 5 and 10 
days of culture. N=4, error bars = SD. ***p < 0.001.  
 
4B.3.7 DNA Quantification 
DNA quantification per scaffold was assessed using a Quant-iTTMPicoGreen® assay kit. Results 
showed that DNA content per scaffold significantly increased in the aorta ECM and heart ECM 
scaffolds after 10 days of culture compared to the PCL only scaffold, as seen in Figure 43. 
Furthermore, the PCL only scaffold appeared to have a higher DNA content after 24 h of culture than 
the other two scaffolds, however, its DNA content stayed fairly constant over the 10 days of culture, 




Figure 43: DNA content of HUVSMCs on all three scaffolds after 1, 5 and 10 days. The HUVSMCs on the two 
ECM scaffolds showed significantly higher DNA content after 10 days of culture compared to the two other 
scaffolds. N=4, error bars = SD. ***p < 0.001.  
 
4B.3.8 Cell Imaging 
Representative SEM images show the functional cell layers on scaffolds after 10 days of culture 
(Figure 44). The PCL only scaffold and aorta ECM scaffold both show cell alignment, which is a 
phenotypic characteristic of VSMCs. The heart ECM scaffold did not show alignment. Interestingly, 
the aorta ECM scaffold showed the typical ‘hill and valleys’ morphology seen with VSMCs when 




Figure 44: Representative osmium stained SEM images showing seeded HUVSMCs on all thee scaffolds (PCL, 
aorta ECM and heart ECM) after 10 days of culture. 
 
Representative DAPI (nuclei) and phalloidin (f-actin) stained images taken using CARS show that all 
three scaffolds were capable of maintaining healthy HUVSMCs (Figure 45). All images show an 




Figure 45: Representative nuclei (blue) and f-actin (green) stained HUVSMCs seeded on all three scaffolds 
(PCL, aorta ECM and heart ECM) after 10 days of culture. 
4B.3.9 Gene Analysis 
RT-qPCR analysis of cell seeded scaffolds showed some interesting trends, as seen in Figure 46. Two 
genes were analysed: myocardin and Interleukin 1 Alpha (IL1-α). Interestingly, myocardin showed no 
real difference between the three scaffolds at each time point, however, in all cases, the expression of 
myocardin increased as culture time increased. Myocardin is the key phenotypic gene in smooth 
muscle cells and is heavily involved in their contractile functionality 378–381. 
IL1-α is upregulated during smooth muscle cell proliferation 431. Interestingly, IL1-α expression 
increased over time, which falls in line with the cell viability and DNA quantification results, 
suggesting that the cells were proliferating as culture time increased. No real differences were noted 




Figure 46: RT-qPCR results showing Interleukin 1 alpha and myocardin gene expression from HUVSMCs 
cultured on the three scaffolds (PCL, aorta ECM and heart ECM). N=5, error bars = SD. *p < 0.05.  
 
4B.4 Discussion 
Electrospun polymer scaffolds have been extensively utilised in tissue engineering, with PCL being 
widely used due to its FDA approval and its versatility with different solvents and scaffold 
manufacturing techniques 198,209,382. Three different scaffolds with similar fibre diameters (diameters 
ranged from 0.69 µm to 0.77 µm) were electrospun, ensuring that all differences noted in the results 
can be attributed to the scaffold composition and not to the scaffold’s morphology. H&E staining and 
DNA quantification (Figure 39) confirmed that the native tissues had been successfully decellularized 
to the acceptable standards 257. Furthermore, FTIR spectra showed that the decellularized ECMs had 
been successfully incorporated into the electrospun PCL scaffolds. Peaks were noted at the Amide I 
and Amide II bond wavelengths (1654 and 1541 cm-1) in the two ECMs alone and in the two 
PCL:ECM scaffolds. These peaks are characteristic peaks ECM proteins and their presence in the two 
PCL:ECM scaffolds shows that the ECM has been successfully incorporated into the PCL scaffold 432. 
Furthermore, a peak was noted at 1720 cm-1 in the PCL only scaffold and the two PCL:ECM 
scaffolds. This peak is associated with the carboxyl group in the PCL 331. 
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Cell viability and DNA quantification results followed a very similar pattern, which is expected when 
cell number is directly proportional to cell viability. Both sets of results showed a significant increase 
in the two ECM scaffolds after 10 days of culture compared to the PCL only scaffold. Likewise, they 
both showed lower viability and DNA content after 1 day of culture for the ECM scaffolds compared 
to the PCL, however, large increases were noted after 5 days, whereas the PCL only scaffold showed 
no increase. These results suggest that either the aorta or heart ECM scaffold make a more suitable 
scaffold for the culture of SMCs if cell proliferation is the desired result. While over proliferation of 
SMCs is often associated with tumour formation and atherosclerosis, an initial proliferative response 
is desirable to promote new tissue formation 433,434.  
Mechanical characterisation showed some interesting results. Firstly, the two ECM scaffolds both had 
stiffnesses approximately half of the PCL only scaffold for all five strain bands. Furthermore, the two 
ECM scaffolds both had a lower failure strain and a lower ultimate tensile strength than the PCL only 
scaffold. These results show that the inclusion of ECM did alter the mechanical properties of the 
scaffold and the way in which the ECM is incorporated into the fibre needs further study to fully 
assess exactly why the mechanical properties differ between the three scaffolds.  
DAPI (nuclei) and phalloidin (f-actin) staining showed that all three scaffolds were able to maintain 
an SMC phenotype. The cells had an elongated morphology, stretching across several fibres which is 
a key marker for healthy vascular smooth muscle cells 435. Furthermore, as seen in Figure 44, after 10 
days of culture the cells on the aorta ECM scaffold reorganized themselves into bundles of cells. This 
is common phenotypic phenomena noted with VSMCs when culture in vitro, especially when cultured 
on 2D surfaces such as tissue culture plastic 389,436. 
RT-qPCR results showing the gene expression of two key genes revealed some interesting trends. 
Firstly, myocardin gene expression was seen to upregulate on all three scaffolds as the culture time 
was increased. Myocardin is a gene associated with the contractile functionality of SMCs and its 
upregulation is a marker of a maturing SMC 378–381. This would suggest that the SMCs matured on all 
three scaffolds and that the incorporation of ECM had no real impact on this. This result is somewhat 
expected as proliferating SMCs are gaining maturity. Likewise, the expression of IL1-α was seen to 
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be very low after 1 day of culture but increased on all three scaffolds as culture time was increased. 
IL1-α is upregulated in SMCs during cell proliferation, therefore, it would be expected that the two 
ECM scaffolds saw an upregulation of IL1-α as cell viability and DNA content both confirm that the 
cells were proliferating 431,437. However, the upregulation noted on the PCL only scaffold is not 
expected as both cell viability and DNA content suggest that the cells were not proliferating. This 
phenomena could be attributed to a high rate of cell death on the PCL only scaffold meaning that 
while the cells are proliferating, the total number of cells on the scaffold may not be increasing.  
4B.5 Conclusions 
In conclusion, three unique scaffolds were fabricated with very similar morphologies. Vascular ECMs 
were successfully incorporated into the electrospun PCL scaffolds and their incorporation was 
confirmed using FTIR, which showed peaks at wavelengths associated with ECM proteins. VSMCs 
were successfully seeded onto the scaffolds and cultured for a 10 day period. Cell viability and DNA 
content results showed that the two ECM scaffolds were more suited for the seeded VSMCs with a 
final aim of cell proliferation. Furthermore, gene expression analysis showed no real difference 
between the three scaffolds, suggesting that either of the ECM scaffolds is best suited for 




Part C: Mechanical and Biological Characterisation of Aorta ECM scaffolds 
4C.1 Introduction 
Combining ECM with polymers to manufacture electrospun bioscaffolds has previously been utilised 
to harness the repeatable mechanical properties of the polymer with the biochemical and mechanical 
properties of the ECM 198,199,360,438. Electrospinning polymers produces a network of fibres that can be 
heavily tailored depending on the properties desired 217. They can be designed to have isotropic or 
anisotropic mechanical properties, along with 3 dimensional architectural properties that favour cell 
survival and growth 177. It is possible through electrospinning to include bioactive cues into a 
repeatable polymer structure and alter its mechanical and physical properties 198,199,323,438. This has 
huge implications in tissue engineering where mimicking the physical and biological properties of the 
native ECM are major research focusses, especially when the final aim is generation of new 
functional tissue. 
Previous studies have shown that incorporating ECM into electrospun polymer scaffolds alters both 
its mechanical properties and also affects seeded cells. The present study found that the aorta ECM 
scaffold was best suited to the seeding of HUVECs. Therefore, the present study proposed 
electrospinning a combination of aortic ECM with PCL at two different ECM concentrations and 
biomechanically evaluating the resulting fibrous scaffolds.  
4C.2 Materials and Methods 
4C.2.1 Decellularization 
Aorta and heart samples were collected from a 2 year old female cow and decellularized using a 
previously described method. More details can be found in Section 2.2.  
4C.2.2 Electrospinning 
Powdered ECM was dissolved at either 0.25% w/v or 1% w/v into HFIP. PCL was then added to the 
solutions at 8% w/v and dissolved on a roller overnight. PCL only scaffolds were used as controls. 
Solutions were electrospun using an EC-DIG electrospinning system. Samples were electrospun onto 
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an aluminium foil covered mandrel using the following criteria: 0.4 mm needle, 0.8 mL/h, 12 cm, 
+14 kV, -4 kV, 250 RPM and 8 cm distance between mandrel and needle tip. Scaffolds used with 
cells were sterilized for 10mins using 70% v/v ethanol. These electrospinning solutions lead to final 
fibre PCL:ECM ratios of 100:0 (PCL only), 96.875:3.125 (0.25% ECM) and 87.5:12.5 (1% ECM). 
More information can be found in Section 2.1. 
4C.2.3 Scanning Electron Microscopy and Fibre Properties 
Scaffolds were visualised using a scanning electron microscope. Prior to imaging all scaffolds were 
sputter coated with an Emscope SC500A splutter coating using gold-palladium at a ratio of 60:40. 
Cell seeded scaffolds were visualized after 6 days using a previously described osmium based method 
346. 
Scanning electron images were analysed using ImageJ software (NIH). Briefly, SEM images of the 
scaffolds were used with fibre diameter being deduced using the DiameterJ plugin and fibre 
orientation using the OrientationJ plugin 314. A total of 58 fibres were used to measure fibre diameter 
and fibre orientation.  
More details can be found in Section 2.5 and 2.9. 
4C.2.4 Histology 
Native and decellularized samples of aorta were fixed in 10% formalin overnight. This was followed 
by a series of dehydration ranging from 50% to 100% ethanol. Samples were washed in xylene prior 
to embedding in paraffin wax and were then stored at 4ºC. Samples were trimmed to 5 μm thicknesses 
and mounted onto slides for Haematoxylin and Eosin (H and E) staining. Samples then cleared with 
xylene and mounted in DPX. More details can be found in Section 2.4. 
4C.2.5 Mechanical Properties 
Tensile properties were measured using an Instron 3367 testing machine (Instron) with a 50 N load 
cell. More details can be found in Section 2.7. 
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4C.2.6 Contact Angle Measurements 
Contact angle was measured on dry scaffolds. A 5 µL droplet of water was placed onto the scaffold 
and images were captured using a DMK 41AU02 monochrome camera at a frequency of 5 Hz. 
Analysis of the scaffolds was done on ImageJ using the LBADSA plugin 309. N=5. More details can 
be found in Section 2.8. 
4C.2.7 Cell Culture and Scaffold Seeding 
HUVECs were expanded using MCBD 131 medium supplemented with 5% v/v FBS + 1% v/v L-
glutamine + 1% v/v penicillin/streptomycin + 1 mg/L hydrocortisone + 50 mg/L ascorbic acid + 
2 μg/L fibroblast growth factor + 10 μg/L epidermal growth factor + 2 μg/L insulin-like growth factor 
+ and 1 μg/L VEGF. 
HUVECs were lifted for scaffold seeding at 80% confluence. Scaffolds (10 mm diameter) were 
punched out of the electrospun sheet, sterilized in 70% ethanol and then placed into 48-well plates and 
soaked in serum free MCDB 131 medium overnight. Wetting medium was removed and scaffolds 
were then seeded at a density of 350,000 cells/cm2. Briefly, cells were drip seeded in 30 µL of 
medium onto the middle of the scaffold. After 30 mins a further 20 µL of medium was added to stop 
the cells from drying out. After a further 30 mins, medium in each well was topped up to 500 µL. 
More details can be found in Section 2.3 and 2.12. 
4C.2.8 Cell Viability 
The assay was performed at 3 days and 6 days as per manufacturer’s instructions. Briefly, 
measurements were taken at ex: 525 nm and em: 580-640 nm. For each condition group, n=4. More 
details can be found in Section 2.13. 
4C.2.9 DNA Quantification 
Native and decellularized samples were tested for total DNA content using a Quant-




4C.2.10 Fourier Transform Infrared Spectroscopy 
FTIR was used to confirm the successful inclusion of ECM into the PCL fibres. FTIR spectra were 
recorded in the wave range of 400-4000 cm-1 at a resolution of 1 cm-1. N=5. More details can be found 
in Section 2.11. 
4C.2.11 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 
ANOVA with post-hoc Fisher test. 
4C.3 Results 
4C.3.1 Decellularization 
Bovine aorta was successfully decellularized using a 0.5% w/v SDS perfusion protocol. Relative 
DNA was measured using a Quant-iT™PicoGreen assay kit and showed a 96.5% drop in DNA 
content after decellularization, as seen in Figure 47. Furthermore, H and E staining showed that the 
nuclear content of the aorta had been successfully removed from the tissue, as seen in Figure 47. 
 
Figure 47: Bovine aorta was successfully decellularized using a 0.5% SDS protocol. (A) DNA content results 
showing a 96.5% decrease in DNA content. H and E staining of (B) and (D) native aortic tissue and (C) and (E) 
decellularized aortic tissue. 
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4C.3.2 Scaffold Properties 
All three scaffolds were successfully electrospun using the same parameters, as seen in Figure 48. All 
three scaffolds were manufactured with very similar fibre morphologies. Fibre diameters ranging from 
0.90 ± 0.19 µm to 0.97 ± 0.19 µm were noted across the three scaffolds, meaning that any differences 
noted between the three scaffolds can be attributed to the inclusion of ECM into the fibres and not due 
to differing fibre morphologies. Similarly, all three scaffolds had very similar fibre orientations with 
peaks noted at 45°. 
 
Figure 48: Assessment of scaffold morphology. SEM images of all three electrospun scaffolds (PCL, 0.25% 





4C.3.3 Fourier Transform Infrared Spectroscopy 
FTIR results showed that the aortic ECM was successfully incorporated into the electrospun fibres. 
Spectra were taken for the PCL fibres alone, the ECM alone and both ECM/PCL scaffolds. 
Characteristic peaks from the PCL and ECM could be seen in both ECM/PCL scaffolds, with larger 
peaks noted in the 1% ECM scaffold compared to the 0.25% ECM scaffold, suggesting that more 
ECM had been incorporated into the scaffold, as expected. Peaks can be seen at wavelength bands of 
1705-1715, 1650-1660 and 1535-1545 cm-1 (Figure 49), which can be attributed to the carboxyl group 
in the PCL, and the amide I and amide II groups in the ECM, respectively 331,432. 
 
Figure 49: Representative FTIR spectra of the PCL scaffold; 0.25% aorta ECM scaffold; and 1% aorta ECM 
scaffold showing peaks at the i) carboxyl group, ii) amide I group and iii) amide II group. 
 
4C.3.4 Mechanical Properties 
Tensile testing was performed using an Instron tensile tester and showed significant differences in 
each scaffold’s properties. All scaffolds were stretched until failure. The PCL scaffold showed the 
highest Young’s modulus in the 0–5% strain range at 19.2 ± 1.7 MPa, decreasing to 16.1 ± 1.9 MPa 
for the 0.25% aorta ECM scaffold and then decreasing again to 13.5 ± 0.7 MPa for 1% aorta ECM 
scaffold. The Young’s modulus dropped in each subsequent strain band with the trend of the higher 
ECM concentration showing lower Young’s modulus reversing after 15% strain, as seen in the stress 
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strain curve in Figure 50. At approximately 20% strain the PCL only scaffold becomes very plastic, 
with the 1% aorta ECM scaffold remaining somewhat elastic and the 0.25% ECM scaffold being in 
between the two. This phenomena suggests that the incorporation of ECM is directly linked to the 
increase in scaffold elasticity into the higher strain range.  
 
 
Figure 50: Representative stress vs strain curve for the three scaffolds (PCL, 0.25% aorta ECM and 1% aorta 
ECM). 
 
It was also noted during tensile testing that the higher ECM concentrations lead to lower failure 
strains. The 1% aorta ECM and 0.25% aorta ECM scaffolds had failure strains 47% (p > 0.001) and 
2.6% (no significance) lower than the PCL only scaffold, respectively (Table 20). Likewise, the 
ultimate tensile strength of the scaffolds increased by 84.3% (p > 0.001) and 77.9% (p > 0.001) for 
1% aorta ECM and 0.25% aorta ECM compared to the PCL only scaffold, respectively (Table 20). 
Values for compliance were calculated based on eq. (2). Compliance was seen to increase with ECM 
concentration: the 0.25% ECM and 1% ECM scaffolds had compliance values 19% (p > 0.05) and 
42% (p > 0.01) larger than the PCL-only scaffold (Table 20).  
Table 20: Mechanical properties and contact angles of all three scaffolds (PCL, 0.25% aorta ECM and 1% 
aorta ECM). 
 PCL 0.25% ECM 1% ECM 
Ultimate tensile strength (MPa) 4.26 ± 0.33$ 7.58 ± 1.59 7.85 ± 1.03 
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Failure strain (%) 464 ± 40 452 ± 59 244 ± 29$ 
Compliance (mL/mmHg) 0.049 ± 0.004$ 0.059 ± 0.006 0.070 ± 0.004 
Contact angle after 0.2s (º) 114.4 ± 8.9 89.5 ± 37.7 75.4 ± 25.6 
Contact angle after 5s (º) 98.7 ± 25.2& 68.8 ± 43.6 22.2 ± 10.5& 
* Results with matching symbols (&) are significantly different to each other (p<0.05). Results with the $ symbol are significantly different 
to the two other scaffolds (p<0.05). 
4C.3.5 Contact Angle Measurements 
Contact angle measurements showed some interesting results on the effects of incorporating ECM 
into the electrospun scaffolds. It was noted that incorporating ECM increased the hydrophilicity of the 
scaffold, as seen in Table 20. Contact angle measurements after 0.2 s showed decreases in contact 
angles of 31.1% and 21.8% in the 1% aorta ECM and 0.25% aorta ECM scaffolds compared to the 
PCL only scaffold, respectively. The same trend was noted after 5 s which showed that incorporating 
ECM decreased the contact angle by 77.5% and 30.3% in the 1% aorta ECM scaffold and the 0.25% 
aorta ECM scaffold compared to the PCL only scaffold, respectively.  
4C.3.6 Cell Viability 
Cell viability showed no significant difference between the three scaffolds and showed no change in 
viability between 3 and 6 days of culture, as seen in Figure 51. 
 
Figure 51: Cell viability of HUVECs seeded on the three scaffolds (PCL, 0.25% aorta ECM and 1% aorta 




4C.3.7 Scanning Electron Microscopy 
SEM images of HUVECs after 6 days of culture on all three scaffolds show confluencies ranging 
from 68 to 81% and appear to show cells with very similar morphologies, as seen in Figure 52. These 
results validate the cell viability results, suggesting that all three scaffolds were capable of 
accommodating a healthy monolayer of HUVECs. 
 
Figure 52: SEM images showing a healthy monolayer of HUVECs on all three scaffolds (PCL, 0.25% aorta 
ECM and 1% aorta ECM). 
 
4C.4 Discussion 
The present study used PCL, a commonly used polymer for tissue engineering application, especially 
in electrospinning 177,198. Three similar scaffolds were electrospun using the same parameters, 
demonstrating the repeatable properties that electrospinning PCL possesses. Furthermore, the 
inclusion of ECM had very little effect on how the solution spun, with fibre diameter being similar for 
all three scaffolds (0.90, 0.94 and 0.97 µm). Having three very similar scaffold morphologies ensured 
that the only difference noted between scaffolds was the PCL:ECM ratio (100:0, ~ 97:3 and ~ 88:12). 
This meant results noted between the different scaffolds could be attributed to the PCL:ECM ratio. 
The DNA quantification and H&E staining (Figure 47) confirmed that the native aortic tissue had 
been successfully decellularized. FTIR analysis was used to ensure that the decellularized ECM had 
been successfully incorporated into the electrospun fibres (Figure 49). These results showed peaks in 
the decellularized ECM and in the two PCL:ECM scaffolds at the Amide I and Amide II bonds which 
are two characteristic peaks of ECM proteins 326,432. Interestingly, as ECM concentration increased, 
PCL 0.25% ECM 1% ECM 
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the size of the peak at these two Amide bonds also increased, suggesting that increasing ECM 
concentration led to more ECM being incorporated into the PCL fibres. All three scaffolds showed 
peaks at the Carboxyl group which can be attributed to the PCL 409. FTIR is a surface characterization 
method that has been shown to measure to depths of up to 5 μm 439 – the fibres in this study are all 
under 1μm thick, suggesting that a full characteristic profile of the fibre is being achieved through 
FTIR. 
Tensile testing exposed some interesting results that demonstrate the effect of including ECM into the 
electrospun fibres. The 1% ECM scaffold had a lower stiffness than the PCL only scaffold. This can 
be explained by aortic arch ECM (the ECM used in this study) comprising of approximately 40% 
elastin and 20% collagen 20. Elastin has been shown to have a half-life of around 74 years. As people 
age, the quantity of elastin in their aortas decreases, which leads to a very large increase in aortic 
stiffness – a 394% increase in stiffness was noted between the ages of 25 and 70 16,440. This suggests 
that a lower quantity of elastin in the scaffold would lead to a higher stiffness and lower compliance. 
Furthermore, including aortic ECM resulted in a drastic reduction in failure strain, as seen in Table 
20. This can be explained by collagen having a failure strain of 13% and elastin between 100 and 
150% 441, compared to the PCL only scaffold having a failure strain of 464% (our results). Hence, a 
fibre made up of a ~ 88:12 PCL to ECM ratio (1% ECM) would be expected to fail at a lower strain 
than the fibre with a 100:0 PCL to ECM ratio (PCL only). 
Cellular testing and visualization showed that the HUVECs reacted similarly to all three scaffolds. 
Cell viability (Figure 5D) showed no significant differences between the three scaffolds over both 
timepoints suggesting that including ECM had no impact on their proliferation. Similarly, SEM 
images (Figure 5E) show that the HUVECs had similar morphologies on all three scaffolds. Further 
work looking into gene analysis is required to gain a full bioactivity profile for these scaffolds.   
Studies have shown that altering the contact angle of a scaffold can have effects on cell adhesion 
198,296. Furthermore, the addition of ECM to an electrospun polymer scaffold has been shown to reduce 
water contact angle 198. This result was noted in this study, with a 31.1% and 77.5% lower contact 
angle in the 1% ECM scaffold compared to the PCL only scaffold for the 0.2 s measurement and 5 s 
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measurement, respectively. After 0.2 s the PCL only scaffolds had a contact angle of 114.4° 
(hydrophobic 296), compared to 75.4° for the 1% ECM scaffold. While a relatively hydrophilic contact 
angle of approximately 60° has been shown to lead to higher cell adhesion 296, this could also have 
problematic effects and lead to the binding of unwanted cells, proteins and growth factors found in the 
passing blood. It has been shown that blood-contacting devices and tissue engineering substrates 
require an appropriate balance of hydrophilic and hydrophobic entities to ensure local cells can adhere 
and grow, without causing unwanted binding of substances found in the blood 304. Therefore, with the 
final goal for vascular tissue engineering strategies often being in vivo implantation, it is very 
important to consider the fact that the scaffold will be in contact with a variety of constituents that you 
may not want binding to the scaffold. Hence, in certain situations, higher hydrophobicity may be 
desirable to reduce the binding of unwanted substances. This applies for approaches such as bypass 
grafting where local cell attachment to the implant is unwanted. Therefore, being able to control the 
hydrophobicity of the scaffold/implant is desirable. 
4C.5 Conclusions 
In conclusion, aortic ECM was successfully combined at two different concentrations with PCL and 
electrospun to form random orientated nanofiber scaffolds. Increasing the ECM concentration reduced 
stiffness and increased compliance at lower strains, and increased the elasticity of the nanofibers 
beyond its yield strength. Furthermore, increasing the ECM concentration reduced the failure strain 
and increased the ultimate tensile strength of the scaffold, whilst reducing the water droplet contact 
angle. These results have shown that including decellularized ECMs into a scaffold is a viable method 
















There are a range of different strategies used in the treatment of vascular disease, including the use of 
PCL based scaffolds in tissue engineering, with work looking at incorporating ECMs/proteins and 
altering surfaces to increase the biofunctional potential of the scaffold 198,199,320,322. Likewise, work has 
looked at how polymer scaffolds can have their surfaces activated to increase their binding potential 
for proteins. Guler, et al. looked at how plasma coating combined with 1-ethyl-3-(dimethyl-
aminopropyl) carbodiimide hydrochloride (EDC)/N-hydroxyl succinimide (NHS) treatment could 
increase the quantity of albumin protein binding to the surface of the scaffold 331. This work opens up 
the potential for binding cell secreted proteins onto the surfaces of these scaffolds. 
Feeder layer systems have long been used in cell culture to help with the growth and proliferation of a 
desired cell line 442. In short, they work by growing two different cell types next to each other: (i) a 
feeder cell line, and (ii) the target cell line. The feeder cell line is there to secrete growth factors and 
proteins into the medium to feed the target cell line and help with proliferation 442. Furthermore, 
feeder layer systems often allow for serum free cell culture, which is desirable due to the scientific 
and ethical concerns surrounding the use of serums 111,443–445. The principle of the feeder layer system 
is direct paracrinal cell interactions between the two different cell lines. However, the feeder cell line 
could be used separately to create conditioned medium that can then be used at a later date to help 
with the culture of a different cell line.  
Herein, the present study proposes combining the theory behind feeder layer systems and scaffold 
surface activation methods to bind cell secretome to the surface of PCL scaffolds in an attempt to 
increase their biofunctionality and improve their potential as scaffolds for cell seeding. The cell 
secretome from two different cell types (HUVECs and HUVSMCs) were studied to see how they alter 
the performance of seeded cells. 
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Part A: Cell Secretome Study - Feasibility and Optimization 
5A.1 Introduction 
Various studies were underaken to assess the feasibility of binding secreted proteins onto a scaffolds 
surface and to optimize the protocol. Firstly, looking into how cells grew when cultured in medium 
containing cell secretome showed the potential benefits of using cell secretome conditioned medium. 
Carrying this knowledge forward, the aim was to try and bind proteins onto a PCL based scaffold to 
try and improve the scaffold’s biological potential for seeded cells. The preliminary protein binding 
experiments used bovine serum albumin (BSA) dissolved in MES buffer as this is a fairly standard 
protein which can be accurately measured when using the BCA assay, allowing for the calculation of 
bound protein. The basis of these optimization studies are based off a study by Guler, et al. which 
showed how EDC/NHS chemistry could be used to improve a PCL scaffold’s binding potential for 
BSA. Briefly, the EDC/NHS method works by the EDC activating the carboxyl groups on the 
polymer for reaction with the primary amines. This creates an unstable intermediate that can react 
with another amine. The NHS is then added to stabilize this intermediate by converting the unstable 
amine-reactive O-acylurea into a stable amine-reactive NHS ester. 
5A.2 Culturing Endothelial Cells with Conditioned Medium 
Firstly, an experiment was set up to see how seeded HUVECs responded to the different cell culture 
medium conditions. The aim of this was to see if cell secretome conditioned medium had an influence 
on cell growth. Briefly, three different mediums were collected: (1) a cell secretome conditioned 
serum free medium; (2) a serum free medium and (3) a serum containing medium. All three mediums 
used MCDB 131 as a base supplemented with 1% v/v L-glutamine; 1% v/v penicillin/streptomycin; 
1 mg/L hydrocortisone; 50 mg/L ascorbic acid; 2 μg/L fibroblast growth factor ; 10 μg/L epidermal 
growth factor; 2 μg/L insulin-like growth factor; and 1 μg/L vascular endothelial growth factor. The 
following protocols were used to make each medium: 
1) HUVECs were cultured in a T75 flask until 80% confluence using serum containing MCDB 
131 with all the aforementioned supplements. The medium was then changed to 50% serum 
free medium, 50% serum containing medium for 24 h to help slowly bring the cells off of 
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serum. The medium was then changed to the base serum free medium mentioned above and 
cultured for 24 h allowing for the HUVECs to turnover and secrete various proteins and 
cytokines into the serum free medium. The medium was then lifted off and stored for 
subsequent cell feedings. This medium is referred to as conditioned serum free medium. 
2) The aforementioned supplemented base medium with no serum added. This medium is 
referred to as non-conditioned serum free medium. 
3) The aforementioned supplemented base medium with 5% FBS added. This medium is 
referred to as non-conditioned serum medium. 
Once the mediums had been collected, HUVECs were seeded into 48-well plates and cultured with 
one of the three medium types for 40 h. Cell Titer Blue measurements were taken at 16 h and 40 h to 
see how the cells were growing under the three different medium types. While both serum free 
mediums showed significantly lower cell viability after 40 h of culture than the serum supplemented 
medium, the cell secretome conditioned serum free medium did show a significantly higher cell 
viability than non-conditioned serum free medium (Figure 53). This suggests that the cells are 
secreting proteins and cytokines into the medium that are beneficial for cell growth. 
 
 
Figure 53: Cell viability of HUVECs grown on tissue culture plastic with three different medias: conditioned 




5A.3 Scaffold Functionalization to Increase Protein Binding 
The next step was to see how much protein could be bound/absorbed onto the surface of a scaffold. 
The previous experiment showed that cell secretome conditioned medium contained proteins that 
were beneficial for cell survival. This experiment was ran with a known concentration of BSA and an 
electrospun PCL scaffold. The aim of the experiment was to see which scaffold functionalization 
method lead to the most protein attachment. 
Briefly, electrospun scaffolds were subjected to two different variables. Firstly, half of the scaffolds 
were oxygen plasma coated to improve hydrophilicity. Secondly, the scaffolds were subjected to five 
different concentrations of EDC and NHS in MES buffer 331. Briefly, plasma coated scaffolds were 
subjected to 60 s of oxygen plasma at 10.2 W. The EDC and NHS concentrations were based off of 
literature 331. Concentrations of 0/0, 0.5/0.5, 5/5, 50/50 and 200/200 mM of EDC/NHS in 0.5 M MES 
buffer (pH 5.7) were used to incubate the scaffolds and activate the surface as a means of aiding with 
protein binding. Scaffolds were incubated in this solution for 45 mins, washed thrice in PBS and then 
incubated in the protein solution for 4 h to allow for protein binding, whilst being agitate on a plate 
mixer. 
A BCA protein assay was used to calculate the amount of protein bound to the scaffolds surface. The 
total protein content of the incubating BSA solution was calculated before and after incubation to 
deduce the total mass of protein binding to the PCL scaffold during the incubation period. In all 
instances, a higher amount of bound protein was detected on the plasma coated scaffolds compared to 
the non-plasma coated scaffolds, averaging approximately 25% more protein binding, as seen in 
Figure 54. With regards to EDC and NHS concentrations, the 5mM solution lead to increased protein 
binding, both with and without plasma treatment compared to the other concentrations of EDC and 
NHS. Therefore, moving forward, the 5mM EDC and NHS solution were used to activate the surface 




Figure 54: Total mass of bound bovine serum albumin when using four different concentrations of EDC/NHS 
treatment. N=5, error bars = SD.  
 
5A.4 Addition of ECM to Improve Binding of Protein 
The next experiment looked at whether further biofunctionalizing the scaffolds through the 
incorporation of native ECMs into the fibres would have effects on the quantity of bound protein. 
Native aortic bovine ECM was decellularized (Section 2.2) and electrospun (Section 2.1) with PCL 
creating an 88:12 PCL:ECM ratio electrospun fibre like the scaffold created in Chapter 4C. PCL only 
scaffolds were used as controls. The scaffolds underwent plasma treatment (Section 2.6) followed by 
45 mins of incubation in a 5/5 mM NHS/EDC in MES buffer to activate the surface. The scaffolds 
were then incubated for 4 h in either non-conditioned serum free medium or conditioned serum free 




Figure 55: Schematic representation of the scaffold conditioning process. Scaffolds are electrospun and 
functionalized using EDC/NHS chemistry. The scaffolds are then incubated in conditioned medium. 
A BCA assay was then used to deduce the amount of bound protein from the two mediums on either 
the PCL only scaffold or the ECM:PCL blended scaffold. Results showed that the PCL only scaffold 
lead to approximately 2.5 times more protein binding to the surface of the scaffold compared to the 
blended ECM:PCL scaffold, as seen in Figure 56. Therefore, going forward, the PCL only scaffold 
was used to increase the binding potential of the scaffold. 
5A.5 Discussion and Conclusions 
EDC and NHS treatments are commonly used to increase the quantity of free amide and carboxyl 
groups found on the surface of polymers. While the pH of the solution can be altered to increase the 
polymer’s affinity for certain bond types, the exact formulation of the secretome conditioned medium 
was not known, therefore a standard protocol and pH level (pH of 5.7) for all protein types was used. 
A pH of 5.7 was chosen as pH levels lower than this lead to very short active half-life’s, reducing the 
overall effectiveness of the procedure, and pH levels above this reduce the total activation of carboxyl 





Figure 56: Total mass of bound HUVEC secreted protein when using a PCL only scaffold and an ECM:PCL 
blended scaffold for two different media types. N=5, error bars = SD. *p < 0.05. 
 
Part B: Cell Secretome and Endothelial Cells 
5B.1 Introduction 
Electrospinning has been a widely used scaffold manufacturing technique used in vascular tissue 
engineering with endothelial cell lines 310,357,446. Furthermore, the concept of grafting proteins, growth 
factors and peptides onto electrospun scaffold surfaces has also been used in tissue engineering 25,447. 
While these methods have shown promise in the field of vascular tissue engineering, there are still 
shortfalls between the capabilities of lab-based materials and native tissues 129.  
This study proposes utilising the principles of feeder layer systems in combination with known 
scaffold functionalization techniques. To improve the biofunctional properties of the scaffold, 
HUVEC secretome was collected in a serum free medium and bound to the surface of an electrospun 
scaffold. This technique allows for the cell’s paracrinal secretomes to be engrafted onto the surface of 
the scaffold, which might help provide better original cell binding and gene expression in the early 
staged of implantation. 
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5B.2 Methods and Materials 
5B.2.1 Electrospinning 
PCL was dissolved at 20% w/v into a 5:1 mixture of Chlorofrom:Methanol. Briefly, the electrospun 
fibres were spun using the parameters in Table 21 and collected. Scaffolds with a 10 mm diameter 
were punched out. Extra-large fibre diameter scaffolds were used as they have previously shown 
better affinity for HUVECs. More details can be found in Section 2.1. 
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5B.2.2 Scanning Electron Microscopy 
Scaffolds were imaged using a Hitachi TM4000 tabletop SEM as described in Section 2.5. 
5B.2.3 Mechanical Analysis 
Mechanical analysis was performed using an Instron 3367 testing rig with a 50 N load cell. 
Measurements were performed on 40mm x 5mm samples. Samples with a gauge length of 20 mm 
were stretched to failure at 10 mm/min. More details can be found in Section 2.7. 
5B.2.4 Cell Growth 
HUVECs were expanded using MCBD 131 medium supplemented with 5% v/v FBS; 1% v/v L-
glutamine; 1% v/v penicillin/streptomycin; 1mg/L hydrocortisone; 50 mg/L ascorbic acid; 2 μg/L 
fibroblast growth factor; 10 μg/L epidermal growth factor; 2 μg/L insulin-like growth factor; and 
1 μg/L vascular endothelial growth factor. HUVECs were lifted for scaffold seeding at 80% 
confluence. More details can be found in Section 2.3. 
5B.2.5 Cell Secretome Collection 
Briefly, HUVECs were cultured in a T75 flask to 70% confluence in cell MCDB 131 culture media 
containing FBS (as described in Section 5A.2.4). The media was then changed to 50:50 culture media 
containing FBS and culture media without any FBS for a further 24 h of culture. This was done to 
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slowly take the cells off of FBS before they were cultured serum free. The cells were then changed 
over to serum free media (10 mL) and cultured for 24 h, allowing sufficient time for the cells to 
release secretome (cytokines, proteins, etc.) into the serum free media. The media was then removed 
and used to soak the scaffolds.  
5B.2.6 Scaffold Functionalization and Secretome Binding 
Scaffolds underwent two steps of functionalization before being soaked in secretome filled media. 
Firstly, the scaffolds underwent 1min of oxygen plasma coating at 10.2 W to improve their surface 
energy and hydrophilicity. The scaffolds were then soaked in 5 mM of EDC and 5 mM of NHS in 
0.5 M of MES buffer (pH 5.7) for 1h to create binding sites on the scaffold for binding proteins and 
cytokines in the secretome media. This was followed by three PBS washes. The scaffolds were then 
soaked in 250 µL of secretome filled media for 4 h, whilst being agitated to assist with the binding of 
factors. The scaffolds were then quickly dipped in PBS (1 s) to remove excess media before being 
seeded with cells. Scaffolds soaked in serum free media containing no secretome and PBS were used 
as controls. 
5B.2.7 Protein Quantification 
Protein quantification was used to measure the quantity of protein being bound/absorbed onto the 
scaffolds surface during the 4 h soaking phase. Briefly, a BCA protein assay was used with protein 
contents before and after soaking being measured and used to deduce the amount of protein bound to 
the scaffold. The assay was also used to measure the change in protein content of the media after the 
24 h of culture to show how much protein was being added to the media during culture. More details 
can be found in Section 2.14. 
5B.2.8 HUVEC Seeding and Culture 
Once the scaffolds were functionalised and soaked in secretome they were ready for cell seeding. 
Briefly, 75,000 cells in 20 µL of serum free media per scaffold were drip seeded. After 1 h the media 
was topped up with 30 µL of media to ensure the cells did not dry out. After another hour the media 
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was topped up to a total volume of 500 µL. Timepoints of 12 h, 24 h and 48 h were used. More details 
can be found in Section 2.12. 
5B.2.9 HUVEC cell Viability 
The Cell Titer blue assay was performed as per manufacturer’s instructions. The plate was measured 
at ex: 525 nm and em: 580-640 nm. More detail can be found in Section 2.13. 
5B.2.10 Imaging of seeded HUVECs 
Scaffolds were fixed in 10% formalin for 1 h and then washed thrice in PBS for cell imaging. Briefly, 
scaffolds were permeabilized in Triton-X solution before being stained in Phalloidin-iFluor™514 
conjugate for 60 mins to visualize cell nuclei. Scaffolds were then washed thrice in PBS and then 
stained with 300 nM DAPI for 10 mins to visualise f-actin filaments followed by three PBS washes. 
Scaffolds were imaged using a Zeiss Axio Imager 2 microscope. More detail can be found in Section 
2.17. 
5B.2.11 Reverse Transcription Quantative Polymerase Chain Reaction (RT-qPCR) 
RNA was extracted from the cell seeded scaffolds using a Tri-Reagent method and purified using 
Qiagen’s RNeasy spin colum system. Real-time polymerase chain reaction was performed using a 
LightCycler® 480 Instrument II and Sensifast™ SYBR® High-ROX system. Forward and reverse 
sequences were designed and are displayed in Table 22. Relative quantification of RT-PCR results 
was carried out using the 2−∆∆𝑐𝑡 method 350. Gene expression levels were expressed relative to 
GAPDH (housekeeping gene) and normalised to 70% confluent HUVECs on tissue culture plastic. 
More detail can be found in Section 2.18. 
Table 22: Primer sequences used for RT-PCR for the HUVEC secretome conditioned scaffold study. 
Gene Primer Sequence Reference 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
31 GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Matrix metalloproteinase-1 
MMP1 (forward) CGGTTTTTCAAAGGGAATAAGTACT 
31 MMP1 (reverse) TCAGAAAGAGCAGCATCGATATG 
Matrix metalloproteinase-2 MMP2 (forward) CGCTCAGATCCGTGGTGAG 31 
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MMP2 (reverse) TGTCACGTGGCGTCACAGT 
Intercellular Adhesion 
Molecule 1 
ICAM1 (forward) CCTTCCTCACCGTGTACTGG 
448 ICAM1 (reverse) AGCGTAGGGTAAGGTTCTTGC 
Vascular endothelial growth 
factor 
VEGF (forward) AGACCAAAGAAAGATAGAGCAAGACAAG 
31 VEGF (reverse) GGCAGCGTGGTTTCTGTATCG 
Platelet endothelial cell 
adhesion molecule 
CD31 (forward) ACTGGACAAGAAAGAGGCCATCCA 
361 CD31 (reverse) TCCTTCTGGATGGTGAAGTTGGCT 
 
5B.2.12 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 
ANOVA with post-hoc Tukey test. 
5B.3 Results 
5B.3.1 Electrospinning 
Scaffolds were successfully electrospun and showed uniform fibre sizes and a random orientation 
(Figure 57A). Fibre diameters were measured as being 5.95 ± 1.24 µm, which falls in line with the 
optimal fibre diameter for HUVECs deduced in Chapter 3.  
 
Figure 57: Representative SEM showing large fibred scaffold for seeding with HUVECs. 
5B.3.2 Protein binding 
The total mass of protein being bound onto the surface of the scaffolds was assessed using a Pierce™ 
BCA protein assay kit. The conditioned medium was found to have approximately 13% more protein 
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than the serum free medium. This suggests that the HUVECs being cultured caused a net increase in 
the quantity of protein in the medium. Therefore, it can be concluded that the cells are secreting 
proteins and cytokines into the medium. After 4 h of incubation the protein contents of both mediums 
dropped by over 150 ng/mL. This means that approximately 40 ng of protein bound on the secretome 
conditioned scaffolds and 37 ng of protein onto the serum free conditioned scaffolds, as seen in Table 
23. 




Serum free media 




782 ± 35 693 ± 29 
After protein binding 620 ± 40 542 ± 37 
Protein bound/absorbed onto scaffold (µg) 40.6 ± 3.2 37.7 ± 3.0 
 
5B.3.3 Cell Viability 
Cell viability results showed that all three scaffolds were capable of maintaining cell viability when 
cultured using serum free medium, as seen in Figure 58. No significance was noted between the three 
groups at either of the time points. However, a significant increase was noted between 12 h and 48 h 




Figure 58: Cell viability of seeded HUVECs on all three scaffolds (PBS control, serum free media and 
conditioned media) after 12h, 24h and 48h of culture. 
 
5B.3.4 Cell Imaging 
DAPI and phalloidin fluorescence staining of the HUVECs on all three scaffolds at 12 h, 24 h and 
48 h showed some interesting results, as seen in Figure 59. Interestingly, all three scaffolds are 
capable of maintaining the elongated phenotypic morphology of HUVECs up to 48 h of culture in a 
serum-free environment. In all three cases the HUVECs appear to be infiltrating the scaffold as 




Figure 59: Representative DAPI (nuclei) and phallodin (f-actin) stained HUVECs on the three different 
scaffolds 
 
5B.3.5 Reverse Transcription Quantative Polymerase Chain Reaction 
RT-PCR results showed some interesting trends (Figure 60). Firstly, there was a general trend 
whereby the expressions of CD31, VEGF, ICAM1 and MMP2 were all slightly lower in the HUVECs 
seeded onto the scaffold that had been conditioned with cell secretome. While this was mostly not 
significant, there was some significance noted between some of the scaffolds. The expression of 
VEGF on the secretome conditioned scaffold after 48 h of culture was significantly lower than that on 
the control scaffold conditioned with PBS. Likewise, the expression of ICAM1 on the secretome 
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conditioned scaffolds was significantly lower after 48 h compared to the scaffolds conditioned with 
serum free media and the PBS conditioned control. Furthermore, after 48 h of culture the expression 
of MMP2 was also significantly lower on the secretome conditioned scaffold than on the serum free 
medium conditioned scaffold.  
 
Figure 60: RT-PCR gene expression results for seeded HUVECs. Genes analysed: CD31, VEGF, ICAM1, 





Firstly, a scaffold with extra-large fibres (diameter of 5.95 ± 1.24 µm) was successfully electrospun 
with uniform fibre sizes and a random alignment. The extra-large fibre was used due to the seeded 
HUVECs showing increased cell viability and upregulated gene expression compared to the smaller 
fibre sizes, as seen in Chapter 3.  
Interestingly, the quantity of bound protein on the scaffolds soaked in secretome conditioned serum 
free medium and non-conditioned serum free medium were both fairly similar: 40.6 µg and 37.7 µg, 
respectively, which accounts for an increase of approximately 7.5% when soaked in the secretome 
media. Furthermore, the total mass of protein in the mediums was approximately 13% higher in the 
secretome conditioned media compared to the non-conditioned media before any soaking had taken 
place. This means that a higher proportion of the proteins in the non-conditioned medium were 
binding to the scaffold’s surface compared to the proteins in the secretome conditioned medium. This 
may be due to the proteins being secreted by the HUVECs having a lower binding affinity with the 
functionalized PCL compared to the proteins already found in the serum free medium. Work by Coad, 
et al. found that different proteins (human serum albumin and streptavidin) with different chemical 
structures had different binding affinities to plasma coated polymers 449. 
The exact formulation of the secretome conditioned medium is unknown, as a full proteomic study or 
the use of a Luminex assay would need to be carried out. However, work by Fromer, et al. found that 
HUVEC conditioned serum free medium contained an increased quantity of endolglin, fibroblast 
growth factor – 1 (FGF-1), FGF-2, and hepatocyte growth factor (HGF), compared to the non-
conditioned medium containing serum 203. Interestingly, the conditioned medium contained a reduced 
amount of VEGF compared to the serum containing non-conditioned medium, albeit the concentration 
was still very high 203. Therefore, it would be expected that these proteins would all be found within 
the secretome conditioned medium in this study. However, this study was not able to confirm exactly 
which proteins had bound to the surface of the scaffold. 
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While this study does not look into exactly which proteins have bound to the surface of the scaffold, 
work by Edlund, et al. found that, when treated with EDC and NHS, VEGF was successfully grafted 
onto the surface of PCL 447. Interestingly, VEGF was found to be one of the most prevalent proteins in 
HUVEC conditioned medium, therefore it would be expected that VEGF is binding to the surface of 
the scaffolds in this study 203. 
The PCR results show some interesting trends between the three groups. There was a general trend 
whereby the expressions of CD31, VEGF, ICAM1 and MMP2 were all slightly lower in the HUVECs 
seeded onto the scaffold that had been conditioned with cell secretome conditioned medium. While 
these trends were mostly not significant, there was some significance noted between some of the 
scaffolds. As previously mentioned, the expression of VEGF on the secretome conditioned scaffold 
after 48h of culture was significantly lower than that on the control scaffold conditioned with PBS. 
Previous work by Fromer, et al. found that HUVECs secreted VEGF into their culture mediums, 
therefore elevating the total quantity of VEGF in the medium 203. This may explain why VEGF 
expression was lower on the scaffolds soaked in the secretome conditioned medium, as the seeded 
HUVECs may not need to express as much VEGF into their surroundings due to the existing presence 
of VEGF already bound to the scaffold. Furthermore, VEGF expression on the two medium 
conditioned scaffolds increased over time, which may be caused by the VEGF present on the scaffold 
being turned over and used by the HUVECs, requiring them to increase the expression of VEGF to 
maintain HUVEC proliferation and migration 450. 
Likewise, the expression of ICAM1 on the secretome conditioned scaffolds was significantly lower 
after 48 h compared to the scaffolds conditioned with serum free media and the PBS conditioned 
control. These interesting trends do suggest that the conditioning medium may have played an impact 
on the gene expression of the seeded HUVECs.  
MMP2 is involved in the breakdown and remodelling of ECM 451. Its downregulation in the scaffolds 
soaked in secretome conditioned medium could suggest homeostasis amongst the cells. Furthermore, 
MMP upregulations are often associated with degenerative diseases such as osteoarthritis and vascular 
disease, therefore are not necessarily desirable 451,452.  
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Interestingly, both the cell viability results and the DAPI/phalloidin staining show that all three 
scaffolds are capable of maintaining healthy HUVECs over a 48 h serum-free culture period. The 
staining shows elongated HUVECs, which is phenotypic characteristic associated with healthy 
HUVECs 453. Furthermore, cell viability results showed no significant increase in viability over the 
48h culture period for all three scaffolds.  
This study has shown that the expression of certain genes can be controlled through the binding of cell 
secretomes onto the surface of the scaffold. Whilst the expression changes noted were small, a general 
trend can be seen suggesting that the bound proteins are having an effect on the seeded HUVECs. 
Going forward, a full proteomic study of the cell secretome medium and of the conditioned scaffolds 
would give more insight into why these trends are being seen. However, being able to control gene 
expression whilst also maintaining cell survival over the first 48h of attachment (when cultured 
serum-free) does have benefits for tissue engineering where initial cell infiltration and binding are 
required for the success of the implant. 
5B.5 Conclusions 
In this study, cell secretome conditioned medium was created by culturing HUVECs with serum-free 
medium for 24 h. It contained an elevated quantity of protein compared to the serum-free medium 
suggesting that the HUVECs were secreting proteins into the medium. Furthermore, approximately 
37-40 µg of protein was successfully bound to the PCL scaffold. Cell viability showed that all three 
scaffolds were capable of maintaining cell growth when cultured in a serum-free environment over a 
48 h period. Additionally, the binding of proteins (both from the cell secretome conditioned medium 
and the serum-free medium) to the scaffolds had effects on the gene expression noted from the seeded 
HUVECs. Most notably, several genes were downregulated on the secretome conditioned medium. 
These results show the potential benefits to binding cell secretome to the surface of the scaffold. 
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Part C: Cell Secretome and Smooth Muscle Cells 
5C.1 Introduction 
Electrospinning is a widely used scaffold manufacturing technique used in all facets of tissue 
engineering 177,311,347. Furthermore, the technique has been widely used with smooth muscle cell 
lines 446,454,455. In addition to this, engrafting proteins, growth factors and peptides onto electrospun 
scaffold surfaces has also shown promise in tissue engineering as a means of altering the scaffold’s 
surface properties 25,447. However, there is still a shortfall between the capabilities of lab-based 
materials and native tissues 129.  
Herein, this study proposes collecting HUVSMC secretome in a serum free medium and binding the 
proteins to the surface of an electrospun scaffold to improve the biofunctional properties of the 
scaffold. This method allows for the cell’s secreted proteins to be engrafted onto the surface of the 
scaffold, which might help provide better cell binding and gene expression in the early staged of 
implantation. 
5C.2 Methods and Materials 
5C.2.1 Electrospinning 
PCL was dissolved at 8% w/v into HFIP. Briefly, the electrospun fibres were spun using the 
parameters in Table 24 and collected. Scaffolds with a 10 mm diameter were punched out. A small 
fibre diameter scaffolds were used as they have previously shown better affinity for HUVSMCs. More 
details can be found in Section 2.1. 
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5C.2.2 Scanning Electron Microscopy 
Scaffolds were imaged using an SEM with a 15 kV accelerating voltage and a 10 mm working 
distance. More details can be found in Section 2.5. 
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5C.2.3 Mechanical Analysis 
Mechanical analysis was performed using an Instron testing rig. Samples with 40 x 5 mm dimensions 
were cut out for measurements. A gauge length of 20 mm was used and samples were stretched to 
failure at 10 mm/min. More details can be found in Section 2.7. 
5C.2.4 Cell Growth 
HUVSMCs were expanded to passage 4 in a 5% CO2/37°C atmosphere. HUVSMCs were expanded 
using smooth muscle cell growth medium and then cultured using DMEM supplemented with 10% 
v/v FBS; 1% v/v penicillin/streptomycin; 1% v/v non-essential amino acids and 1% insulin transferrin 
selenium (ITS). HUVSMCs were lifted for scaffold seeding at 80% confluence. More details can be 
found in Section 2.3. 
5C.2.5 Cell Secretome Collection 
Briefly, HUVSMCs were cultured in a T75 flask to 70% confluence in supplemented DMEM. The 
media was then changed to 50:50 culture media containing FBS and culture media without any FBS 
for a further 24 h of culture. This was done to wean the cells off of FBS before they were cultured 
serum free. The cells were then changed over to serum free media (10 mL) and cultured for 24 h, 
allowing sufficient time for the cells to release secretome (cytokines, proteins, etc.) into the serum 
free media. The media was then removed and used to soak the scaffolds. The serum free medium used 
is the same as mentioned in 5C.2.4 but without serum. 
5C.2.6 Scaffold Functionalization and Secretome Binding 
Scaffolds underwent two different steps of functionalization before being soaked in secretome filled 
media. Firstly, scaffolds were oxygen plasma coated for 1min at 10.2 W to improve their surface 
energy and hydrophilicity. The scaffolds were then bathed in 5 mM of EDC and 5 mM of NHS in 
0.5 M of MES buffer (pH 5.7) for 45 mins to create binding sites on the scaffold for the proteins in the 
secretome media. The scaffolds were then soaked in 250 µL of secretome filled media for 4h, whilst 
being agitated to assist with the binding of factors. The scaffolds were then seeded with cells. Soaking 
in serum free media containing no secretome and PBS were used as controls. 
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5C.2.7 Protein Quantification 
Protein quantification was used to measure the quantity of protein being bound/absorbed onto the 
scaffolds surface during the 4 h soaking phase. Briefly, a BCA protein assay was used. Protein 
contents before and after soaking were measured and used to deduce the amount of protein bound to 
the scaffold. The assay was also used to measure the change in protein content of the media after the 
24 h of culture to show how much protein was being added to the media during culture. More details 
can be found in Section 2.14 
5C.2.8 Cell Seeding and Culture 
Once the scaffolds were functionalised and soaked in secretome they were ready for cell seeding. 
Briefly, 25,000 cells in 20 µL of serum free media per scaffold were drip seeded. After 1 h the media 
was topped up with 30 µL of media to ensure the cells did not dry out. After another hour the media 
was topped up to a total volume of 500 µL. Timepoints of 12 h, 24 h and 48 h were used. More details 
can be found in Section 2.12. 
5C.2.9 Cell Viability 
The assay was performed as per manufacturer’s instructions. Measurements were taken at at ex: 
525 nm and em: 580-640 nm. More details can be found in Section 2.13. 
5C.2.10 Cell Imaging 
Scaffolds were fixed in 10% formalin then permeabilized in Triton-X solution before being stained in 
Phalloidin-iFluor™514 conjugate for 60 mins and DAPI for 10mins. Scaffolds were imaged using a 
Zeiss Axio Imager 2 microscope. More details can be found in Section 2.17. 
5C.2.11 Reverse Transcription Quantative Polymerase Chain Reaction (RT-qPCR) 
RNA was extracted from the cell seeded scaffolds using a Tri-Reagent method and purified using 
Qiagen’s RNeasy spin colum system. Real-time polymerase chain reaction was performed using a 
LightCycler® 480 Instrument II and Sensifast™ SYBR® High-ROX system. Forward and reverse 
sequences were either designed or taken from literature and are displayed in Table 25. Relative 
quantification of RT-PCR results was carried out using the 2−∆∆𝑐𝑡 method 350. Gene expression levels 
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were expressed relative to GAPDH (housekeeping gene) and normalised to 70% confluent 
HUVSMCs on tissue culture plastic. More details can be found in Section 2.18. 
Table 25: Primer sequences used for RT-PCR gene expression analysis on seeded HUVSMCs. 
Gene Primer Sequence Reference 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
31 
GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Smooth muscle actin alpha 1 
Α-actin1 (forward) CCGACCGAATGCAGAAGGA 
377 
Α-actin1 (reverse) ACAGAGTATTTGCGCTCCGAA 
Myocardin 
Myocardin (forward) GGGTCTGAGCATTCCTTGCT Self-
designed Myocardin (reverse) CTGGACGTTTCAGTGGTGGT 
Mesenchyme homeobox 2 
MEOX-2 (forward) AAAAGCGACAGCTCAGACTC 
289 
MEOX-2 (reverse) TTGCTGTCCACCCTTTACCC 
Interleukin 1 alpha 
IL1-α (forward) GCGTTTGAGTCAGCAAAGAAG Self-
designed IL1-α (reverse) GCCGTGAGTTTCCCAGAAGA 
 
5C.2.12 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 
ANOVA with post-hoc Tukey test. 
5C.3 Results 
5C.3.1 Electrospinning 
Scaffolds with a small fibre diameter were successfully electrospun showing uniform fibre diameter 
and a random alignment as seen in Figure 61. Fibre diameters were measured as being 





Figure 61: SEM image of the small diameter fibre electrospun scaffolds used for the binding of HUVSMC 
secretome. 
5C.3.2 Protein Binding 
The BCA protein assay was used to deduce the quantity of protein bound to the scaffolds, as seen in 
Table 26. Briefly, there was a 2.23% increase in protein content in the medium after 24 h of culture on 
a confluent monolayer of HUVSMCs. Interestingly, more protein from the serum free media bound to 
the scaffold than the conditioned media: 57.2 µg and 28.5 µg, respectively. These results suggest that 
the protein constituents of the media are altered during the 24 h of culture on the monolayer of 
HUVSMCs. 




Serum free media 




1238 ± 23 1211 ± 55 
After protein binding 1124 ± 40 983 ± 37 




5C.3.3 Cell Viability 
Cell viability showed some interesting trends, as seen in Figure 62. Firstly, there were no differences 
noted with cell viability between the scaffolds soaked with secretome conditioned medium and the 
scaffolds soaked in serum free medium. However, the PBS soaked scaffold with no protein binding 
showed the highest cell viability at all timepoints with approximately 75% more viability than the two 
other scaffolds after 12 h and 24 h of culture, and 125% more viability after 48 h of culture. However, 
this difference was not significant. Furthermore, viability was maintained between 12 h and 24 h for 
all three scaffolds, with viability falling after the 24 h timepoint.  
 
Figure 62: Cell viability of seeded HUVSMCs on all three scaffolds (PBS control, serum free media and 
conditioned media) after 12, 24 and 48 h of culture. N=4. *p < 0.05. 
5C.3.4 Cell Imaging 
DAPI (nuclei) and phalloidin (f-actin) fluorescence staining of the HUVSMCs on all three scaffolds at 
12 h, 24 h and 48 h showed some interesting results, as seen in Figure 63. Firstly, all three scaffolds 
were capable of maintaining healthy HUVSMCs up to the 24 h mark whilst cultured serum free. The 
cells adopted an elongated phenotypic morphology. Interestingly, at the 48 h mark, the scaffolds 
conditioned with secretome containing medium and serum-free medium both appeared to have mostly 
rounded cells, which is a sign of apoptosis 362. On the other hand, the control scaffold conditioned 




Figure 63: Representative DAPI (nuclei) and phalloidin (f-actin) stained HUVSMCs on the three scaffolds (PBS 
control serum free media and conditioned media) after 12, 24 and 48 h. 
 
5C.3.5 Reverse Transcription Quantative Polymerase Chain Reaction 
RT-PCR results showed some interesting trends between the three scaffolds, as seen in Figure 64. 
Firstly, all three scaffolds had very similar expression of smooth muscle alpha actin 1, with a 
downregulation noted over time. Likewise, the expression of Interleukin 1 alpha dropped over time 
for the secretome conditioned media scaffold and the PBS conditioned scaffold. On the other hand, 
the expression of interleukin 1 alpha did rise between 24 h and 48 h of culture on the serum-free 
conditioned scaffold, albeit without any significance. MEOX2 expression was seen to increase on all 
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three scaffolds between 12 h and 48 h of culture. Furthermore, Myocardin expression dropped 
between 12 h and 48 h of culture for the secretome conditioned scaffold and the PBS conditioned 
scaffold. On the other hand, my0cardin expression increased on the serum-free conditioned scaffold 
between 12 h and 48 h of culture. Significance was noted between the expressions of myocardin on 
the secretome conditioned scaffold and the serum-free conditioned scaffold after 48 h of culture, with 
the latter showing higher expression.  
 
Figure 64: Gene expression results for four HUVSMC related genes: Myocardin, Alpha Actin 1, MEOX2 and 
Interleukin 1 alpha (IL1-α), on HUVSMC seeded on all three scaffold conditions. CM = condition media, SFM 




A scaffold was successfully electrospun with a small fibre diameter (1.42 ± 0.24 µm) showing 
uniform fibre size and a random fibre alignment. The small fibre diameter was chosen as this scaffold 
showed higher cell viability when seeded with HUVSMCs compared to the scaffolds with larger fibre 
diameters, as seen in Chapter 3B. 
The BCA protein quantification assay revealed some interesting results regarding the quantity of 
bound protein from each of the two media types. Firstly, there was a net increase in the protein 
content in the secretome media compared to its serum-free counterpart. This suggests that the 
HUVSMCs are releasing some proteins into the media, however, the exact quantity cannot be 
concluded as the cells will be using up the protein already present in the media, whilst releasing other 
proteins. Furthermore, the BCA protein quantification assay showed that a lot more protein in the 
serum free media bound to the scaffolds than the secretome containing media. Work by Coad, et al. 
found that different proteins (Human serum albumin and Streptavidin) with structures and molecular 
weights (66.5 kDa vs 53 kDa) had different binding affinities to plasma coated polymers 449. 
Furthermore, work by Dupont, et al. showed that the proteins secreted by human arterial smooth 
muscle cells had a range of different atomic mass contents ranging from 95 kDa to 20 kDa 456. 
Therefore, these results suggest that the protein profile of the secretome media is different to that of 
the serum-free media, which indicates that there has been a high turnover of proteins within the 
media. A full proteomic analysis of the constituents of the secretome media is required to get a full 
image of the make-up of the HUVSMC secretome profile.  
Cell viability analysis showed some interesting results regarding to how the HUVSMCs bound and 
proliferated on the scaffolds. At all three timepoints, the PBS conditioned scaffold had higher cell 
viability than the two media conditioned scaffolds (approximately 75% higher after 12 h and 24 h, and 
150% higher after 48 h). These results suggest that the seeded HUVSMCs had difficulty attaching to 
the scaffolds that had been conditioned with the two protein containing mediums. However, the DAPI 
and phalloidin stained scaffolds show that all three scaffolds were able to accommodate a healthy 
layer of HUVSMCs, displaying phenotypic characteristics after 12 h and 24 h 389,436. The CellTiter-
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Blue® Cell Viability Assay is an assay that measures the metoabolic capacity of cells, therefore, it 
doesn’t necessarily correlate with the total number of cells bound to the scaffold. This means that the 
lower cell viability noted in the two media conditioned scaffolds may be caused by the bound proteins 
reducing the metabolic capacity of the cells, as opposed to a lower quantity of cell binding. The DAPI 
and phalloidin stained scaffolds after 48 h of culture showed that the PBS conditioned scaffold was 
able to maintain HUVSMCs with a healthy phenotypic morphology 389,436. In contrast, the HUVSMCs 
seeded onto the serum-free media conditioned scaffolds and to some extent, the HUVSMCs seeded on 
the secretome conditioned scaffolds both showed cell rounding, which is a sign of apoptosis 362. 
Myocardin is a key phenotypic gene in SMCs and is involved in their contractile functionality 378,379. 
The secretome conditioned scaffold and the PBS conditioned scaffold both showed downregulations 
over the 48h of culture. As SMCs proliferate and mature, an upregulation of this gene would be 
expected. Likewise, the expression of smooth muscle alpha actin 1 also dropped over time for all 
three scaffolds. Alpha actin 1, much like myocardin, is a key phenotypic gene associated with SMC 
maturity and contractility 377. In addition, cell viability results suggest that the cells are not 
proliferating, which falls in line with the results found with myocardin expression and smooth muscle 
alpha actin 1 expression. Furthermore, the expression of IL1-α and MEOX2 also supports the theory 
that the cells are not proliferating. IL1-α is upregulated in SMCs during cell proliferation, therefore, 
its downregulation suggests that the cells are losing their proliferative potential on all three 
scaffolds 431,437. Furthermore, the upregulation of MEOX2 has been shown to supress SMC 
proliferation and migration 289. All three scaffolds showed an upregulation of MEOX2 between 12h 
and 48h of culture, which falls in line with IL1-α downregulation. 
While the DAPI (nuclei) and phalloidin (f-actin) results show that the scaffolds were capable of 
maintaining a healthy layer of SMCs, the gene expression results and the cell viability results suggest 
that the cells which are bound to the scaffold after 48 h are losing their proliferative capabilities and 
the contractile functionality. However, this study does show that the proteins from both serum free 
media and cell secretome conditioned media can both be bound to a scaffolds surface. Furthermore, 
the binding of proteins did have an effect on cell viability and the phenotypic characteristics of the 
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seeded cells. These results suggest that binding cell secretome does have promise in tissue 
engineering applications where altering gene expression can be desirable. 
5C.5 Conclusions 
In this study, cell secretome conditioned medium was created by culturing HUVSMCs with serum-
free medium for 24 h. The conditioned medium had a slightly elevated quantity of protein compared 
to the serum-free medium suggesting that the HUVSMCs were secreting proteins into the medium. 
Furthermore, an increased proportion of the proteins found in the serum-free media were bound to the 
scaffolds compared to the proteins in the secretome conditioned media (57.2 µg and 28.5 µg). This 
suggests that the proteins found in the secretome conditioned media have different structural makeups 
and different affinities for plasma coated and EDC/NHS functionalized polymer scaffolds. Cell 
viability was increased on the PBS conditioned scaffold compared to the two media conditioned 
scaffolds, suggesting that the bound protein is either affecting cell binding or it is affecting the 
metabolic capacity of the cells. Furthermore, gene expression results suggests that the scaffolds lead 
to reduced HUVSMC contractile functionality and proliferative capabilities. These results suggest that 
the binding of cell secretome to polymer scaffolds can alter the performance of seeded cells and does 


















There are a variety of different environmental stimuli found in vivo that are often not replicated in ex 
vivo experiments. Examples of these environmental stimuli include various mechanical forces, such as 
pressure, shear stress and strain; biochemical stimuli from neighbouring cells types; and varying 
oxygen levels 457–466. These environmental factors play a crucial role in maintaining healthy functional 
cells and their replication in vitro allows for more accurate modelling of the native environment 457,463.  
Cells found in the arteries (endothelial cells and smooth muscle cells) undergo cyclic pressures due to 
the force of blood being forced around the body by the heart 8. Depending on how far along the 
vasculature, the pressures seen by the cells can range from 120 mmHg in the aortic arch down to close 
to 0 mmHg in the capillaries 8. During each heart beat the pressure felt by the local cells will increase 
and decrease cyclically at the same frequency as the heart is beating 8. 
By mimicking the pressures seen by the native cells, a more physiologically accurate secretome 
profile can be generated in vitro.  Binding the proteins generated under these physiological conditions 
to a scaffold will provide the seeded cells with the biochemical cues that are seen by the native cells 
when in their native environment.  
Likewise, looking at how the aorta ECM/PCL scaffolds perform under hypoxic conditions will give a 
better image of how these scaffolds might perform in an in vivo environment. Endothelial cells have a 
differing cell response when undergoing hypoxic stress 467. Hypoxia has been shown to stimulate 
endothelial cells to express various vasoactive substances and matrix regulating proteins 467. 
Furthermore, hypoxia is heavily linked with inflammatory diseases and other vascular disease related 
to ageing 468. Therefore, experimenting under hypoxic conditions creates a more accurate image of 
how these scaffolds might perform in vivo and allows us to test scaffolds in a disease state.  
In this Chapter, two different ways of incorporating native environmental stimuli into these studies 
were looked at. Firstly, this present study proposes stimulating cells in a hydrostatic pressure 
bioreactor in order to alter their secretome profiles for subsequent binding onto scaffolds (Section 
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6A). Hypoxia combined with aorta ECM/PCL scaffolds were then assessed to see how they altered 




Part A: Hydrostatic Pressure Cell Secretome and Endothelial Cells  
6A.1 Introduction 
Hydrostatic pressure bioreactors have been widely utilised in tissue engineering applications as a 
means of creating a more physiologically relevant environment for the cells 469. They have been used 
on both ‘soft’ tissues such as the heart and vessels and ‘hard’ tissues such as bone and cartilage 470–473.  
There are a range of different hydrostatic pressure bioreactors that have been developed for in vitro 
experimentation, which fall under two general methods. Firstly, several studies have used a simple 
bioreactor design which relies on the scaffold being sealed into a medium filled flexible bag/tube and 
placed into a water filled biochamber 474–476. This water filled biochamber can then be compressed to 
very high pressures (+ 50 MPa). These designs are mostly used for cartilage and bone tissue 
engineering due to the high pressure which can be administered. Secondly, several studies have 
looked at bioreactors where the scaffold is immersed in culture medium that is in direct contact with 
the pressurized air 477–479. This incubator air is passed through a compressor and enters the bioreactor 
and directly transmits this higher pressure to the medium, which in turn transmits it to the scaffold. 
This method allows for a low pressure to be applied to the cells and is usually used with softer tissues, 
such as vessels.  
As mentioned in Chapter 5, feeder layer systems have been utilised in cell culture to help with the 
growth of certain cell lines 442. The principle of the feeder cell system is to allow for direct paracrinal 
cell communication between the two cell lines. However, this can be done indirectly through the 
collection of the paracrinal cell secretomes in a serum free medium. The proteins from this medium 
will then be bound to a scaffold.  
The aim of this study is to see how culturing cells under hydrostatic pressure alters their secretome 
profile compared to culturing at atmospheric pressure. By binding these proteins to a scaffold, the aim 
is to create a biofunctionalized scaffold containing the paracrinal secretomes released by the HUVECs 
when cultured under hypoxic conditions. 
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6A.2 Bioreactor Development 
The bioreactor system was developed with the aim of compressing the cells with physiologically 
relevant pressures in the range found in the aorta and arteries. With this in mind, a bioreactor was 
developed where the surrounding air was compressed, transmitting the pressure directly to the media 
which in turn compresses the cells. In order to culture as many cells as possible, the aim was to design 
a bioreactor that could either accommodate well plates or tissue culture flasks. The design is simple 
and works by extracting air from an incubator and compressing it, as seen in Figure 65. The air is then 
brought to the desired pressure using a set of two control valves before going through an air filter to 
sterilize the air. The air is then fed into an air-tight box that can be placed into an incubator. This air-
tight box is large enough to accommodate three tissue culture flasks. The box is held under constant 
pressure with a very low flow rate of new compressed incubator air fed into it, ensuring the cells 
receive the required oxygen from the air. 
A pressure of 50 mmHg was used as this has been shown to have a similar effect on the level of gene 
expression as higher pressures (up to 150 mmHg). However, 50 mmHg does provide a lower 
proliferative index (the rate of proliferation was lower) compared to the higher pressures 458. With this 
in mind, the main focus of this study is to generate a cellular secretome profile that differs from the 
secretome profile generated under atmospheric pressure. For this reason, 50 mmHg was used. 
The system was set up with an air filter before the compressed air entered the bioreactor. The air filter 
used was an in-line HEPA filtration unit (Whatman®) designed to retain 99.97% of all particles 
≥ 0.3 μm in air. This filter is specifically designed to prevent contamination in incubators, therefore 
was well suited for the removal of contaminants going into the bioreactor. The air being compressed 
was taken directly from the incubator (37°C and 5% CO2). The compressor (ORAZIO®) used was a 
low decibel oil-free compressor. A low decibel compressor was used as to avoid noise pollution in the 





Figure 65: Schematic of bioreactor set up. Air is removed from an incubator (37°C and 5%CO2) and 
compressed in an oil free air compressor. The compressed air is then fed through two valves to bring it down to 
50 mmHg and through a filter (≥ 0.3 µm) before being brought back into the bioreactor.  
6A.3 Methods and Materials 
6A.3.1 Electrospinning 
PCL was dissolved at 20% w/v into a 5:1 mixture of Chlorofrom:Methanol. Briefly, the electrospun 
fibres were spun and collected. Scaffolds with a 10mm diameter were punched out. Extra-large fibre 
diameter scaffolds were used as they have previously shown better affinity for HUVECs (Chapter 
3A). Electrospinning parameters can be seen in Table 27. More details can be found in Section 2.1. 
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6A.3.2 Scanning Electron Microscopy 
Scaffolds were imaged using a Hitachi TM4000 tabletop SEM as described in section 2.5. 
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6A.3.3 Mechanical Analysis 
Mechanical analysis was performed using an Instron 3367 testing rig with a 50 N load cell. Samples if 
40 mm x 5 mm were cut out. Measurements were performed to failure at 10 mm/min with a gauge 
length of 20 mm. More details can be found in Section 2.7. 
6A.3.4 Cell Growth 
HUVECs were expanded to passage 7 in using MCBD 131 medium supplemented with 5% v/v FBS; 
1% v/v L-glutamine; 1% v/v penicillin/streptomycin; 1 mg/L hydrocortisone; 50 mg/L ascorbic acid; 
2 μg/L fibroblast growth factor; 10 μg/L epidermal growth factor; 2 μg/L insulin-like growth factor; 
and 1 μg/L vascular endothelial growth factor. HUVECs were lifted for scaffold seeding at 80% 
confluence. More details can be found in Section 2.3. 
6A.3.5 Cell Secretome Collection 
Briefly, HUVECs were cultured in a T75 flask to 70% confluence in cell MCDB 131 culture media 
containing FBS (as described in Section 6A.3.4). The media was then changed to 50:50 culture media 
containing FBS and culture media without any FBS for a further 24 h of culture. The cells were then 
changed over to serum free media (10 mL) and cultured for 24 h in the hydrostatic pressure bioreactor 
at 50 mmHg. The media was then removed and used to soak the scaffolds. Alongside this, secretome 
media was also being collected from cells cultured at atmospheric pressure in an incubator to use as a 
control. The four conditions used in this study are: Hydrostatic pressure conditioned media (HP CM); 
atmospheric pressure conditioned media (AP CM); serum-free media (SF M); and PBS. 
6A.3.6 Scaffold Functionalization and Secretome Binding 
Scaffolds underwent 1min of plasma coating at 10.2 W to increase their surface energy and 
hydrophilicity. The scaffolds were then bathed in 5 mM of EDC and 5mM of NHS in 0.5M of MES 
buffer (pH 5.7) for 45 mins to create binding sites on the scaffold for the proteins in the secretome 
media. The scaffolds were then soaked in 250 µL of hydrostatic pressure secretome filled media for 
4 h, whilst being agitated to assist with the binding of factors. The scaffolds were then seeded with 
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cells. Soaking in atmospheric pressure obtained secretome filled media, serum free media containing 
no secretome and PBS were used as controls. More detail can be found in Sections 2.6 and 2.15. 
6A.3.7 Protein Quantification 
Protein quantification was used to measure the quantity of protein being bound/absorbed onto the 
scaffolds surface during the 4 h soaking phase. Briefly, a BCA protein assay was used. Protein 
contents before and after soaking were measured and used to deduce the amount of protein bound to 
the scaffold. More detail can be found in Section 2.14. 
6A.3.8 Cell Seeding and Culture 
Once the scaffolds were functionalised and soaked in secretome they were ready for cell seeding. 
Briefly, 75,000 cells per scaffold were drip seeded in 20 µL of serum free media. After 1 h the media 
was topped up with 30 µL of media to ensure the cells did not dry out. After another hour the media 
was topped up to a total volume of 500 µL. Timepoints of 12 h, 24 h and 48 h were used. Scaffolds 
were cultured at atmospheric pressure in 37°C and 5% CO2. More detail can be found in Section 2.3 
and 2.12. 
6A.3.9 Cell Viability 
The assay was performed as per manufacturer’s instructions at timepoints of 12 h, 24 h and 48 h. 
More detail can be found in Section 2.13. 
6A.3.10 Cell Imaging 
Briefly, scaffolds were permeabilized in Triton-X solution before being stained in Phalloidin-
iFluor™514 conjugate and 300 nM DAPI. Scaffolds were imaged using a Zeiss Axio Imager 2 
microscope. More detail can be found in Section 2.17. 
6A.3.11 Reverse Transcription Quantative Polymerase Chain Reaction (RT-qPCR) 
The method used for PCR is described in section 2.18. Forward and reverse sequences were designed 
and are displayed in Table 22. Relative quantification of RT-PCR results was carried out using the 
2−∆∆𝑐𝑡 method 350. Gene expression levels were expressed relative to GAPDH (housekeeping gene) 
and normalised to 70% confluent HUVECs on tissue culture plastic. 
196 
 
Table 28: Primer sequences used for RT-PCR on seeded HUVECs. 
Gene Primer Sequence Reference 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
31 GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Matrix metalloproteinase-1 
MMP1 (forward) CGGTTTTTCAAAGGGAATAAGTACT 
31 MMP1 (reverse) TCAGAAAGAGCAGCATCGATATG 
Matrix metalloproteinase-2 
MMP2 (forward) CGCTCAGATCCGTGGTGAG 
31 MMP2 (reverse) TGTCACGTGGCGTCACAGT 
Vascular endothelial growth 
factor 
VEGF (forward) AGACCAAAGAAAGATAGAGCAAGACAAG 
31 VEGF (reverse) GGCAGCGTGGTTTCTGTATCG 
Platelet endothelial cell 
adhesion molecule 
CD31 (forward) ACTGGACAAGAAAGAGGCCATCCA 
361 CD31 (reverse) TCCTTCTGGATGGTGAAGTTGGCT 
 
6A.3.12 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 
ANOVA with post-hoc Tukey test. 
6A.4 Results 
6A.4.1 Electrospinning 
Scaffolds were successfully electrospun and showed a large fibre morphology with uniform fibre sizes 
and a random alignment (Figure 66Figure 57). Scaffolds had fibre diameters of 5.63 ± 0.65 µm, which 




Figure 66: Representative SEM image showing the extra-large fibre diameter scaffold for seeding with 
HUVECs in the hydrostatic pressure secretome study. 
 
6A.4.2 Protein Binding 
The total mass of protein being bound onto the surface of the scaffolds was assessed using a Pierce™ 
BCA protein assay kit and can be seen in Figure 67. Interestingly, both secretome containing 
mediums had approximately the same amount of protein binding: 51.8ng and 47.2g, for the 50mmHg 
pressure secretome and the atmospheric pressure secretome, respectively.  
 
Figure 67: Total mass of protein bound (cell secretome) to each scaffold. Hydrostatic pressure conditioned 
media (HP CM); atmospheric pressure conditioned media (AP CM); serum-free media (SF M); and PBS. N=6, 




6A.4.3 Cell Viability 
Cell viability results revealed some interesting trends between the four different scaffolds, as seen 
inFigure 68. Firstly, after 12 h of culture, cell viability was very similar across the four different 
scaffolds, suggesting that the binding of the different proteins did not have much of an effect on cell 
adhesion or cell viability. However, after 24 h and 48 h of culture, the two scaffolds that were 
functionalized with the secretome media (50 mmHg hydrostatic pressure and atmospheric pressure) 
showed higher cell viability than the serum-media scaffold and PBS conditioned scaffold.   
 
Figure 68: Cell viability of seeded HUVECs on all four scaffolds after 12 h, 24 h and 48 h of culture. N=4, 
error bar = SD. *p < 0.05. Hydrostatic pressure conditioned media (HP CM); atmospheric pressure 
conditioned media (AP CM); serum-free media (SF M); and PBS. 
 
6A.4.4 Cell Imaging 
DAPI (nuclei) and phalloidin (f-actin) fluorescence staining of the HUVECs on all four scaffolds at 
12 h, 24 h and 48 h showed some interesting results, as seen inFigure 69. Interestingly, all four 
scaffolds were capable of maintaining the elongated phenotypic morphology of HUVECs up to 48h of 




Figure 69: Representative DAPI (nuclei) and phalloidin (f-actin) stained HUVECs seeded on the four different 
scaffolds. Hydrostatic pressure conditioned media (HP CM); atmospheric pressure conditioned media (AP 




6A.4.5 Reverse Transcription Quantative Polymerase Chain Reaction 
RT-PCR results showed some interesting trends (Figure 70). Firstly, there was a general trend across 
all four scaffolds where the expression of CD31 increased over time. This suggests that the expression 
of CD31 is mostly mediated by cell maturity and not by the different proteins bound to the scaffold. 
Likewise, the expression of MMP1 increased with time for all four scaffold conditions. However, the 
expressions were higher on the three media conditioned scaffolds compared to the PBS conditioned 
scaffold. Similarly, MMP2 expression was slightly higher on the two scaffolds conditioned with 
secretome medium than the serum free medium and PBS conditioned scaffold. Interestingly, VEGF 
expression was very similar on all three scaffolds conditioned in medium, with all three higher than 





Figure 70: Gene expression results on the seeded HUVECs of CD31, VEGF, MMP2 and MMP1 after 12 h, 24 h 
and 48 h of culture. HP CM = Hydrostatic pressure secretome conditioned medium, AP CM = Atmospheric 
pressure secretome conditioned medium, SF M= serum free medium. N=5, error bars = SD. *p < 0.05.  
 
6A.5 Discussion  
Hydrostatic pressure has been shown to upregulate and downregulate a variety of different genes in 
ECs 458,480. For example, work has shown that ECs downregulate the expression of vascular 
endothelial-cadherin  when exposed to pressures of between 50-150 mmHg, resulting in increased 
proliferation and cell lengthening 458. Likewise, work has shown that exposure to physiological 
pressures for as little as 4 h increases HUVEC proliferation through the activation of the αv integrin 
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480. Therefore, it can be assumed that culturing HUVECs under 50 mmHg of hydrostatic pressure for 
24 h would lead to alterations in their secretome profiles. Interestingly, work by Prystopiuk, et al. 
found that endothelial cells undergo a two-phase response to hydrostatic pressure: an initial response 
after 1 h and a further response to chronic application of pressure after 24 h 481. They found that the 
majority of the chronic response is due to the increase in actin density and a loss of endothelial barrier 
cell function 481.  
Interestingly, the expression of CD31 increased over time for all four scaffolds, suggesting that its 
expression was not affected by the binding of hydrostatic pressure HUVEC secretome. CD31 is an 
angiogenic gene involved in the creation of new vasculature, therefore its upregulation is desirable in 
the early stages of tissue formation 482. VEGF, another angiogenic gene involved in cell migration and 
proliferation showed very little difference between the three media conditioned scaffolds across all 
three timepoints 450. However, these three scaffolds did appear to promote a slight upregulation of 
VEGF compared to the PBS conditioned scaffold, albeit with no significance. While an upregulation 
of angiogenic genes such as CD31 and VEGF may be desirable in the short run, their overexpression 
has been associated with tumour formation in various tissue types 55,370. 
Like CD31, MMP1 expression also increased over time for all four scaffolds. While this suggests that 
the expression of MMP1 is mostly mediated by cell maturity, the three media conditioned scaffolds 
did show slightly increased expression compared to the PBS conditioned scaffold. The same applies 
for MMP2 expression, where a relative downregulation was noted in the PBS conditioned scaffold 
compared to three media conditioned scaffolds. MMP1 and MMP2 are two genes associated with 
matrix remodelling and their relative upregulation in the media conditioned scaffolds suggests that the 
bound proteins might be stimulating collagen deposition 451.  
Furthermore, interesting results were seen in the quantity of protein binding. The study found that 
more of the proteins found in the two conditioned medias bound to the scaffold compared to the 
serum-free media. As previously mentioned in Chapter 5, work by Coad, et al. found that different 
proteins with different structural makeups (66.5 kDa vs 53 kDa) had different binding affinities to 
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plasma coated polymers 449. Therefore, the differences in the quantity of binding protein may be a 
results of the secreted proteins having different structures. 
Cell viability showed some interesting trends between the four different scaffolds. At 24 h and 48 h, 
the cells seeded onto the two scaffolds that had been conditioned with secretome media (AP CM and 
HP CM) had a higher cell viability than that of the scaffolds conditioned with serum-free media and 
PBS. Furthermore, this trend was not noted after 12 h of culture, suggesting that the binding of 
proteins from the cell secretome had the effect of increasing cell viability but not cell attachment. Cell 
viability dropped for all four scaffolds over time due to the cells being cultured serum-free. 
These results suggest that the binding of the proteins from the two secretome conditioned mediums 
did increase cell viability compared to the serum free media conditioned scaffold and the PBS 
conditioned scaffold. However, when looking at gene expression, the two secretome conditioned 
scaffolds and the serum free conditioned scaffold had very similar effects on gene expression, with 
the PBS conditioned scaffold showing differences for certain genes. This may suggest that the 
proteins found in the serum-free medium before undergoing secretome conditioning may be the ones 
that are having an effect on gene expression. 
6A.6 Conclusions 
In conclusion, proteins from three different types of serum-free culture media were bound to a 
scaffold; two of which had been conditioned with HUVEC secretome at two different pressures 
(50mmHg and atmospheric pressure). The proteins from these two conditioned mediums and a serum-
free unconditioned media were bound to electrospun scaffolds and then seeded with HUVECs. These 
present results show that the binding of proteins from the two HUVEC conditioned mediums lead to 
higher cell viability after 48 h of culture compared to the serum-free media conditioned scaffold and 
the PBS conditioned scaffold. Furthermore, gene expression analysis suggested that the binding of 
proteins from all three mediums used lead to alteration in the expression of certain genes, such as 
VEGF, MMP1 and MMP2 compared to the PBS control. These results show the potential of binding 
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the secretome from mechanically stimulated HUVECs to an electrospun scaffold to enhance its 




Part B: Hypoxia and endothelial cells 
6B.1 Introduction 
Hypoxia in the vasculature is one of the leading causes of vascular diseases, such as pulmonary artery 
disease and atherosclerosis 483,484. Therefore, it is of crucial importance that these hypoxic conditions 
are studied in in vitro experiments in order to more accurately mimic the diseased environment. 
Hypoxia’s effect on ECs have been widely studied in vitro, with a range of results showing a cascade 
of biological responses 485. For example, work by Busse, et al. found that ECs are responsible for the 
vasodilatory response of arteries to hypoxia 486. Furthermore, work by Faller, found that prolonged 
exposure to hypoxia lead ECs to produce factors that induce SMC proliferation and remodelling 467. 
Furthermore, while PCL only scaffolds seeded with ECs have previously been studied in hypoxic 
conditions 487, the incorporation of ECM and its effects on the performance of seeded ECs when 
cultured under hypoxic conditions have not been reported. Previous findings from Chapter 4 found 
that the incorporation of aorta ECM into the scaffold increased HUVEC cell viability. Therefore, this 
study aims to look at how PCL only and PCL/ECM scaffolds perform as platforms for seeded 
HUVECs in both normoxic and hypoxic culture conditions. 
6B.2 Methods and Materials 
6B.2.1 Decellularization 
Bovine aorta ECM was perfusion decellularized using 0.5% w/s SDS, as described in section 2.2. 
6B.2.2 Electrospinning 
Decellularized ECM was milled into a powder and dissolved in HFIP at 0.25% w/v along with 8% 
w/v PCL. This created a scaffold with a 3:97 ratio of ECM:PCL. The PCL only scaffold was created 
using an 8% w/v solution of PCL in HFIP. Electrospinning parameters are shown in Table 29. More 
detail can be found in Section 2.1. 
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Table 29: Electrospinning parameters used to create the small diameter fibres (PCL and PCL/ECM blend) for 
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6B.2.3 Scanning Electron Microscopy 
Scaffolds were imaged using a Hitachi TM4000 tabletop SEM as described in section 2.5. 
6B.2.4 Cell Seeding and Culture 
HUVECs were cultures using MCBD 131 medium supplemented with 5% v/v FBS; 1% v/v L-
glutamine; 1% v/v penicillin/streptomycin; 1 mg/L hydrocortisone; 50 mg/L ascorbic acid; 2 μg/L 
fibroblast growth factor; 10 μg/L epidermal growth factor; 2 μg/L insulin-like growth factor; and 
1 μg/L vascular endothelial growth factor. HUVECs (P7) were lifted at 80% confluence for scaffold 
seeding. Scaffolds were drip seeded at 50,000 cells/scaffold, as described in section 2.12. All 
scaffolds were cultured in Normoxia (16% O2 / 5% CO2) for 2 h to assist with cell binding. Scaffolds 
in the Normoxia group were left in the normoxic incubator. Scaffolds in the Hypoxia group were 
transferred over to an incubator set at 2% O2 / 5% CO2. The timepoints started after this 2 h period of 
normoxic incubation. See section 2.12 for more detail on cell culture.  
6B.2.5 Cell Viability 
The CellTiter-Blue® assay was performed as per manufacturer’s instructions at timepoints of 12 h, 
24 h and 48 h, as described in section 2.13. 
6B.2.6 DNA Quantification 
DNA quantification was performed as per manufacturer’s protocol using a Quant-IT™ Picogreen® 
dsDNA assay. The assay was used to calculate the amount of protein bound to each scaffold. See 
section 2.16 for more details.  
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6B.2.7 Cell Imaging 
Briefly, scaffolds were permeabilized in Triton-X solution before being stained in Phalloidin-
iFluor™514 conjugate and 300 nM DAPI. Scaffolds were imaged using a Zeiss Axio Imager 2 
microscope. See section 2.17 for more detail. 
Cell seeded scaffolds visualized using SEM were fixed in 4% glutaraldehyde overnight before 
undergoing osmium tetroxide staining. Scaffolds were imaged using a Hitachi TM4000 tabletop SEM. 
See section 2.17 for more detail.  
6B.2.8 Reverse Transcription Quantative Polymerase Chain Reaction 
The method used for PCR is described in section 2.18. Forward and reverse sequences were designed 
and are displayed in Table 22. Relative quantification of RT-PCR results was carried out using the 
2−∆∆𝑐𝑡 method 350. Gene expression levels were expressed relative to GAPDH (housekeeping gene) 
and normalised to 70% confluent HUVECs on tissue culture plastic. More detail can be found in 
Section 2.18. 
Table 30: Primer sequences used for RT-PCR on seeded HUVECs in the hypoxia study. 
Gene Primer Sequence Reference 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH (forward) GTCTCCTCTGACTTCAACAG 
31 
GAPDH (reverse) GTTGTCATACCAGGAAATGAG 
Basic Fibroblast Growth Factor 
FGF2 (forward) CACCTATAATTGGTCAAAGTGGTTG Self- 
designed FGF2 (reverse) AAACGAGGGAGAAAGGATGGA 
Hypoxia-inducible factor 1-
alpha 
HIF1-α (forward) ACTTGGCAACCTTGGATTGG Self- 
designed HIF1-α (reverse) GTGCAGTGCAATACCTTCCA 
Nitric Oxide Synthase 3 
eNOS (forward) AGATGTTCCAGGCTACAATCCGCT 
361 
eNOS (reverse) TGTATGCCAGCACAGCTACAGTGA 
 
6B.2.9 Statistical Analysis 
Data was expressed as mean ± 1 standard deviation. Statistical analysis was performed using one-way 





SEM images of the electrospun scaffolds showed that each scaffold had uniform fibre diameter and a 
random alignment, as seen in Figure 71. The PCL scaffold had a fibre diameter of 2.19 ± 0.25 µm and 
the aorta ECM scaffold had a fibre diameter of 1.67 ± 0.42 µm. 
 
Figure 71: Representative SEM images of the two electrospun scaffolds. The PCL scaffold is composed of 100% 
PCL. The ECM scaffolds is 97% PCL and 3% ECM. Both scaffolds have a small diameter morphology. 
 
6B.3.2 Cell Viability 
Cell viability results showed some interesting results, as seen in Figure 72. There was no real 
difference between the HUVECs cultured on the PCL scaffold and the ECM scaffold in a hypoxic 
environment, however, under normoxic conditions the HUVECs on the PCL scaffold showed 
significantly higher viability than those on the ECM scaffold at 12 h and 48 h of culture.  
Furthermore, significance was also noted between the HUVECs culture on the ECM scaffolds under 
hypoxic and normoxic conditions after 12 h of culture, with the hypoxic culture showing higher 
viability. Likewise, the HUVECs cultured on the PCL scaffold had significantly higher viability after 




Figure 72: Cell viability results for HUVECs seeded on the two different scaffolds cultured under both normoxic 
conditions and hypoxic conditions. N=4, error bars = SD. 
 
6B.3.3 DNA Quantification 
DNA quantification results followed the exact same trends as the cell viability results, as seen in 
Figure 73. The PCL scaffold showed significantly higher quantities of DNA after 12 h and 48 h of 
culture in normoxic conditions compared to the ECM scaffold. Furthermore, significance was also 
seen between the ECM scaffolds after 12 h of culture and the PCL scaffolds after 24 h of culture, with 




Figure 73: DNA content of the seeded HUVECs on each scaffold cultured under both normoxic and hypoxic 
conditions. N=4, error bars = SD. 
 
6B.3.4 Cell Imaging 
Representative DAPI and phalloidin stained cells on both scaffolds under normoxic and hypoxic 
conditions can be seen in Figure 74. Both scaffolds under both culture conditions showed good cell 
spreading after 12 h of culture. Interestingly, the HUVECs on the ECM scaffold cultured in normoxic 
conditions after 48h showed more elongation, which is a key phenotypic marker of healthy HUVECs 
453.  
The representative SEM images of HUVECs seeded onto the two scaffolds and cultured for 48 h 
under both normoxic and hypoxic conditions showed some interesting results, as seen in Figure 75. In 
both normoxic culture and hypoxic culture the ECM scaffold showed increased cell coverage 
compared to the PCL scaffold. The ECM scaffold had approximately 80% and 70% confluence when 
cultured in normoxic and hypoxic conditions, respectively. The PCL scaffolds had approximately 




Figure 74: Representative DAPI (blue, nuclei) and phalloidin (green, f-actin) stained HUVECs on both 





Figure 75: Representative SEM images of osmium stained HUVECs on both scaffolds (PCL and ECM/PCL 
blend)  under normoxic and hypoxic conditions after 48h of culture. 
 
6B.3.5 Reverse Transcription Quantative Polymerase Chain Reaction 
RT PCR analysis showed some interesting trends in how the scaffold composition and the culturing 
conditions affected the seeded HUVECs, as seen in Figure 76. Firstly, there was a general trend 
whereby FGF2 expression was lower in the cells cultured in a hypoxic environment. FGF2 is a key 
gene for EC angiogenesis 58. The expression of eNOS showed very little difference between the two 
scaffolds and the two culture conditions. It is a central regulator of EC function and plays an 
important role in the maintenance of endothelial homeostasis 488. Likewise, the expression of HIF1a 
showed no real trend across the two different scaffolds and two culturing conditions. HIF1a is a gene 




Figure 76: Gene expression results of the seeded HUVECs for three genes: FGF2, eNOS and HIF1a. Data 
normalized to 80% confluent HUVECs on tissue culture plastic. N=4, error bars = SD. 
 
6B.4 Discussion 
Polymers and decellularized ECMs both have their advantages when used as materials in 
scaffolds 246,363. By combining the two materials, the aim is to harness the beneficial properties of both 
to create a reproducible scaffold that contains the bioactive factors of the ECM. Likewise, running 
experiments in hypoxic conditions allows for a more accurate image of how the scaffolds will perform 




Cell viability results showed no real difference between the scaffolds cultured under hypoxic and 
normoxic conditions. Interestingly, under hypoxic culture, the two scaffolds showed no real difference 
in cell viability across all three timepoints, suggesting that the ECM scaffolds would be able to sustain 
cell survival in an in vivo environment where hypoxic conditions are present. Work by Jundzill, et al. 
has shown that conventional PCL only scaffolds do improve vascularization when implanted into a in 
vivo hypoxic environment 491. Therefore, being able to create a biofunctionalized scaffold that 
contains native ECM components and showing that it performs in a similar way to PCL only scaffolds 
in an in vitro environment is beneficial for vascular tissue engineering applications. As show in 
Chapter 4, incorporating ECM into scaffolds had the effect of altering their mechanical properties to 
more closely resemble that of native tissues. Therefore, having a platform that allows for changes in 
the mechanical properties of the scaffold, but does not alter cellular performance is desirable for a 
range of tissue engineering applications where local mechanical properties can vary. For example, 
studies have shown different stiffness values for the saphenous vein, ranging from 2.25 MPa to 
23.7 MPa 301,302. 
Furthermore, the SEM images of osmium stained HUVECs on the two scaffolds under both culture 
conditions show that the ECM scaffold was able to maintain higher confluency of cells than the PCL 
only scaffold. These results differ slightly from the cell viability results which suggest no differences 
between the cells. However, cell viability is a metabolic activity assay which does not necessarily 
correlate to the total number of HUVECs on the scaffold. Therefore, cell viability alone cannot be 
used to conclude the number of cells on the scaffold. 
Interestingly, eNOS (a central regulator of EC function and endothelial homeostasis) has been shown 
to downregulate in ECs under hypoxic conditions due to the presence of miR-200b 488,492. The present 
study’s results show very little differences between the scaffolds cultured in normoxia or hypoxia. 
However, the study by Janaszak‑Jasiecka, et al. found that the majority of this downregulation of the 
eNOS gene happened in the first 12 h of culture with no more downregulation noted after 16 h of 
culture 492. Therefore, the timepoints used in this study may not give an overall image of how the cells 
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are responding in the first 12 h of culture, where the majority of eNOS downregulation has been 
noted.  
FGF2 is responsible for neovascularization and angiogenesis 58. Its upregulation is heavily linked with 
tumour formation 58. The present study’s results show no significance. Likewise, HIF1-alpha is a gene 
responsible for apoptosis in ECs when they are subject to hypoxic conditions 489. The present study’s 
results found very little difference between the two different culture environments. This may suggest 
that these electrospun scaffolds possess shielding properties against the upregulation of FGF2 and 
HIF1-alpha. This may suggest that these scaffolds both slow down angiogenesis and apoptosis in a 
hypoxic environment. 
6B.5 Conclusions 
In conclusion, this study showed that PCL/ECM scaffolds and PCL scaffolds were both capable of 
maintaining cell viability when cultured in a hypoxic environment. The incorporation of ECM into the 
fibres had no real effect on the level of gene expression for FGF2, eNOS and HIF1-α when cultured in 
both hypoxic and normoxic conditions. However, as previously shown, the incorporation of ECM 
alters the mechanical properties of the scaffold. Therefore, being able to create different platforms 
with different mechanical properties without altering gene expression in a hypoxic environment has 
benefits for vascular tissue engineering where hypoxia is prevalent and is often the main cause for the 


















7.1.1 Discussion of Results 
The aim of this thesis was to investigate the effect of altering the composition and morphology of 
electrospun scaffolds on the function of two different vascular cell sources: HUVECs and 
HUVSMCs. Firstly, the effect of changing electrospun fibre diameter was investigated. Following on 
from this, the effect of incorporating two different sources of decellularized ECMs into the 
electrospun PCL fibres was studied 493,494. Finally, the effect of binding cell secretome to an 
electrospun scaffold and how this alters cellular behaviour was investigated. The thesis then looks at 
two ways of altering culture environment in combination with the electrospun scaffolds.  
Currently vascular disease accounts for upwards of 30% of all deaths across Europe 110. One of the 
major contributors are diseases such as atherosclerosis and hyperplasia which result in the gradual 
narrowing of vessels, subsequently leading to blockages, which will eventually lead to further 
complications and death 90,108. These blockages are often treated with bypass grafts, a relatively simple 
procedure that deviates blood flow around a blockage through a new passage. While bypass grafting 
is a fairly standard procedure, there are still many limitations associated with the use of synthetic 
grafts. Most notably, a large reduction in patency after only a few years when dealing with small 
diameter vessels 129. Therefore, it is imperative that further study is carried out looking at how the 
bypass graft material and structure can be enhanced to improve mechanical properties and cell 
survival. 
Electrospinning is a scaffold manufacturing technique that creates a network of homogenous fibres 
that resemble to collagenous network found in many different ECMs 495. Electrospun scaffolds have 
been widely used in cardiovascular tissue engineering, with applications ranging from bypass grafts 
and stents to heart valves 176,179,214,398,400. The polymer chosen in this thesis was PCL due to its 
biocompatibility, FDA approval and ease of use in the electrospinning process 218,496,497. One 
advantage of using PCL is its controllable degradation rate and non-toxic degradation by-
products 364,413. Depending on the starting molecular weight of the PCL, it can take up to 2 years to 
degrade to a point where it loses its mechanical strength, allowing plenty of time for the engrafted 
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cells to deposit their own ECM 364,497. Furthermore, PCL has also shown good electrospinning 
potential when used in conjunction with decellularized ECM and proteins, improving the bioactive 
properties of the scaffold 198,199,386. Additionally, studies have shown that proteins and peptides can be 
grafted onto PCL, opening up the potential of binding cell secretome to these electrospun scaffolds 25. 
Other polymers have also been widely used in the realm of vascular tissue engineering, such as poly 
(D,L-lactide-co-glycolide) and polylactic acid 352,355,498. 
Scaffold morphology and topography have both shown to have drastic effects on cellular performance 
for a variety of different cell types 177,194,499. This has also been shown in cardiovascular tissue 
engineering, with work looking at endothelial cells, smooth muscle cells and cardiomyocytes 355,357,500. 
Previous studies have shown that altering the morphology and topography of polymer scaffolds had 
effects on both the spreading and proliferation of endothelial cells 357. Additionally, previous work has 
also shown that fibre alignment had a big impact on the expression of α-smooth muscle actin in 
vascular smooth muscle cells; a key marker of smooth muscle cell maturity 454. The work conducted 
in this thesis found some interesting results when scaffold morphology was altered (Chapter 3). 
Increasing the fibre diameter had the effect of increasing the infiltration depth of the both HUVECs 
and HUVSMCs. This finding was somewhat expected as the pore width increased linearly with the 
fibre diameter, creating bigger voids for the cells to penetrate into the scaffold. Studies have shown 
that increasing the size of pores does increase the ease at which cells can penetrate the scaffold 385,501. 
Interestingly, for both the HUVECs and HUVSMCs, the jump between a surface monolayer cell 
culture and a 3D cell culture happened between the large (3.37 µm and 3.91 µm, respectively) and 
extra-large (4.83 µm and 5.91 µm, respectively) fibre diameters. 3D cell cultures of endothelial cells 
have shown favourable results with respect to the expression of key proteins 34,366. This phenomenon 
can be attributed to 3D cell cultures more closely mimicking the native ECM and may explain why 
this study found increases in the gene expression of CD31; a key angiogenic gene, when fibre 
diameter was increased, allowing for the infiltration of cells. However, with the HUVSMCs, the small 
fibre diameter (0.77 µm) lead to higher cell viability along with the formation of a cell monolayer, 
which in turn showed the ‘hill and valley’ morphology that is commonly seen with SMCs in vitro 
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389,390. These results show that the smallest fibre diameter is well suited to the culture of HUVSMCs, 
however, this may not be optimal for long-term 3D cell cultures in vivo, where cell infiltration is 
required, as VSMCs are found interwoven around the ECM in thick layers of 40 to 60 cells 372.  
The next set of studies (Chapter 4) looked at how the incorporation of two different bovine ECM 
sources into the PCL scaffold altered their mechanical properties and biological properties as 
platforms for cell seeding. Work has previously shown that the incorporation of ECM into electrospun 
fibres has benefits for meniscal and cartilage tissue engineering applications 198,199. They found that 
ECM could easily be dissolved into a polymer/HFIP solution at high concentrations of up to 8% w/v. 
In these studies, ECM was dissolved into a PCL/HFIP solution at concentrations of 0.25% w/v and 
1% w/v, resulting in a homogenous solution that electrospun uniform and consistent fibres. Both 
studies looking at aorta ECM and heart ECM, which showed that the incorporation of ECM did have 
an effect on the seeded HUVECs and HUVSMCs. Furthermore, the incorporation of ECM had clear 
effects on the mechanical properties of the scaffold. In summary these results indicate that 
incorporating ECM can be used to modify mechanical and biological responses in scaffold. 
Interestingly, all of the scaffolds used in this thesis, with increasing fibre diameters and different 
quantities of ECM in them were found to have stiffnesses that fell in a similar realm to those noted in 
the literature for native vessels. The stiffnesses of the scaffolds ranged between 1.42 MPa and 
22.58 MPa depending on the particular strain bracket being looked at. Values found in literature 
include longitudinal stiffnesses of 23.7 MPa and circumferential stiffnesses of 4.2 MPa and 2.25 MPa 
for the saphenous vein 301,302. While there are a range of stiffnesses found for native vessels, the 
scaffolds designed in these study all fall within these values, suggesting that they would be capable of 
enduring the local environment seen by the native vessels. Moreover, the range of values noted in 
these studies shows the flexibility that electrospinning PCL scaffold possesses. 
Next, the secretomes of two cell types (HUVECs and HUVSMCs) were collected in serum-free 
medium and then bound to the surface of scaffolds (Chapter 5). Interestingly, a higher quantity of the 
proteins in the HUVEC condition media bound onto the scaffold compared to the HUVSMC 
conditioned media. This may indicate that the proteins released from the two cell types have different 
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structures, as work by Coad, et al. found that different proteins had different affinities for plasma 
treated polymers 449. Furthermore, the binding of HUVEC secretome lead to a slight decrease in the 
expression of several key genes for the seeded HUVECs, whereas the binding of HUVSMC 
secretome lead to very little change in the gene expression of seeded HUVSMCs.  
Finally, the effect of two different environmental factors were studied to assess the performance of 
electrospun scaffolds in more physiologically relevant scenarios: hydrostatic pressure and hypoxia 
(Chapter 6). Firstly, a secretome conditioned HUVEC media was generated under hydrostatic 
pressures and was bound onto the surface of PCL scaffolds. These results showed that the binding of 
proteins from this hydrostatic pressure conditioned media and a similar atmospheric pressure 
conditioned media increased cell viability compared to the scaffolds conditioned with serum-free 
media and PBS. Additionally, some trends were noted in gene expression between the PBS 
conditioned scaffold and the three other scaffolds, suggesting that the main proteins involved in 
altering the gene expression may be found in the serum-free media before any conditioning takes 
place. Furthermore, the effect of hypoxia on PCL and ECM/PCL scaffolds was assessed. Results 
showed that the ECM scaffold lead to a higher cell confluency than the PCL scaffold when cultured in 
hypoxia and normoxia. These studies show the potential of these scaffolds when used in 
physiologically relevant environments and the importance of preconditioning scaffolds.  
Overall, this thesis has shown that altering both morphology and composition of electrospun scaffolds 
influences the mechanical properties of the scaffold and the performance of seeded vascular cells. 
7.1.2 Methods Review 
The two cell lines used in this thesis: HUVECs and HUVSMCs, have both been widely used in in 
vitro experiments to study all aspects of vascular disease including vascular function and 
hypoxia 25,31,460,502–505. These cell lines allow us to assess the functionality of different experimental 
conditions without the requirement of expensive, time consuming studies using animal models. 
Furthermore, two vascular cell lines from the same source (human umbilical vein) were used in these 
studies to keep consistency between the separate experiments.  
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While electrospinning has been widely used in tissue engineering applications and allows for a range 
of different scaffold morphologies to be created 177,220, the methods used in this thesis do possess some 
drawbacks. Results showed some variability between the fibre diameters achieved across studies. 
Temperature and humidity have been shown to drastically effect the outcome of electrospinning 506. A 
study by De Vrieze, et al. found that the average diameter of electrospun fibres can change by up to 
100% by changing ambient air temperature from 10°C to 20°. Likewise, they found that increasing 
relative humidity to above 60% lead to no fibre formation 506. Therefore, creating an environment 
where temperature and humidity can both be controlled will improve the repeatability of these studies 
and ensure that fibre sizes stay uniform. 
Decellularization of natively sourced tissues has been on the increase in tissue engineering, where 
wasted tissue can be used for its biochemical properties 198,199,256. This study used heart and aorta 
ECMs from bovine sources. The samples were sourced from a local abattoir and would have been 
wasted otherwise. Using bovine heart and aorta ECM does have its benefits for tissue engineering due 
to the relatively similar structural characteristics found in them compared to their human 
counterparts 19,20. Additionally, bovine ECMs have been used in FDA approved medical devices 257. 
However, the use of a human source of ECM would have created a more physiologically accurate 
electrospun scaffold for in vitro experimentation.  
The decellularization method used in this thesis relies on the perfusion of 0.5% SDS through the 
tissue. While SDS is a widely used detergent for the removal of cellular content 271,507, it does have its 
shortfalls. Overexposure to SDS and using SDS at too high a concentration have both been shown to 
damage the ECM 261. Work by He, et al. showed that increasing the SDS concentration to above 
0.25% w/v had detrimental effects on the retention of VEGF and bFGF in decellularized kidney ECM. 
They also showed that increasing exposure time from 4 h to 8 h significantly reduced sulfated 
glycosaminoglycan content in the ECM 261. While these results don’t directly translate across to the 
vascular tissue sources used in this thesis, it is worth considering how the decellularization protocol 
used in this thesis (0.5% w/v SDS and 36 h of decellularization) is altering the ECM’s composition. 
Other decellularization methods have been successfully utilised in tissue engineering, including the 
222 
 
use of other detergents such as Triton X-100 and CHAPS; the use of enzymes such as trypsin and 
deoxyribonucleic; and mechanical methods such a high pressure and freeze-thaw cycles 263. The use 
of other detergents and freeze-thaw cycles can be less detrimental to the structure of the ECM, but 
may result in less decellularization 508,509. Enzymes, like the use of SDS have also been shown to have 
effects on the structural function of the decellularized tissue 510. 
While HFIP is a widely used solvent for electrospinning purposes due to its high stability and uniform 
fibre creation, it does have its drawbacks when used with ECMs and proteins 256,310,311. Studies have 
shown that collagen (one of the major components of the ECMs used) can have approximately 45% of 
its triple helical structure denatured into gelatin in the presence of HFIP 276. While these FTIR results 
confirm that ECM protein is still present in the tissue after decellularization, the Amide I and Amide 
II bonds are characteristic of both collagen and gelatin, therefore no conclusion can be made on 
structural makeup of the ECM after electrospinning. The quantity of collagen found in the ECM 
before and after contact with the HFIP could be measured using an alkaline hydrolysis/hydroxyproline 
assay, which is sensitive to levels well below native collagen levels 511. Nonetheless, collagen has 
been widely used with HFIP for the manufacturing of electrospun scaffolds, with results showing a 
positive influence on seeded cells 256,375.  
One method used to assess the efficacy of decellularization was DNA quantification with a Quant-iT 
PicoGreen dsDNA assay 340. Furthermore, the Quant-iT PicoGreen dsDNA assay was also used to 
measure the DNA content found on the seeded scaffolds. This assay uses fluorescence and is 1000 
times more sensitive than conventional absorbance methods, capable of measuring down to 
250 pg/mL. There are alternative methods widely used to measure the DNA content such as the use of 
flow cytometry or a Nanodropper 512,513. This assay used in conjunction with cell viability can give a 
good overarching image of the number of cells. However, due to the porous nature of these scaffolds, 
many of the detached dead cells may still be entrapped within the structure of the scaffold and would 
increase the DNA contents of the scaffold.  
Cell viability was measured using a CellTiter-Blue® assay, which relies on oxidation-reduction to 
indicate the mitochondrial activity of the cells. Mitochondrial activity is directly linked to the 
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metabolic viability of cells and not the total number of cells, therefore cell numbers cannot always be 
concluded from the CellTiter-Blue® assay. Studies have shown that these types of oxidation-reduction 
assays can give false-positives and that substrates found within the media can interfere with the 
viability measurements 514,515. Furthermore, the accuracy of results with these assays could be affected 
by the porous nature of these scaffolds. If the active agent remains entrapped within the porous 
scaffold, it would not be accounted for when analysing the fluorescence of the sample 516. In order to 
reduce the likelihood of this occurring, the plates were mixed before measurements were taken. 
Sterilization in this thesis was achieved using 70% v/v ethanol, which is sufficient for in vitro studies, 
but is not a clinically translatable method of terminal sterilization. Studies have shown that some 
methods of terminal sterilization do have detrimental effects on the structure, mechanical integrity and 
cell hosting abilities of decellularized ECM 257,324. The majority of currently marketed biological 
devices that use decellularized ECMs are terminally sterilized using either gamma irradiation, 
ethylene oxide or electron beam processing, which shows that decellularized ECMs can be efficiently 
sterilized before being translated to the clinic 517. Furthermore, peracetic acid as a terminal 
sterilization method has been shown to have no effect on the structure or mechanical strength of 
ECM, whilst also maintaining its ability to host cells 324. Therefore, translating this work to a clinical 
setting where an approved terminal sterilization method is required would rely on one of the 
aforementioned sterilization methods.  
Plasma coating was used in Chapter 6 as a means of increasing the hydrophilicity of the scaffold and 
the quantity of available hydroxyl groups for the binding of proteins. While this is a regularly used 
method to coat polymer scaffolds 296,297,449, the application of plasma onto the scaffold needs to be 
even across the whole scaffold and over all the scaffolds being coated. Plasma coating significantly 
increased the amount of protein that could bind to the scaffold’s surface, therefore it was imperative 
that all the scaffolds were equally coated. This was achieved by limiting the number of scaffolds 
being coated at one time, ensuring there was no overlap between adjacent scaffolds.  
EDC and NHS treatment was used to further functionalize the surface of the scaffold. This is a widely 
used technique that has shown to help with the binding of proteins and peptides 331,336. It is imperative 
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that EDC and NHS is completely removed from the surface of the scaffold before the binding of 
protein and subsequent cell seeding. Remnant EDC and NHS can lead to the formation of unwanted 
by-products that can negatively impact the seeded cells 518. This can happen when the concentration of 
EDC and NHS are too high. Likewise, using a concentration that is too low will lead to incomplete 
activation of the polymer surface, reducing the quantity of bound protein. Furthermore, the activation 
yield achieved by the EDC/NHS functionalization was not assessed in this study. This can be 
achieved using the Beer-Lambert law which looks at the ratio of FTIR peaks at two wavelengths 
(1772 cm-1 and 2615 cm-1) 331. However, Guler, et al. found that the EDC/NHS concentrations with 
the highest activation yield were also the concentrations that lead to the most protein binding. 
Therefore, subsequent studies went forward with the 0.5 mM NHS and 0.5 mM EDC concentrations 
which led to the most BSA binding in the feasibility studies. Two further methods which have also 
been used in literature to assess the presence of amine bonds are the Ninhydrin test and Chloranil 
test 447. The Chloranil test can also be used quantitatively to measure the amount of amine bonds 
being closed off by binding protein 447. 
RT-PCR was used to analyse the gene expression profiles of the seeded cells. While this method gives 
an indication of how the cells are reacting to their substrates, gene expression is not directly correlated 
to protein synthesis due to the complicated post-translational mechanisms involved 519. The primers 
used in this thesis were either taken from literature, where they had been shown to work effectively 
under similar experimental conditions to the equipment used in this thesis, or they were designed 
online. Primers were designed to cross exon-exon junctions, which reduces the possibility of genomic 
DNA amplification. Furthermore, optical density was used to measure the purity of the RNA post 
purification to ensure there was no contamination from the phenol and PCL 520. Further work is 
required to assess cell function and protein production including the use of enzyme linked 
immunoabsorbant assay (ELISA) and mass spectrometry 521,522.  
Tensile testing was used as the predominant method of mechanical analysis for these scaffolds as 
means of deducing how the mechanical characteristics of the scaffolds influences cells. Stiffness 
values (Young’s modulus) were deduced from the stress vs strain data. In order to ensure minimal 
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error was introduced during the handling process, a C-shaped card mount was created to stabilise the 
sample before testing. This ensured the sample was the correct gauge length each time. Any slack in 
the sample would result in a larger gauge length which would affect the results. Error can also be 
introduced through the use of different strain rates. Studies have shown that changing the strain rate 
can have drastic effects on the measured stiffness, ultimate tensile strength and yield stress of 
polymers 523,524. Therefore, the strain rate was kept consistent between studies. Further error can be 
introduced through the incorrect measurement of sample width and thickness, as these measurements 
are required to deduce the cross-sectional area. This was reduced by taking several measurements 
across each sample.  
Scaffold seeding was a potential source of error between the different scaffolds. Care was taken when 
seeding to ensure the cells were always in suspension and hadn’t sunk to the bottom of the cell/media 
suspension. Scaffolds were seeded across groups and timepoints to ensure that any time-dependant 
error (such as sinking cells) was spread across the groups and not isolated to a particular group.  
The imaging of cells was performed using staining and fluorescent imaging. DAPI (nuclei) and 
phalloidin (f-actin) were used to stain for the cell nucleus and actin filaments within the cell 
cytoplasm. They are widely used to visualize the structure and morphology of the cell 525. However, 
this is a qualitative technique that only allows for cell visualization. Immunohistochemical (IHC) 
staining allows for certain desired antibodies to be bound to their respective antigens. When used 
alongside appropriate negative and positive controls they can be indicative of antigen presence and 
can be used qualitatively 526. 
7.1.3 Future Work 
Only four different fibre diameters were studied in each of the sections of Chapter 3. Moving forward, 
it would be beneficial to look at a wider range of fibre diameters in order to analyse the full spectrum 
of fibre diameters and their effect on the seeded cells. In both studies, the depth of cell infiltration 
drastically increased between the large and extra-large fibre diameters, therefore looking at diameters 
in between these two scaffolds would allow us to see at exactly what fibre diameter infiltration starts 
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to happen. Additionally, trying to match the fibre diameters between the two studies (HUVECs and 
HUVSMCs) would allow us to compare the results of the two studies. 
The rate of PCL and ECM degradation need to be considered. Implants need to be able to maintain 
structural integrity until adequate tissue regeneration has taken place. The rate at which the PCL is 
absorbed and metabolised needs to be carefully considered to ensure the proper support is given to the 
regenerating tissue. Work by Sun, et al. found that there was a linear correlation between the loss of 
molecular weight of PCL and time elapsed in vivo 497. Further work by Lam, et al found that the 
mechanical strength of PCL was maintained until about 15,000 Mw 364. These results show that the 
molecular weight of the PCL can be easily tailored to match the regeneration rate of the native tissue 
once it is known. Animal studies should be run to get an idea of the approximate regeneration rate of 
the diseased tissues when in contact with these scaffolds. This would allow us to alter the molecular 
weight of the PCL used. Furthermore, the degradation of the scaffold’s ECM components into the 
media needs to be studied, as the effect of incorporating ECM into PCL on the overall mechanical 
properties is not known. Work by Marrese, et al. found that the gelatin component of PCL/gelatin 
electrospun scaffolds left the fibres and dissipated into the media 527. They used AFM to measure the 
surface roughness of the scaffold and found it increased as the gelatin left the fibres 527. This method 
could be used in future studies to look at how much of the ECM is leaving the fibres. Likewise, a 
BCA protein assay could also be used to measure any increases in media protein content. 
Alternatively, the PCL/ECM fibres could be cross-linked to maintain protein content in the fibres, 
however, this can reduce scaffold porosity and studies looking at polymer/collagen electrospun 
scaffolds found that this does not completely remove the problem of protein dissolution 415,527. 
When manufacturing a scaffold with bioactive components it is essential to investigate toxicity. The 
work presented in Chapter 4, 5 and 6 all looks at incorporating or binding protein sources to a 
scaffold. ECM components from bovine sources have already been successfully used in medical 
implants, suggesting that the ECMs used in this study are non-toxic and safe to use 257. However, 
animal to animal variability and different ECM sources within the body are compositionally different. 
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Therefore, in vivo evaluation and clinical studies are required to evaluate the safety and 
biocompatibility of the ECM and protein bound scaffolds used in this thesis. 
Proteomic analysis of the ECM components within the scaffold and of the cell secretome bound to the 
scaffolds is required to fully understand the results within this thesis. Mass spectrometry-based 
proteomics is a widely used technique for large-scale protein characterization 528. Unfortunately, due 
to the complex nature of proteomes and the intricate techniques required, analysing these in the ECM 
and cell secretome was not deemed as an effective use of resources. However, moving forward with a 
clearer image of how these scaffolds perform, the clear next step would be performing proteomics on 
both the scaffolds and secretome.  
As previously mentioned, the surface activation yield and binding efficiency of the plasma coated and 
EDC/NHS treated scaffolds were not assessed for protein binding. This can be achieved using the 
Beer-Lambert law which uses FTIR peaks at two wavelengths (1772 cm-1 and 2615 cm-1) 331. This 
would allow us to assertively conclude which EDC/NHS concentrations had the greatest activation 
yield. However, the present studies found that the quantity of protein binding onto the scaffold’s 
surface was not sufficient to be picked up in FTIR analysis. Alternative methods such as the 
Ninhydrin test and Chloranil test can be used to qualitatively test for binding efficiency as they rely on 
a colour change in the presence of open bonds 447. The Chloranil test has also been used 
quantitatively, whereby the more colour change means more open bonds 447. The use of these two 
tests moving forward would allow for measurement of the binding efficiency of each EDC/NHS 
treatment.  
A shelf-life study looking at how long-term storage affects the proteins bound to the scaffolds (from 
Chapter 5) is required for the end goal of product commercialization. With translatability from lab to 
implant in mind, it is imperative that the shelf-life of these scaffolds is examined. The conditions 
under which proteins are stored can have massive effects on the shelf-life of the protein, with 4°C 
storage typically resulting in a 1 month shelf-life and proteins stored at -80°C typically lasting 
years 529. Furthermore, if the bonds between the protein and PCL scaffold degrade over time, then the 
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quantity of bound protein will also drop. This step is imperative for assessing the translatability of 
these scaffolds.  
This study looked at HUVEC and HUVSMC cultures separately. Future work should look at co-
culturing these two cell lines together on the different scaffolds. These two cell types are found 
together in the vasculature and undergo paracrine interaction resulting in a variety of different 
endothelial functions 530. Likewise, the co-culture of ECs and SMCs has been widely done in vitro 
with results showing that they self-regulate each other through the release of various different proteins 
and cytokines 504,531,532. These studies showed that each cell type reacted differently to the individual 
scaffolds. For example, the extra-large fibre diameter increased angiogenic gene expression in the 
HUVECs, but the smallest fibre diameter increased cell viability and cell spreading in the HUVSMCs. 
Therefore, it would be interesting to see how combining these two fibres in a co-culture system would 
enhance cell function. Similarly, it would also be interesting to see how the binding of HUVEC 
secretome would alter the performance of seeded HUVSMCs, and vice versa with the HUVSMC 
secretome and seeded HUVECs. As mentioned above, these two cells release a variety of cytokines 
that alter each other’s functions, therefore, it would be expected that binding these factors to a 
scaffold would alter cell functionality.   
On the topic of binding cell secretome to a scaffold, looking at how other mechanical stimuli such as 
strain and shear stress affect the secretome profile released from these two cell types would lead to 
some interesting results. Studies have shown that strain and shear stress both alter cell function and 
protein expression from endothelial cells and smooth muscle cells 533. Work by Patrick Jr, et al. found 
that HUVECs under shear stress increased the expression of ICAM, VCAM and bFGF, which are all 
angiogenic genes that stimulate the formation of new vasculature 533. Likewise, mechanical strain has 
been shown to increase the expression of PDGF-B and PDGF-β in vascular SMCs 534. These two 






The aims outlined for this thesis were: 
1) Manufacture electrospun scaffolds with differing morphologies and assess their impact on 
HUVECs and HUVSMCs. 
2) Incorporate decellularized vascular ECMs into polymer scaffolds and assess their impact on 
HUVECs and HUVSMCs. 
3) Bind cell secretome to polymer scaffolds to further biofunctionalize them and assess their 
impact on HUVECs and HUVSMCs. 
4) Use physiologically relevant environmental conditions to alter cell secretome and cell 
functionality. 
This thesis has successfully contributed to each of these aims. The studies presented in this thesis 
represent investigations of novel electrospun scaffolds as platforms for vascular tissue engineering. 
Each aim has been addressed in individual Chapters. 
In Chapter 3, a range of different scaffold morphologies were investigated. Scaffolds were electrospun 
with increasing fibre diameters and were assessed as platforms for the growth of HUVECs and 
HUVSMCs. The scaffolds produced all had different fibre diameters and were random in their 
alignment. Results showed that altering the fibre diameter lead to increases in cell infiltration, cell 
viability and gene expression.  
Chapter 4 looked at incorporating decellularized ECMs into the electrospun fibres, in order to increase 
the bioactive potential of the scaffolds. Bovine aorta and heart ECM sources were successfully 
decellularized and incorporated into the electrospun PCL fibres. The addition of ECM altered the 
mechanical properties of the scaffold and biological responses of the seeded cells. The incorporation 
of ECM into the scaffold increased cell viability for both cells used. Furthermore, no real trends in 
gene expression were noted. Therefore, incorporating ECM allowed for the mechanical properties of 
the scaffold to be altered whilst maintaining cell viability and without altering the gene expression.  
Chapter 5 looked at how binding cell secretome to the surface of the scaffold altered their bioactive 
potential as platforms for cell seeding. Cell secretome conditioned media was collected for both cell 
types and was successfully bound onto the surface of the PCL scaffolds. Binding the proteins from the 
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HUVEC secretome conditioned media to the scaffold had the effect of slightly reducing the 
expression of several key phenotypic and angiogenic genes. Additionally, the binding of proteins from 
the HUVSMC secretome media and the serum-free media to the scaffold had the effect of reducing 
cell viability compared to the PBS conditioned scaffold. This Chapter represents the first time the 
secretome from two vascular cell types has been bound to the surface of a scaffold with subsequent 
cellular performance analysed. 
Chapter 6 then looked at how environmental factors could be used to alter cellular performance on 
PCL and PCL/ECM scaffolds and to look at how these factors could alter the HUVEC secretome 
profile. The incorporation of ECM into the scaffolds did not alter their performance in a hypoxic 
environment. Moreover, hydrostatic pressure induced cell secretome and atmospheric pressure 
induced secretome could both be bound to scaffolds and maintained cell viability.   
Overall, this thesis has used a combination of novel techniques to manufacture a range of scaffolds 
that mimic some of the native arterial properties, both in terms of morphology, biological composition 
and mechanical properties. The results from this thesis highlight the potential that these scaffolds have 
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Appendix 1: The Influence of Aorta Extracellular Matrix in 





































Appendix 2: Hybrid Cardiovascular Sourced Extracellular Matrix 
Scaffolds as Possible Platforms for Vascular Tissue Engineering 
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